

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
25 September 2003 (25.09.2003)

PCT

(10) International Publication Number  
WO 03/078614 A2(51) International Patent Classification<sup>7</sup>: C12N 9/00

Jan [NL/NL]; Win Sonneveldstraat 17, NL-6708 NA Wageningen (NL).

(21) International Application Number: PCT/IB03/01562

(22) International Filing Date: 18 March 2003 (18.03.2003)

(74) Agents: MARSHALL, Cameron, J. et al.; Carpmals &amp; Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data:  
60/365,769 19 March 2002 (19.03.2002) US  
60/368,047 26 March 2002 (26.03.2002) US(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.(71) Applicant (*for all designated States except US*): PLANT RESEARCH INTERNATIONAL B.V. [NL/NL]; Droeveendaalsesteeg 1, NL-6708 PB Wageningen (NL).(84) Designated States (*regional*): ARIPO patent (GI, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BAKKER, Hendrikus, Antonius, Cornelius [DE/DE]; Drachenfeld 75, NL30627 Hanover (DE). FLORACK, Dionisius, Elisabeth, Antonius [NL/NL]; Van Doesburglaan 160, NL-6708 MD Wageningen (NL). BOSCH, Hendrik,

[Continued on next page]

(54) Title: GNTIII EXPRESSION IN PLANTS



(57) Abstract: The invention relates to the field of glycoprotein processing in transgenic plants used as cost efficient and contamination safe factories for the production of recombinant biopharmaceutical proteins or pharmaceutical compositions comprising these glycoproteins. The invention provides a plant comprising a functional mammalian enzyme providing mammalian GnTIII that is normally not present in plants, said plant additionally comprising at least a second mammalian protein or functional fragment thereof that is normally not present in plants.



**Published:**

— without international search report and to be republished  
upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## GNTIII EXPRESSION IN PLANTS

### FIELD OF THE INVENTION

The invention relates to expression of a mammalian N-acetylglucosaminyl-transferase III (GnTIII) enzyme in plants and its use in producing glycoproteins with bisected oligosaccharides and increased amount of terminal GlcNAc residues. The invention further relates to a hybrid protein comprising the catalytic site of GnTIII and transmembrane domain of Golgi apparatus and/or endoplasmic reticulum (ER) protein or modified GNTIII comprising ER retention signals and its use in producing glycoproteins with oligosacchararides that lack immunogenic xylose and fucose residues.

### BACKGROUND OF THE INVENTION

N-Acetylglucosaminyltransferases (GlcNAc-transferases) are "branching" enzymes that add an Nacetylglucosamine (GlcNAc) residue to one of the mannoses of the trimannosyl core structure of typical Nlinked glycans. At least six GlcNAc-transferases are known with little or no sequence homology. Besides different protein structures, these GlcNAc-transferases also have different enzymatic properties and substrate specificity. All are typical type II transmembrane proteins with a cytoplasmic domain, a transmembrane anchor and an extracellular stem region with catalytic domain.

A remarkable GlcNAc-transferase is GlcNAc-transferase III (GnTIII). GnTIII, also known as UDP-Nacetylglucosamine:β-D-mannoside β(1,4)-N-acetylglucosaminyl-transferase III (EC 2.4.1.144), inserts bisecting GlcNAc residues in complex-type N-linked glycans of cellular glycoproteins (for a review see Taniguchi, *et al.*, "A glycomic approach to the identification and characterization of glycoprotein function in cells transfected with glycosyltransferase genes" *Proteomics* 1:239247, 2001). GnTIII adds the GlcNAc through a β(1,4) linkage to the β-linked mannose of the trimannosyl core structure of the N-linked glycan. GnTIII was first identified in hen oviduct (Narasimhan S., "Control of glycoprotein synthesis. UDP-GlcNAc:glycopeptide β 4-Nacetylglucosaminyltransferase III, an enzyme in hen oviduct which adds GlcNAc in β14 linkage to the β-linked mannose of the trimannosyl core of N-glycosyl oligosaccharides" *The Journal of Biological Chemistry* 257:10235-10242, 1982) but a high level of activity has also been reported in various types of rat hepatomas, human serum, liver and hepatoma tissues of patients with hepatomas and liver cirrhosis (Ishibashi, *et al.*, "N-acetylglucosaminyltransferase III in human serum and liver and hepatoma tissues: increased activity in liver cirrhosis and hepatoma patients" *Clinical Chimica Acta* 185:325, 1989; Narishimhan, *et al.*, "Expression of N-acetylglucosaminyltransferase III in hepatic nodules during rat liver carcinogenesis promoted by orotic acid" *Journal of Biological Chemistry* 263:1273-1281, 1988; Nishikawa, *et al.* "Determination of N-acetylglucosaminyltransferases III, IV and V in normal and hepatoma tissues of rats" *Biochimica et Biophysica Acta* 1035:313-318, 1990; Pascale, *et al.*, "Expression of N-acetylglucosaminyltransferase III in hepatic nodules generated by different models of rat liver carcinogenesis" *Carcinogenesis* 10:961964, 1989). Bisected oligosaccharides on glycoproteins have

been implicated in antibody-dependent cellular cytotoxicity (ADCC). ADCC is a lytic attack on antibody-targeted cells and is triggered upon binding of lymphocyte receptors to the constant region (Fc) of antibodies. Controlled expression of GnTIII in recombinant Chinese Hamster Ovary (CHO) production cell lines that lack GnTIII activity resulted in antibodies with bisected oligosaccharides with optimized ADCC activity (Davies, *et al.*, "Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for Fc $\gamma$ RIII" *Biotechnology and Bioengineering* 74:288-294, 2001; Umana, *et al.*, "Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity" *Nature Biotechnology* 17:176-180, 1999). The ADCC activity correlated well with the level of Fc region-associated bisected complex oligosaccharides present on the recombinant antibody (Umana, *et al.*, "Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity" *Nature Biotechnology* 17:176-180, 1999). Bisecting GlcNAc residues resulting from GnTIII activity affect the conformation of the sugar chains in such a way that other glycosyltransferases such as GlcNAc-transferase II and  $\alpha$ 1,6-fucosyltransferase, but not  $\beta$ (1,4)-galactosyltransferase, can no longer act (Taniguchi, *et al.*, 2001). Overexpression of GnTIII in CHO cells is lethal.

In contrast to typical mammalian production cell lines such as CHO cells, transgenic plants are generally recognized as a safe production system for therapeutic proteins. Plant glycoproteins, however, differ in oligosaccharide structure with those from mammals in several aspects. They lack terminal galactose and sialic acid, have an additional core xylose and differently linked core fucose ( $\alpha$ -1,3) instead of ( $\alpha$ -1,6). Like CHO and other pharmaceutical production cell lines they also completely lack bisected oligosaccharides. Plants have the capacity to generate the common core structure, GN2M3GN2 but predominantly M3 GN2 variants are found, indicating removal of terminal GN by hexosaminidases.

Biogenesis of N-linked glycans begins with the synthesis of a lipid linked oligosaccharide moiety (G1c3Man9GlcNAc2-) which is transferred *en bloc* to the nascent polypeptide chain in the endoplasmic reticulum (ER). Through a series of trimming reactions by exoglycosidases in the ER and cis-Golgi compartments the so-called "high mannose" (Man9GlcNAc2 to Man5GlcNAc2) glycans are formed. Subsequently, the formation of complex type glycans starts with the transfer of the first GlcNAc onto Man5GlcNAc2 by GnTI and further trimming by mannosidase II (Mann) to form GlcNAcMan3 GlcNAc2. Complex glycan biosynthesis continues while the glycoprotein is progressing through the secretory pathway with the transfer in the Golgi apparatus of the second GlcNAc residue by GnTII as well as other monosaccharide residues onto the GlcNAcMan3GlcNAc2 under the action of several other glycosyl transferases. Plants and mammals differ with respect to the formation of complex glycans. In plants, complex glycans are characterized by the presence of  $\beta$ (1,2)-xylose residues linked to the Man-3 and/or an  $\alpha$ (1,3)-fucose residue linked to GlcNAc1, instead of an  $\alpha$ (1,6)-fucose residue linked to the GlcNAc-1 (Lerouge, P., *et al.*, "N-glycoprotein biosynthesis in plants: recent developments and future trends" *Plant Mol Biol* 38:31-48, 1998). Genes encoding the corresponding xylosyl (XylT) and fucosyl (FucT) transferases have been

isolated (Strasser R, "Molecular cloning and functional expression of  $\beta$  1, 2-xylosyltransferase cDNA from *Arabidopsis thaliana*" *FEBS Lett.* 472:105-8, 2000; Leiter, H., *et al*, "Purification, cDNA cloning, and expression of GDP-L-Fuc:Asn-linked GlcNAc  $\alpha$  1,3-fucosyltransferase from mung beans" *J Biol Chem.* 274:21830, 1999). Xylose and fucose epitopes are known to be highly  
5 immunogenic and possibly allergenic which may pose a problem when plant are used for the production of therapeutic glycoproteins. Moreover, blood serum of many allergy patients contains IgE directed against these epitopes which make particularly these patients at risk to treatments with xylose and fucose containing recombinant proteins. In addition, this carbohydrate directed IgE in sera might cause false positive reaction in *in vitro* tests using plant extracts since there is evidence  
10 that these carbohydrate specific IgE's are not relevant for the allergenic reaction. Plants do not possess  $\beta$ (1,4)galactosyltransferases nor  $\alpha$ (2,6)sialyltransferases and consequently plant glycans lack the  $\beta$ (1,4)galactose and terminal  $\alpha$ (2,6)NeuAc residues often found on mammalian glycans (Vitale and Chrispeels, "Transient N-acetylglucosamine in the biosynthesis of phytohemagglutinin: attachment in the Golgi apparatus and removal in protein bodies" *J Cell Biol* 99:133-140, 1984;  
15 Lerouge, P., *et al.*, "N-glycoprotein biosynthesis in plants: recent developments and future trends" *Plant Mol Biol* 38:31-48, 1998).

The final glycan structures are not only determined by the mere presence of enzymes involved in their biosynthesis but to a large extent by the specific sequence of the various enzymatic reactions. The latter is controlled by discrete sequestering and relative position of these enzymes  
20 throughout the ER and Golgi, which is mediated by the interaction of determinants of the transferase and specific characteristics of the sub-Golgi compartment for which the transferase is destined. A number of studies using hybrid, molecules have identified that the transmembrane domains of several glycosyltransferases play a central role in their sub-Golgi sorting (Grabenhorst E., *et al.*, *J. Biol. Chem.* 274:36107-36116, 1999; Colley, K., *Glycobiology*.7:1-13, 1997, Munro, S., *Trends Cell Biol.*  
25 8:11-15, 1998; Gleeson P.A., *Histochem. Cell Biol.* 109:517-532, 1998).

Similar to mammalian production cell lines used in pharmaceutical industry, glycoproteins produced in plants lack GnTIII activity. Plants not only lack GnTIII activity but are completely devoid of GnTIII-like sequences. In addition, plants also lack GnTIV, GnTV and GnTVI sequences and moreover, sialic acid residues. (For an overview of the major glycosylation attributes of  
30 commonly used cell expression systems including plants see, Jenkins, *et al.*, "Getting the glycosylation right: implications for the biotechnology industry" *Nature Biotechnology* 14:975-979, 1996). Nevertheless, plants are a very potent production system. Plants are generally accepted as safe and are free of particles infectious to humans. Plant production is easy scalable and N-linked glycosylation can be controlled (Bakker, *et al.*, "Galactose-extended glycans of antibodies produced  
35 by transgenic plants" *Proc. Nat. Acad. Sci. USA* 98:2899-2904, 2001).

Transgenic tobacco plants that produce galactosylated recombinant monoclonal antibodies (Mabs) upon introduction of the human gene for  $\beta$ (1,4)-galactosyltransferase have been reported (hGalT; Bakker, *et al.*, "Galactose-extended glycans of antibodies produced by transgenic plants" *Proc. Nat. Acad. Sci. USA* 98:2899-2904, 2001; WO01/31044 and WO01/31045).

Therapeutic glycoproteins can be improved by altering their glycosylation pattern (Davies, *et al.*, "Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FcγRIII" *Biotechnology and Bioengineering* 74:288-294, 2001; Umana, *et al.*, "Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity" *Nature Biotechnology* 17:176-180, 1999; Fukuta, *et al.*, "Remodeling of sugar chain structures of human interferon-γ" *Glycobiology* 10:421-430, 2000; Misaizu, *et al.*, "Role of antennary structure of N-linked sugar chains in renal handling of recombinant human erythropoietin" *Blood* 86:4097-4104, 1995; Sburlati, *et al.*, "Synthesis of bisected glycoforms of recombinant IFN-β by overexpression of β-1,4-N-acetylglucosaminyl-transferase III in Chinese Hamster Ovary cells" *Biotechnology Prog.* 14:189-192, 1998). Higher oligosaccharide antennarity of EPO, for example, leads to increased *in vivo* activity due to reduced kidney filtration (Misaizu, *et al.*, "Role of antennary structure of N-linked sugar chains in renal handling of recombinant human erythropoietin" *Blood* 86:4097-4104, 1995). Biosynthesis of such superior glycoforms can be achieved with the "standard" glycosylation machinery of normal production cell lines by two methodologies. The first is by enriching specific glycoforms during purification and the second is by introducing mutations in the polypeptide chain. The latter makes it possible to shift the glycosylation site within the glycoprotein resulting in different glycosylation patterns as the result of differences in accessibility. A complementary route is through genetic engineering of the production cell line itself. New glycosylation patterns can be obtained through expression of glycosyltransferase and glycosidase genes in production cell lines. These genes code for enzymes that either add or remove specific saccharides to and from the glycan of cellular glycoproteins. Several glycosyltransferase genes have been introduced in CHO cells to manipulate glycoform biosynthesis. One of them is GnTIII. Glycosyltransferase GnTIII is involved in branching of the N-linked glycan and results in bisecting GlcNAc residues. CHO cells and other production cell lines typically lack GnTIII activity (Stanley, P. and C.A. Campbell, "A dominant mutation to ricin resistance in chinese hamster ovary cells induces UDP-GlcNAc: glycopeptide β-4-N-acetylglucosaminyl-transferase III activity" *Journal of Biological Chemistry* 261:13370-13378, 1984). Expression of GnTIII in CHO resulted in bisected complex oligosaccharides as expected but overexpression resulted in growth inhibition and was toxic to cells. Similarly, overexpression of GnTV, another glycosyltransferase that introduces triantennary sugar chains, also resulted in growth inhibition suggesting that this may be a general feature of glycosyltransferase overexpression (Umana, *et al.*, "Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity" *Nature Biotechnology* 17:176-180, 1999).

Therefore, there is a need to provide a means for producing glycoprotein in plants with human compatible non-immunogenic bisecting oligosaccharides.

## SUMMARY OF THE INVENTION

The invention relates to expression of a mammalian N-acetylglucosaminyl-transferase III (GnTIII) enzyme in plants and its use in producing glycoproteins with bisected oligosaccharides and

increased amount of terminal GlcNAc residues. The invention further relates to a hybrid protein comprising the catalytic site of GnTIII and transmembrane domain of Golgi apparatus and/or endoplasmic reticulum (ER) protein or modified GNTIII comprising ER retention signals and its use in producing glycoproteins with oligosacchararides that lack immunogenic xylose and fucose residues.

In one embodiment, the present invention contemplates a plant host system comprising or expressing a mammalian UDP-Nacetylglucosamine:( $\beta$ -D-mannoside  $\beta$ (1,4)-Nacetylglucosaminyltransferase (GnTIII) enzyme (nucleotide sequence: SEQ ID NO.: 1, Genbank I.D. number AL022312 (Dunham, I., *et al.*, *Nature* 402:489-495, 1999); protein sequence: SEQ ID NO.: 2, Genbank I.D. number Q09327), wherein said GnTIII inserts bisecting Nacetyl glucosamine (GlcNAc) residues in complex-type N-linked glycans of a glycoprotein present in said plant host system

In a specific embodiment of the invention, the plant host system further comprises a heterologous glycoprotein or functional fragment thereof comprising bisected oligosaccharide, particularly galactose residues. The GnTIII inserts bisecting N-GlcNAc residues onto said heterologous glycoprotein.

In one embodiment, the present invention contemplates to a method for obtaining a plant host system expressing a heterologous glycoprotein comprising bisecting oligosaccharides. In one embodiment, the method comprises crossing a plant expressing a heterologous glycoprotein with a plant expressing said GnTIII, harvesting progeny from said crossing and selecting a desired progeny plant expressing said heterologous glycoprotein and expressing mammalian GnTIII. Alternatively, said plant host system may be obtained by introducing into a plant or portion thereof a nucleic acid encoding said mammalian GnTIII and a nucleic acid encoding said heterologous glycoprotein and isolating a plant or portion thereof expressing said heterologous glycoprotein and expressing mammalian GnTIII that is normally not present in plants. Furthermore, the invention is directed to a method for obtaining said heterologous glycoprotein from said plant comprising obtaining a plant host system using either of the procedures described above and further isolating said heterologous glycoprotein.

In another embodiment, it is contemplated that the plant host system of the present invention further comprises a functional mammalian enzyme providing N-glycan biosynthesis that is normally not present in plants thereby, for example, providing the capacity to extend an N-linked glycan by the addition of a galactose as described in WO 01 /21045 (herein incorporated by reference). In another embodiment, the present invention further contemplates a plant host system, wherein said plant host system comprises crossing a plant, said plant comprising a functional protein such as a transporter protein or a enzyme (*e.g.*, a mammalian protein) or functional fragment thereof wherein said protein provides N-glycan biosynthesis, with a plant comprising said mammalian GnTIII. In another embodiment, the present invention contemplates harvesting the progeny from said crossing and selecting a desired progeny plant expressing said functional protein such as, for example, a transporter protein or enzyme or functional fragment thereof. In yet another embodiment of the

present invention, it is contemplated that the expressed protein provides N-glycan biosynthesis and the mammalian GnTIII. In still yet another embodiment, the present invention contemplates a plant host system, wherein a nucleic acid encoding the GnTIII and a nucleic acid encoding a functional protein (for example, a transporter or an enzyme [e.g., mammalian] or functional fragment thereof) providing N-glycan biosynthesis and isolating said plant or portion thereof expressing the functional protein or functional fragment thereof providing N-glycan biosynthesis and said mammalian GnTIII. Although the present invention is not limited to any particular theory or mechanism, it is believed that such a combination increases galactosylation of a heterologous glycoprotein. Additionally, in one embodiment, it is contemplated that GnTIII and other proteins providing N-glycosylation such as GaIT can also be introduced simultaneously via one transformation vector.

In one embodiment, the present invention contemplates a plant host system comprising expressing said heterologous glycoprotein (wherein, said heterologous glycoprotein has increased galactosylation) and methods for obtaining said plant host cell system and said heterologous glycoprotein. In another embodiment, the plant host cell system may be obtained by either crossing a plant wherein the plant comprises mammalian GnTIII and a functional protein (for example, a transporter or an enzyme [e.g., mammalian] or functional fragment thereof that provides N-glycan biosynthesis not normally found in plants) with a plant comprising a heterologous glycoprotein and, then, selecting said progeny plants. In yet another embodiment, it is contemplated that said heterologous glycoprotein may be obtained by introducing nucleic acid sequences encoding 1) said GnTIII, 2) said functional protein or enzyme providing N-glycan biosynthesis not normally found in plants and 3) said heterologous glycoprotein into said plant or portion thereof and isolating said plant or portion thereof expressing said nucleic acid sequences. In another embodiment of the present invention, it is contemplated that the heterologous glycoproteins will be isolated or purified from the plant host systems.

In one embodiment of the present invention, a hybrid protein is contemplated, wherein the hybrid protein comprises 1) an isolated hybrid protein comprising a catalytic portion of mammalian GnTIII and 2) a transmembrane portion of a protein from, for example, the endoplasmic reticulum or Golgi apparatus of a eukaryotic cell. In another embodiment, the present invention also contemplates a modified mammalian GnTIII comprising a retention signal such as KDEL for retention of said GnTIII in the ER. In yet another embodiment, the present invention contemplates nucleic acid sequences encoding 1) said hybrid proteins and said modified mammalian GnTIII, 2) vectors comprising said nucleic acid sequences and 3) plant host systems comprising said sequences. In one embodiment, these hybrid proteins and modified GnTIIIs may act to relocalize GnTIII activity in the endoplasmic reticulum (ER) and/or Golgi apparatus. In another embodiment, the present invention contemplates methods for obtaining these hybrid proteins and modified GnTIII proteins by, for example, introducing sequences encoding said hybrid proteins or modified GnTIIIs into a plant or portion thereof. Although the present invention is not limited to any particular theory or mechanism, it is believed that as a result of such relocalization, bisecting GlcNAc is be introduced earlier in the N-glycan biosynthesis sequence of reactions thereby preventing subsequent enzymatic reactions and,



as a consequence, a heterologous protein expressed in a plant host system (for example, the plant host system of the present invention) will lack xylose and fucose and have increased amount of terminal GlcNAc. Accordingly, one embodiment of the present invention contemplates a method to provide a plant host system expressing a heterologous glycoprotein (said plant host system having the capacity to extend an N-linked glycan with galactose) comprising crossing a plant comprising said 1) hybrid protein or said modified GnTIII with a plant comprising said heterologous protein and 2) selecting said desired progeny. In another embodiment, the present invention contemplates introducing into a plant or portion thereof a nucleic acid sequence encoding 1) said modified GnTIII or said hybrid protein and said heterologous glycoprotein and 2) isolating said plant or portion thereof expressing a heterologous glycoprotein with the capacity to extend and N-linked glycan with galactose. In yet another embodiment, the present invention contemplates a method for obtaining said desired heterologous glycoprotein, said method comprising isolating said glycoprotein from said plant or portion thereof.

In one embodiment, the present invention contemplates that the plant-derived glycoprotein or functional fragment thereof may be used for the production of a pharmaceutical composition (for example, an antibody, a hormone, a vaccine antigen, an enzyme, or the like). In another embodiment, the present invention contemplates a pharmaceutical composition comprising a glycoprotein or functional fragment thereof is now also provided.

In one embodiment, the present invention contemplates variants or mutants of GnTIII. The terms "variant" and "mutant" when used in reference to a polypeptide refer to an amino acid sequence that differs by one or more amino acids from another, usually related, polypeptide. In another embodiment, the present invention contemplates variants that have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties. One type of conservative amino acid substitutions refers to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Preferred conservative amino acids substitution groups are: valine (V) -leucine (L) -isoleucine (I), phenylalanine (F) -tyrosine (Y), lysine (K) -arginine (R), alanine (A) -valine (V), and asparagine (N) -glutamine (Q).

In yet another embodiment, the present invention contemplates variants that have "non-conservative" changes (*e.g.*, replacement of a glycine with a tryptophan). Similar minor variations may also include amino acid deletions or insertions (*i.e.*, additions), or both. Guidance in determining which and how many amino acid residues may be substituted, inserted or deleted without abolishing biological activity may be found using computer programs well known in the art, for example, DNASTar software. Variants can be tested in functional assays. For both conservative and non-conservative variants, preferred variants have less than 10 %, preferably less than 5 % and,

still more preferably, less than 2 % changes (whether substitutions, deletions, and so on).

In one embodiment, the present invention contemplates a plant host (cell) system, comprising a mammalian UDP-N-acetylglucosamine:  $\beta$ -D mannoside  $\beta(1,4)$ -N-acetylglucosaminyltransferase (GnTIII) enzyme (or portion or variant thereof, wherein said GnTIII inserts bisecting N-acetylglucosamine (GlcNAc) residues in complex-type N-linked glycans of a glycoprotein present in said plant host system). In another embodiment, the present invention contemplates the plant host, wherein said GnTIII is a human GnTIII. In yet another embodiment, the present invention contemplates the plant host system, wherein said system is a portion of a plant. In yet another embodiment, the present invention contemplates the plant host system, wherein said system is a portion of a plant selected from the group consisting of a cell, leaf, embryo, callus, stem, pericarp, protoplast, root, tuber, kernel, endosperm and embryo. In yet another embodiment, the present invention contemplates the plant host system, wherein said system is a whole plant. In yet another embodiment, the present invention contemplates the plant host system, further comprising a heterologous glycoprotein (or functional fragment thereof). In yet another embodiment, the present invention contemplates the plant host system, wherein said heterologous glycoprotein protein comprises an antibody, or fragment (*e.g.* Fc, Fv, Fab, Fab<sub>2</sub>) thereof. In yet another embodiment, the present invention contemplates the plant host system, wherein said heterologous glycoprotein or functional fragment thereof comprises bisected oligosaccharides. In yet another embodiment, the present invention contemplates the plant host system, wherein said heterologous glycoprotein (or functional fragment thereof) comprises bisected glycans with galactose residues. In yet another embodiment, the present invention contemplates the plant host system, wherein said plant is a tobacco plant. In yet another embodiment, the present invention contemplates the plant host system, which further comprises a functional protein selected from a group consisting of a transporter or a (mammalian) enzyme (or functional fragment thereof) providing N-glycan biosynthesis. In yet another embodiment, the present invention contemplates the plant host system, wherein said enzyme is a (human)  $\beta$ -1,4 galactosyltransferase. In yet another embodiment, the present invention contemplates the plant host system, which further comprises a heterologous glycoprotein, having an increased number of galactose residues. In yet another embodiment, the present invention contemplates a plant host system comprising a nucleic acid sequence encoding a mammalian GnTIII protein. In yet another embodiment, the present invention contemplates a plant host system comprising a vector comprising a nucleic acid sequence encoding a mammalian GnTIII protein. In yet another embodiment, the present invention contemplates the plant host, which further comprises a nucleic acid sequence encoding a functional protein selected from a group consisting of a transporter or a (mammalian) enzyme (or functional fragment thereof) providing N-glycan biosynthesis.

In one embodiment, the present invention contemplates a method (for obtaining a plant host system expressing a heterologous glycoprotein having bisected oligosaccharides) comprising a) crossing a plant expressing a heterologous glycoprotein with a, b) harvesting progeny from said crossing and c) selecting a desired progeny plant (expressing said heterologous glycoprotein and

expressing a mammalian GnTIII that is normally not present in plants). In another embodiment, the present invention contemplates this method, wherein said desired progeny plant expresses said heterologous glycoprotein protein having bisected oligosaccharides. In yet another embodiment, the present invention contemplates this method, wherein said plant host system is a transgenic plant.

5 In one embodiment, the present invention contemplates a method for obtaining a heterologous glycoprotein having bisected oligosaccharides comprising a) introducing a nucleic acid sequence encoding GnTIII that is normally not present in plant into a plant host system and a nucleic acid sequence encoding a heterologous glycoprotein and b) isolating said heterologous glycoprotein. In another embodiment, the present invention contemplates this method, wherein said nucleic acid  
10 sequences are introduced into a plant cell and said plant cell is regenerated into a plant. In yet another embodiment, the present invention contemplates the same method, wherein said nucleic acid sequences are introduced into a plant host system by transforming said plant host system with a vector comprising a acid sequence encoding GnTIII that is normally not present in plant into a plant and a nucleic acid sequence encoding a heterologous glycoprotein. In yet another embodiment, the  
15 present invention contemplates the method, wherein said nucleic acid sequences are introduced into a plant host system by transforming said plant host system with a vector comprising a nucleic acid sequence encoding GnTIII that is normally not present in plant into a plant and a nucleic acid sequence encoding a heterologous glycoprotein. In yet another embodiment, the present invention contemplates the method, wherein said nucleic acid sequences are introduced into a plant host system  
20 by transforming said plant with a vector comprising a nucleic acid sequence encoding GnTIII that is normally not present in plant into a plant host system and vector comprising a nucleic acid sequence encoding a heterologous glycoprotein. In yet another embodiment, the present invention contemplates a method for obtaining a heterologous glycoprotein having bisected oligosaccharides comprising cultivating the regenerated plant.

25 In one embodiment, the present invention contemplates a method for obtaining a desired glycoprotein (or functional fragment thereof) comprising a) cultivating the plant host system (until said plant has reached a harvestable stage) and b) harvesting said plant (and fractionating to obtain fractionated plant material and c) at least partly isolating said glycoprotein from said fractionated plant material). In another embodiment, the present invention contemplates a plant obtainable by the  
30 contemplated method.

In one embodiment, the present invention contemplates A method for obtaining a plant host system comprising a functional protein selected from a group consisting of a transporter or a (mammalian) enzyme or functional fragment thereof providing N-glycan biosynthesis and a mammalian GnTIII comprising crossing a plant comprising a functional protein such as a transporter  
35 or a (mammalian) enzyme or functional fragment thereof providing N-glycan biosynthesis with a plant according to Claim 5, harvesting progeny from said crossing and selecting a desired progeny plant expressing said functional protein such as a transporter or a (mammalian) enzyme or functional fragment thereof providing N-glycan biosynthesis and said mammalian GnTIII. In another embodiment, the present invention contemplates a transgenic plant obtained according to the

contemplated.

In one embodiment, the present invention contemplates a method for increasing galactosylation of a heterologous glycoprotein expressed in a plant host system comprising introducing a nucleic acid sequence encoding GnTIII and a sequence selected from a group  
5 consisting sequences that encode a transporter or a (mammalian) enzyme or functional fragment not normally present in a plant into said plant host system expressing said heterologous glycoprotein and isolating said glycoprotein.

In one embodiment, the present invention contemplates a plant derived glycoprotein comprising bisected oligosaccharides.

10 In one embodiment, the present invention contemplates the use of a plant host system contemplated by the present invention to produce a desired glycoprotein or functional fragment thereof. In another embodiment, the present invention contemplates that said glycoprotein or functional fragment thereof comprises bisected oligosaccharides. In yet another embodiment, the present invention contemplates a plant-derived glycoprotein or functional fragment thereof obtained  
15 by a method contemplated by the present invention. In yet another embodiment, the present invention contemplates a glycoprotein or functional fragment thereof contemplated by the invention for the production of a pharmaceutical composition. In yet another embodiment, the present invention contemplates a composition comprising a glycoprotein or functional fragment thereof as contemplated by the present invention.

20 In one embodiment, the present invention contemplates an isolated hybrid protein comprising an active site of GnTIII and a transmembrane region of a protein, said protein residing in endoplasmic reticulum or Golgi apparatus of a eukaryotic cell. In another embodiment, the present invention contemplates the protein of the present invention, wherein said protein residing in endoplasmic reticulum or Golgi apparatus of a eukaryotic cell is an enzyme. In yet another  
25 embodiment, the present invention contemplates the protein accord of the present invention, wherein said protein residing in endoplasmic reticulum or Golgi apparatus of a eukaryotic cell is a glycosyltransferase. In yet another embodiment, the present invention contemplates the protein of the present invention, wherein said protein residing in endoplasmic reticulum or Golgi apparatus of a eukaryotic cell is a glycosyltransferase selected from the group consisting of a mannosidaseI,  
30 mannosidaseII, GnTI, GnTII, XylIT and FucT. In yet another embodiment, the present invention contemplates the protein accor of the present invention, wherein said protein residing in endoplasmic reticulum or Golgi apparatus of a eukaryotic cell is a plant protein. In yet another embodiment, the present invention contemplates an isolated nucleic acid sequence encoding the protein of the present invention. In yet another embodiment, the present invention contemplates a vector comprising the  
35 isolated nucleic acid sequence of the present invention. In yet another embodiment, the present invention contemplates a plant comprising the isolated nucleic acid sequence of the present invention. In yet another embodiment, the present invention contemplates the plant(s) of the present invention which further comprises a nucleic acid sequence encoding a heterologous glycoprotein.

In one embodiment, the present invention contemplates a method (for providing a transgenic

plant capable of expressing a heterologous glycoprotein with the capacity to extend an N-linked glycan with galactose) comprising a) crossing a transgenic plant with a plant of the present invention, b) harvesting progeny from said crossing and c) selecting a desired progeny plant (expressing said recombinant protein and expressing a functional (mammalian) enzyme involved in (mammalian) N-glycan biosynthesis that is normally not present in plants).

In one embodiment, the present invention contemplates a method for providing a transgenic plant capable of expressing a heterologous glycoprotein with the capacity to extend an N-linked glycan with galactose comprising introducing the nucleic acid sequence of the present invention and a nucleic acid sequence encoding said heterologous glycoprotein.

In one embodiment, the present invention contemplates a method, comprising: a) providing: i) a plant cell, and ii) an expression vector comprising nucleic acid encoding a GNTIII enzyme; and b) introducing said expression vector into said plant cell under conditions such that said enzyme is expressed. In another embodiment, the present invention contemplates the method, wherein said nucleic acid encoding a GNTIII comprises the nucleic acid sequence of SEQ ID NO:1.

In one embodiment, the present invention contemplates a method, comprising: a) providing: i) a plant cell, ii) a first expression vector comprising nucleic acid encoding a GNTIII enzyme, and iii) a second expression vector comprising nucleic acid encoding a heterologous glycoprotein; and b) introducing said first and second expression vectors into said plant cell under conditions such that said hybrid enzyme and said heterologous protein are expressed. In another embodiment, the present invention contemplates the method, wherein said heterologous protein is an antibody or antibody fragment.

In one embodiment, the present invention contemplates A method, comprising: a) providing: i) a first plant comprising a first expression vector, said first vector comprising nucleic acid encoding a GNTIII enzyme, and ii) a second plant comprising a second expression vector, said second vector comprising nucleic acid encoding a heterologous protein; and b) crossing said first plant and said second plant to produce progeny expressing said hybrid enzyme and said heterologous protein.

In one embodiment, the present invention contemplates a plant, comprising first and second expression vectors, said first vector comprising nucleic acid encoding a GNTIII enzyme, said second vector comprising nucleic acid encoding a heterologous protein. In another embodiment, the present invention contemplates the, wherein said heterologous protein is an antibody or antibody fragment.

## BRIEF DESCRIPTION OF THE FIGURES

Figures 1A and 1B show MALDI-TOF mass spectra of (A) N-linked glycans isolated from leaves of control tobacco plant and (B) N-linked glycans isolated from leaves of selected GnTM-17 tobacco plant transformed with human GnTIII. See, Table 1 for structures.

Figure 2 shows processing of high mannose type glycan (M9) to complex type glycans under the subsequent action of ManI, GnTI, ManII, and GnTII. It is also indicated what glycan structures the action of GalT and/or GnTIII at different points

in chain of reactions would lead. The reactions catalyzed by fucosyltransferases and xylosyltransferases are not indicated. Core GlcNAc (Gn) is not indicated. Gn = GlcNAc, Gn<sup>b</sup> = bisecting GlcNAc, G = galactose and M = mannose.

Figures 3A and 3B show (A) the T-DNA construct carrying the genes encoding glycan modifying enzymes to produce efficiently galactosylated bisected glycans that are devoid of immunogenic xylose and fucose and (B) the T-DNA construct carrying antibody light chain and heavy chain genes. TmXyl = transmembrane domain of xylosyltransferase, TmGnTI = transmembrane domain of GnT, P = promoter, R = selection marker, L = antibody light chain and H = antibody heavy chain.

Figures 4A and 4B show the nucleotide sequence (SEQ ID NO: 1, underlined portion of Figure 4(A) the protein sequence (SEQ ID NO: 2, underlined portion of Figure 4B) of *GnTIII* including a c-myc tag. Residues that can undergo conservative amino acid substitutions are defined in the DEFINITIONS section.

Figure 5A and 5B show a (A) map of the plasmid pDAB4005 and (B) the nucleotide sequence of the plasmid pDAB4005 (SEQ ID NO: 8).

Figure 6A and 6B show a (A) map of the plasmid pDAB7119 and (B) the nucleotide sequence of the plasmid pDAB7119 (SEQ ID NO: 9) including splice sites.

Figure 7A and 7B show a (A) map of the plasmid pDAB8504 and (B) the nucleotide sequence of the plasmid pDAB8504 (SEQ ID NO: 10).

Figure 8A and 8B show a (A) map of the plasmid pDAB7113 and (B) the nucleotide sequence of the plasmid pDAB7113 (SEQ ID NO: 11) including splice sites.

Figures 9A and 9B show MALDI-TOF mass spectra of glycoproteins from control and GnTIII corn. Comparison of mass spectra of N-glycans of glycoproteins isolated from calli of (A) control corn and of (B) selected GnTIII-corn. GnTIII corn was obtained through transformation with human GnTIII gene sequence and selection was performed by lectin blotting using E-PHA. See Table 3 for an annotation of the data contained in Figures 9A and 9B.

Figure 10 shows the full nucleotide sequence of *GnTIII* without a c-myc tag (SEQ ID NO: 7).

Figure 11 shows a MALDI-TOF mass spectra of glycoproteins from control and GnTIII corn-2. See, Table 4 for structures and abbreviations.

Figure 12 shows a representative blot of samples of transgenic maize callus for altered lectin binding due to expression of the *GnTIII* gene.

Figure 13 shows a representative blot of samples of transgenic maize callus for c-myc epitope expression.

Figures 14 A and 14B show a MALDI-TOF mass spectra of glycoproteins from (A) control and (B) GnTIII corn plants.

## DEFINITIONS

The terms "protein" and "polypeptide" refer to compounds comprising amino acids joined via peptide bonds and are used interchangeably. A "protein" or "polypeptide" encoded by a gene is not

limited to the amino acid sequence encoded by the gene, but includes post-translational modifications of the protein.

5 The term "glycoprotein" refers to proteins with covalently attached sugar units, either bonded via the OH group of serine or threonine (O glycosylated) or through the amide NH<sub>2</sub> of asparagine (N glycosylated). "Glycoprotein" may include, but is not limited to, for example, most secreted proteins (serum albumin is the major exception) and proteins exposed at the outer surface of the plasma membrane. Sugar residues found include, but are not limited to: mannose, N acetyl glucosamine, N acetyl galactosamine, galactose, fucose and sialic acid.

10 Where the term "amino acid sequence" is recited herein to refer to an amino acid sequence of a protein molecule, "amino acid sequence" and like terms, such as "polypeptide" or "protein" are not meant to limit the amino acid sequence to the complete, native amino acid sequence associated with the recited protein molecule. Furthermore, an "amino acid sequence" can be deduced from the nucleic acid sequence encoding the protein.

15 The term "portion" when used in reference to a protein (as in "a portion of a given protein") refers to fragments of that protein. The fragments may range in size from four amino acid residues to the entire amino sequence minus one amino acid.

20 The term "chimera" when used in reference to a polypeptide refers to the expression product of two or more coding sequences obtained from different genes, that have been cloned together and that, after translation, act as a single polypeptide sequence. Chimeric polypeptides are also referred to as "hybrid" polypeptides. The coding sequences includes those obtained from the same or from different species of organisms.

25 The term "fusion" when used in reference to a polypeptide refers to a chimeric protein containing a protein of interest joined to an exogenous protein fragment (the fusion partner). The fusion partner may serve various functions, including enhancement of solubility of the polypeptide of interest, as well as providing an "affinity tag" to allow purification of the recombinant fusion polypeptide from a host cell or from a supernatant or from both. If desired, the fusion partner may be removed from the protein of interest after or during purification.

30 The term "homolog" or "homologous" when used in reference to a polypeptide refers to a high degree of sequence identity between two polypeptides, or to a high degree of similarity between the three-dimensional structure or to a high degree of similarity between the active site and the mechanism of action. In a preferred embodiment, a homolog has a greater than 60 % sequence identity, and more preferably greater than 75% sequence identity, and still more preferably greater than 90 % sequence identity, with a reference sequence.

35 As applied to polypeptides, the term "substantial identity" means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 80 percent sequence identity, preferably at least 90 percent sequence identity, more preferably at least 95 percent sequence identity or more (e.g., 99 percent sequence identity). Preferably, residue positions which are not identical differ by conservative amino acid substitutions.

The terms "variant" and "mutant" when used in reference to a polypeptide refer to an amino

acid sequence that differs by one or more amino acids from another, usually related polypeptide. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties. One type of conservative amino acid substitutions refers to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Preferred conservative amino acids substitution groups are: valine (V) - leucine (L) -isoleucine (I), phenylalanine (F) -tyrosine (Y), lysine (K) -arginine (R), alanine (A) - valine (V), and asparagine (N) -glutamine (Q). More rarely, a variant may have "non-conservative" changes (*e.g.*, replacement of a glycine with a tryptophan). Similar minor variations may also include amino acid deletions or insertions (*i.e.*, additions), or both. Guidance in determining which and how many amino acid residues may be substituted, inserted or deleted without abolishing biological activity may be found using computer programs well known in the art, for example, DNASTar software. Variants can be tested in functional assays. Preferred variants have less than 10 %, and preferably less than 5 %, and still more preferably less than 2 % changes (whether substitutions, deletions, and so on).

The term "domain" when used in reference to a polypeptide refers to a subsection of the polypeptide which possesses a unique structural and/or functional characteristic; typically, this characteristic is similar across diverse polypeptides. The subsection typically comprises contiguous amino acids, although it may also comprise amino acids which act in concert or which are in close proximity due to folding or other configurations.

The term "gene" refers to a nucleic acid (*e.g.*, DNA or RNA) sequence that comprises coding sequences necessary for the production of an RNA, or a polypeptide or its precursor (*e.g.*, proinsulin). A functional polypeptide can be encoded by a full length coding sequence or by any portion of the coding sequence as long as the desired activity or functional properties (*e.g.*, enzymatic activity, ligand binding, signal transduction, etc.) of the polypeptide are retained. The term "portion" when used in reference to a gene refers to fragments of that gene. The fragments may range in size from a few nucleotides (*e.g.*, ten nucleotides) to the entire gene sequence minus one nucleotide. Thus, "a nucleotide comprising at least a portion of a gene" may comprise fragments of the gene or the entire gene.

The term "gene" also encompasses the coding regions of a structural gene and includes sequences located adjacent to the coding region on both the 5' and 3' ends for a distance of about 1 kb on either end such that the gene corresponds to the length of the full-length mRNA. The sequences which are located 5' of the coding region and which are present on the mRNA are referred to as 5' non-translated sequences. The sequences which are located 3' or downstream of the coding region and which are present on the mRNA are referred to as 3' non-translated sequences. The term "gene"



encompasses both cDNA and genomic forms of a gene. A genomic form or clone of a gene contains the coding region interrupted with non-coding sequences termed "introns" or "intervening regions" or "intervening sequences." Introns are segments of a gene which are transcribed into nuclear RNA (hnRNA); introns may contain regulatory elements such as enhancers. Introns are removed or  
5 "spliced out" from the nuclear or primary transcript; introns therefore are absent in the messenger RNA (mRNA) transcript. The mRNA functions during translation to specify the sequence or order of amino acids in a nascent polypeptide.

In addition to containing introns, genomic forms of a gene may also include sequences located on both the 5' and 3' end of the sequences which are present on the RNA transcript. These  
10 sequences are referred to as "flanking" sequences or regions (these flanking sequences are located 5' or 3' to the non-translated sequences present on the mRNA transcript). The 5' flanking region may contain regulatory sequences such as promoters and enhancers which control or influence the transcription of the gene. The 3' flanking region may contain sequences which direct the termination of transcription, posttranscriptional cleavage and polyadenylation.

15 The term "heterologous" when used in reference to a gene refers to a gene encoding a factor that is not in its natural environment (*i.e.*, has been altered by the hand of man). For example, a heterologous gene includes a gene from one species introduced into another species. A heterologous gene also includes a gene native to an organism that has been altered in some way (*e.g.*, mutated, added in multiple copies, linked to a non-native promoter or enhancer sequence, etc.). Heterologous  
20 genes may comprise gene sequences that comprise cDNA forms of a gene; the cDNA sequences may be expressed in either a sense (to produce mRNA) or anti-sense orientation (to produce an anti-sense RNA transcript that is complementary to the mRNA transcript). Heterologous genes are distinguished from endogenous genes in that the heterologous gene sequences are typically joined to nucleotide sequences comprising regulatory elements such as promoters that are not found naturally  
25 associated with the gene for the protein encoded by the heterologous gene or with gene sequences in the chromosome, or are associated with portions of the chromosome not found in nature (*e.g.*, genes expressed in loci where the gene is not normally expressed).

A "heterologous glycoprotein" is a glycoprotein originating from a species other than the plant host system. The glycoprotein may include but is not limited to antibodies, hormones, growth  
30 factors, and growth factor receptors, antigens, cytokines and blood products.

A "plant host system" may include, but is not limited to, a plant or portion thereof which includes, but is not limited to, a plant cell, plant organ and/or plant tissue. The plant may be a monocotyledon (monocot) which is a flowering plant whose embryos have one cotyledon or seed  
35 leaf and includes but is not limited to lilies, grasses, corn (*Zea mays*), rice, grains including oats, wheat and barley, orchids, irises, onions and palms. Alternatively, the plant may be a dicotyledon (dicot) which includes, but is not limited to, tobacco (*Nicotiana*), tomatoes, potatoes, legumes (*e.g.*, alfalfa and soybeans), roses, daisies, cacti, violets and duckweed. The plant may also be a moss which includes, but is not limited to, *Physcomitrella patens*. The invention is further directed to a method for obtaining said bisected GlcNAc in a plant host system by introducing a nucleic acid

encoding said GnTIII into a plant or portion thereof and expressing said GnTIII and isolating said plant or portion thereof expressing said GnTIII.

The term "nucleotide sequence of interest" or "nucleic acid sequence of interest" refers to any nucleotide sequence (*e.g.*, RNA or DNA), the manipulation of which may be deemed desirable for any reason (*e.g.*, treat disease, confer improved qualities, *etc.*), by one of ordinary skill in the art. Such nucleotide sequences include, but are not limited to, coding sequences of structural genes (*e.g.*, reporter genes, selection marker genes, oncogenes, drug resistance genes, growth factors, *etc.*), and non-coding regulatory sequences which do not encode an mRNA or protein product (*e.g.*, promoter sequence, polyadenylation sequence, termination sequence, enhancer sequence and other like sequences). The present invention contemplates host cells expressing a heterologous protein encoded by a nucleotide sequence of interest along with one or more hybrid enzymes.

The term "structural" when used in reference to a gene or to a nucleotide or nucleic acid sequence refers to a gene or a nucleotide or nucleic acid sequence whose ultimate expression product is a protein (such as an enzyme or a structural protein), an rRNA, an sRNA, a tRNA, *etc.*

The terms "oligonucleotide" or "polynucleotide" or "nucleotide" or "nucleic acid" refer to a molecule comprised of two or more deoxyribonucleotides or ribonucleotides, preferably more than three, and usually more than ten. The exact size will depend on many factors, which in turn depends on the ultimate function or use of the oligonucleotide. The oligonucleotide may be generated in any manner, including chemical synthesis, DNA replication, reverse transcription, or a combination thereof.

The terms "an oligonucleotide having a nucleotide sequence encoding a gene" or "a nucleic acid sequence encoding" a specified polypeptide refer to a nucleic acid sequence comprising the coding region of a gene or in other words the nucleic acid sequence which encodes a gene product. The coding region may be present in either a cDNA, genomic DNA or RNA form. When present in a DNA form, the oligonucleotide may be single-stranded (*i.e.*, the sense strand) or double-stranded. Suitable control elements such as enhancers/promoters, splice junctions, polyadenylation signals, *etc.* may be placed in close proximity to the coding region of the gene if needed to permit proper initiation of transcription and/or correct processing of the primary RNA transcript. Alternatively, the coding region utilized in the expression vectors of the present invention may contain endogenous enhancers/promoters, splice junctions, intervening sequences, polyadenylation signals, *etc.* or a combination of both endogenous and exogenous control elements.

The term "recombinant" when made in reference to a nucleic acid molecule refers to a nucleic acid molecule which is comprised of segments of nucleic acid joined together by means of molecular biological techniques. The term "recombinant" when made in reference to a protein or a polypeptide refers to a protein molecule which is expressed using a recombinant nucleic acid molecule.

As used herein, the terms "complementary" or "complementarity" are used in reference to nucleotide sequences related by the base-pairing rules. For example, the sequence 5'-AGT-3' is complementary to the sequence 5'-ACT-3'. Complementarity can be "partial" or "total." "Partial"

complementarity is where one or more nucleic acid bases is not matched according to the base pairing rules. "Total" or "complete" complementarity between nucleic acids is where each and every nucleic acid base is matched with another base under the base pairing rules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands.

A "complement" of a nucleic acid sequence as used herein refers to a nucleotide sequence whose nucleic acids show total complementarity to the nucleic acids of the nucleic acid sequence. For example, the present invention contemplates the complements of SEQ ID NO: 1.

The term "homology" when used in relation to nucleic acids refers to a degree of complementarity. There may be partial homology (*i.e.*, partial identity) or complete homology (*i.e.*, complete identity). A partially complementary sequence is one that at least partially inhibits a completely complementary sequence from hybridizing to a target nucleic acid and is referred to using the functional term "substantially homologous." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or Northern blot, solution hybridization and the like) under conditions of low stringency. A substantially homologous sequence or probe (*i.e.*, an oligonucleotide which is capable of hybridizing to another oligonucleotide of interest) will compete for and inhibit the binding (*i.e.*, the hybridization) of a completely homologous sequence to a target under conditions of low stringency. This is not to say that conditions of low stringency are such that non-specific binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (*i.e.*, selective) interaction. The absence of non-specific binding may be tested by the use of a second target which lacks even a partial degree of complementarity (*e.g.*, less than about 30 % identity); in the absence of non-specific binding the probe will not hybridize to the second non-complementary target.

When used in reference to a double-stranded nucleic acid sequence such as a cDNA or genomic clone, the term "substantially homologous" refers to any probe which can hybridize to either or both strands of the double-stranded nucleic acid sequence under conditions of low stringency as described *infra*.

When used in reference to a single-stranded nucleic acid sequence, the term "substantially homologous" refers to any probe which can hybridize to the single-stranded nucleic acid sequence under conditions of low stringency as described *infra*.

The following terms are used to describe the sequence relationships between two or more polynucleotides: "reference sequence," "sequence identity," "percentage of sequence identity" and "substantial identity." A "reference sequence" is a defined sequence used as a basis for a sequence comparison; a reference sequence may be a subset of a larger sequence, for example, as a segment of a full-length cDNA sequence given in a sequence listing or may comprise a complete gene sequence. Generally, a reference sequence is at least 20 nucleotides in length, frequently at least 25 nucleotides in length, and often at least 50 nucleotides in length. Since two polynucleotides may each (1) comprise a sequence (*i.e.*, a portion of the complete polynucleotide sequence) that is similar between

the two polynucleotides, and (2) may further comprise a sequence that is divergent between the two polynucleotides, sequence comparisons between two (or more) polynucleotides are typically performed by comparing sequences of the two polynucleotides over a "comparison window" to identify and compare local regions of sequence similarity. A "comparison window," as used herein, 5 refers to a conceptual segment of at least 20 contiguous nucleotide positions wherein a polynucleotide sequence may be compared to a reference sequence of at least 20 contiguous nucleotides and wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (*i.e.*, gaps) of 20 percent or less as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two 10 sequences. Optimal alignment of sequences for aligning a comparison window may be conducted by the local homology algorithm of Smith and Waterman [Smith and Waterman, *Adv. Appl. Math.* 2: 482 (1981)] by the homology alignment algorithm of Needleman and Wunsch [Needleman and Wunsch, *J. Mol. Biol.* 48:443 (1970)], by the search for similarity method of Pearson and Lipman [Pearson and Lipman, *Proc. Natl. Acad. Sci. (U.S.A.)* 85:2444 (1988)], by computerized 15 implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by inspection, and the best alignment (*i.e.*, resulting in the highest percentage of homology over the comparison window) generated by the various methods is selected. The term "sequence identity" means that two polynucleotide sequences are identical (*i.e.*, on a nucleotide-by-nucleotide 20 basis) over the window of comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (*e.g.*, A, T, C, G, U, or I) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (*i.e.*, the window size), and multiplying the 25 result by 100 to yield the percentage of sequence identity. The terms "substantial identity" as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 85 percent sequence identity, preferably at least 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison window of at least 20 nucleotide positions, frequently over a window of at least 25-50 30 nucleotides, wherein the percentage of sequence identity is calculated by comparing the reference sequence to the polynucleotide sequence which may include deletions or additions which total 20 percent or less of the reference sequence over the window of comparison. The reference sequence may be a subset of a larger sequence, for example, as a segment of the full-length sequences of the compositions claimed in the present invention.

35 The term "hybridization" refers to the pairing of complementary nucleic acids. Hybridization and the strength of hybridization (*i.e.*, the strength of the association between the nucleic acids) is impacted by such factors as the degree of complementarity between the nucleic acids, stringency of the conditions involved, the  $T_m$  of the formed hybrid, and the G:C ratio within the nucleic acids. A single molecule that contains pairing of complementary nucleic acids within its structure is said to be

"self-hybridized."

The term " $T_m$ " refers to the "melting temperature" of a nucleic acid. The melting temperature is the temperature at which a population of double-stranded nucleic acid molecules becomes half dissociated into single strands. The equation for calculating the  $T_m$  of nucleic acids is well known in the art. As indicated by standard references, a simple estimate of the  $T_m$  value may be calculated by the equation:  $T_m = 81.5 + 0.41(\% G + C)$ , when a nucleic acid is in aqueous solution at 1 M NaCl (See e.g., Anderson and Young, Quantitative Filter Hybridization, in *Nucleic Acid Hybridization* [1985]). Other references include more sophisticated computations that take structural as well as sequence characteristics into account for the calculation of  $T_m$ .

The term "stringency" refers to the conditions of temperature, ionic strength, and the presence of other compounds such as organic solvents, under which nucleic acid hybridizations are conducted. With "high stringency" conditions, nucleic acid base pairing will occur only between nucleic acid fragments that have a high frequency of complementary base sequences. Thus, conditions of "low" stringency are often required with nucleic acids that are derived from organisms that are genetically diverse, as the frequency of complementary sequences is usually less.

"Low stringency conditions" when used in reference to nucleic acid hybridization comprise conditions equivalent to binding or hybridization at 42 °C in a solution consisting of 5X SSPE (43.8 g/l NaCl, 6.9 g/l  $\text{NaH}_2\text{PO}_4(\text{H}_2\text{O})$  and 1.85 g/l EDTA, pH adjusted to 7.4 with NaOH), 0.1% SDS, 5X Denhardt's reagent [50X Denhardt's contains per 500 ml: 5 g Ficoll (Type 400, Pharmacia), 5 g BSA (Fraction V; Sigma)] and 100 µg/ml denatured salmon sperm DNA followed by washing in a solution comprising 5X SSPE, 0.1% SDS at 42 °C when a probe of about 500 nucleotides in length is employed.

"Medium stringency conditions" when used in reference to nucleic acid hybridization comprise conditions equivalent to binding or hybridization at 42 °C in a solution consisting of 5X SSPE (43.8 g/l NaCl, 6.9 g/l  $\text{NaH}_2\text{PO}_4(\text{H}_2\text{O})$  and 1.85 g/l EDTA, pH adjusted to 7.4 with NaOH), 0.5 % SDS, 5X Denhardt's reagent and 100 µg/ml denatured salmon sperm DNA followed by washing in a solution comprising 1.0X SSPE, 1.0 % SDS at 42 °C when a probe of about 500 nucleotides in length is employed.

"High stringency conditions" when used in reference to nucleic acid hybridization comprise conditions equivalent to binding or hybridization at 42 °C in a solution consisting of 5X SSPE (43.8 g/l NaCl, 6.9 g/l  $\text{NaH}_2\text{PO}_4(\text{H}_2\text{O})$  and 1.85 g/l EDTA, pH adjusted to 7.4 with NaOH), 0.5 % SDS, 5X Denhardt's reagent and 100 µg/ml denatured salmon sperm DNA followed by washing in a solution comprising 0.1X SSPE, 1.0 % SDS at 42 °C when a probe of about 500 nucleotides in length is employed.

It is well known that numerous equivalent conditions may be employed to comprise low stringency conditions; factors such as the length and nature (DNA, RNA, base composition) of the probe and nature of the target (DNA, RNA, base composition, present in solution or immobilized, etc.) and the concentration of the salts and other components (e.g., the presence or absence of formamide, dextran sulfate, polyethylene glycol) are considered and the hybridization solution may

be varied to generate conditions of low stringency hybridization different from, but equivalent to, the above listed conditions. In addition, the art knows conditions that promote hybridization under conditions of high stringency (*e.g.*, increasing the temperature of the hybridization and/or wash steps, the use of formamide in the hybridization solution, etc.).

5        Additionally, the term "equivalent," when made in reference to a hybridization condition as it relates to a hybridization condition of interest, means that the hybridization condition and the hybridization condition of interest result in hybridization of nucleic acid sequences which have the same range of percent (%) homology. For example, if a hybridization condition of interest results in hybridization of a first nucleic acid sequence with other nucleic acid sequences that have from 50 %  
10       to 70 % homology to the first nucleic acid sequence, then another hybridization condition is said to be equivalent to the hybridization condition of interest if this other hybridization condition also results in hybridization of the first nucleic acid sequence with the other nucleic acid sequences that have from 50 % to 70 % homology to the first nucleic acid sequence.

      When used in reference to nucleic acid hybridization the art knows well that numerous  
15       equivalent conditions may be employed to comprise either low or high stringency conditions; factors such as the length and nature (DNA, RNA, base composition) of the probe and nature of the target (DNA, RNA, base composition, present in solution or immobilized, etc.) and the concentration of the salts and other components (*e.g.*, the presence or absence of formamide, dextran sulfate, polyethylene glycol) are considered and the hybridization solution may be varied to generate conditions of either  
20       low or high stringency hybridization different from, but equivalent to, the above-listed conditions.

      The term "wild-type" when made in reference to a gene refers to a gene that has the characteristics of a gene isolated from a naturally occurring source. The term "wild-type" when made in reference to a gene product refers to a gene product that has the characteristics of a gene product isolated from a naturally occurring source. The term "naturally-occurring" as applied to an  
25       object refers to the fact that an object can be found in nature. For example, a polypeptide or polynucleotide sequence that is present in an organism (including viruses) that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory is naturally-occurring. A wild-type gene is frequently that gene which is most frequently observed in a population and is thus arbitrarily designated the "normal" or "wild-type" form of the gene. In  
30       contrast, the term "modified" or "mutant" when made in reference to a gene or to a gene product refers, respectively, to a gene or to a gene product which displays modifications in sequence and/or functional properties (*i.e.*, altered characteristics) when compared to the wild-type gene or gene product. It is noted that naturally-occurring mutants can be isolated; these are identified by the fact that they have altered characteristics when compared to the wild-type gene or gene product.

35       Thus, the terms "variant" and "mutant" when used in reference to a nucleotide sequence refer to an nucleic acid sequence that differs by one or more nucleotides from another, usually related nucleotide acid sequence. A "variation" is a difference between two different nucleotide sequences; typically, one sequence is a reference sequence.

      The term "polymorphic locus" refers to a genetic locus present in a population that shows

variation between members of the population (*i.e.*, the most common allele has a frequency of less than 0.95). Thus, "polymorphism" refers to the existence of a character in two or more variant forms in a population. A "single nucleotide polymorphism" (or SNP) refers a genetic locus of a single base which may be occupied by one of at least two different nucleotides. In contrast, a "monomorphic locus" refers to a genetic locus at which little or no variations are seen between members of the population (generally taken to be a locus at which the most common allele exceeds a frequency of 0.95 in the gene pool of the population).

A "frameshift mutation" refers to a mutation in a nucleotide sequence, usually resulting from insertion or deletion of a single nucleotide (or two or four nucleotides) which results in a change in the correct reading frame of a structural DNA sequence encoding a protein. The altered reading frame usually results in the translated amino-acid sequence being changed or truncated.

A "splice mutation" refers to any mutation that affects gene expression by affecting correct RNA splicing. Splicing mutation may be due to mutations at intron-exon boundaries which alter splice sites.

The term "detection assay" refers to an assay for detecting the presence or absence of a sequence or a variant nucleic acid sequence (*e.g.*, mutation or polymorphism in a given allele of a particular gene, as *e.g.*, *GnTIII* gene, SEQ ID NO: 1, Figure 4A), or for detecting the presence or absence of a particular protein (*e.g.*, *GnTIII*, SEQ ID NO: 2, Figure 4B) or the structure or activity or effect of a particular protein (*e.g.*, *GnTIII* activity), for detecting glycosylation moieties on a particular protein (*e.g.*, N-linked glycans) or for detecting the presence or absence of a variant of a particular protein.

The term "antisense" refers to a deoxyribonucleotide sequence whose sequence of deoxyribonucleotide residues is in reverse 5' to 3' orientation in relation to the sequence of deoxyribonucleotide residues in a sense strand of a DNA duplex. A "sense strand" of a DNA duplex refers to a strand in a DNA duplex which is transcribed by a cell in its natural state into a "sense mRNA." Thus an "antisense" sequence is a sequence having the same sequence as the non-coding strand in a DNA duplex. The term "antisense RNA" refers to a RNA transcript that is complementary to all or part of a target primary transcript or mRNA and that blocks the expression of a target gene by interfering with the processing, transport and/or translation of its primary transcript or mRNA. The complementarity of an antisense RNA may be with any part of the specific gene transcript, *i.e.*, at the 5' non-coding sequence, 3' non-coding sequence, introns, or the coding sequence. In addition, as used herein, antisense RNA may contain regions of ribozyme sequences that increase the efficacy of antisense RNA to block gene expression. "Ribozyme" refers to a catalytic RNA and includes sequence-specific endoribonucleases. "Antisense inhibition" refers to the production of antisense RNA transcripts capable of preventing the expression of the target protein.

"Amplification" is a special case of nucleic acid replication involving template specificity. It is to be contrasted with non-specific template replication (*i.e.*, replication that is template-dependent but not dependent on a specific template). Template specificity is here distinguished from fidelity of

replication (*i.e.*, synthesis of the proper polynucleotide sequence) and nucleotide (ribo- or deoxyribo-) specificity. Template specificity is frequently described in terms of "target" specificity. Target sequences are "targets" in the sense that they are sought to be sorted out from other nucleic acid. Amplification techniques have been designed primarily for this sorting out.

- 5       Template specificity is achieved in most amplification techniques by the choice of enzyme. Amplification enzymes are enzymes that, under conditions they are used, will process only specific sequences of nucleic acid in a heterogeneous mixture of nucleic acid. For example, in the case of Q $\beta$  replicase, MDV-1 RNA is the specific template for the replicase (Kacian *et al.*, Proc. Natl. Acad. Sci. USA, 69:3038, 1972). Other nucleic acid will not be replicated by this amplification enzyme.
- 10       Similarly, in the case of T7 RNA polymerase, this amplification enzyme has a stringent specificity for its own promoters (Chamberlain *et al.*, Nature, 228:227, 1970). In the case of T4 DNA ligase, the enzyme will not ligate the two oligonucleotides or polynucleotides, where there is a mismatch between the oligonucleotide or polynucleotide substrate and the template at the ligation junction (Wu and Wallace, Genomics, 4:560, 1989). Finally, *Taq* and *Pfu* polymerases, by virtue of their ability to
- 15       function at high temperature, are found to display high specificity for the sequences bounded and thus defined by the primers; the high temperature results in thermodynamic conditions that favor primer hybridization with the target sequences and not hybridization with non-target sequences (H.A. Erlich (ed.), *PCR Technology*, Stockton Press, 1989).

- 20       The term "amplifiable nucleic acid" refers to nucleic acids that may be amplified by any amplification method. It is contemplated that "amplifiable nucleic acid" will usually comprise "sample template."

- 25       The term "sample template" refers to nucleic acid originating from a sample that is analyzed for the presence of "target" (defined below). In contrast, "background template" is used in reference to nucleic acid other than sample template that may or may not be present in a sample. Background template is most often inadvertent. It may be the result of carryover, or it may be due to the presence of nucleic acid contaminants sought to be purified away from the sample. For example, nucleic acids from organisms other than those to be detected may be present as background in a test sample.

- 30       The term "primer" refers to an oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product which is complementary to a nucleic acid strand is induced, (*i.e.*, in the presence of nucleotides and an inducing agent such as DNA polymerase and at a suitable temperature and pH). The primer is preferably single stranded for maximum efficiency in amplification, but may alternatively be double stranded. If double stranded, the primer is first treated to separate its strands before being used to
- 35       prepare extension products. Preferably, the primer is an oligodeoxyribonucleotide. The primer must be sufficiently long to prime the synthesis of extension products in the presence of the inducing agent. The exact lengths of the primers will depend on many factors, including temperature, source of primer and the use of the method.

      The term "probe" refers to an oligonucleotide (*i.e.*, a sequence of nucleotides), whether



occurring naturally as in a purified restriction digest or produced synthetically, recombinantly or by PCR amplification, that is capable of hybridizing to another oligonucleotide of interest. A probe may be single-stranded or double-stranded. Probes are useful in the detection, identification and isolation of particular gene sequences. It is contemplated that any probe used in the present invention will be labeled with any "reporter molecule," so that is detectable in any detection system, including, but not limited to enzyme (*e.g.*, ELISA, as well as enzyme-based histochemical assays), fluorescent, radioactive, and luminescent systems. It is not intended that the present invention be limited to any particular detection system or label.

The term "target," when used in reference to the polymerase chain reaction, refers to the region of nucleic acid bounded by the primers used for polymerase chain reaction. Thus, the "target" is sought to be sorted out from other nucleic acid sequences. A "segment" is defined as a region of nucleic acid within the target sequence.

The term "polymerase chain reaction" ("PCR") refers to the method of K.B. Mullis U.S. Patent Nos. 4,683,195, 4,683,202, and 4,965,188, that describe a method for increasing the concentration of a segment of a target sequence in a mixture of genomic DNA without cloning or purification. This process for amplifying the target sequence consists of introducing a large excess of two oligonucleotide primers to the DNA mixture containing the desired target sequence, followed by a precise sequence of thermal cycling in the presence of a DNA polymerase. The two primers are complementary to their respective strands of the double stranded target sequence. To effect amplification, the mixture is denatured and the primers then annealed to their complementary sequences within the target molecule. Following annealing, the primers are extended with a polymerase so as to form a new pair of complementary strands. The steps of denaturation, primer annealing, and polymerase extension can be repeated many times (*i.e.*, denaturation, annealing and extension constitute one "cycle"; there can be numerous "cycles") to obtain a high concentration of an amplified segment of the desired target sequence. The length of the amplified segment of the desired target sequence is determined by the relative positions of the primers with respect to each other, and therefore, this length is a controllable parameter. By virtue of the repeating aspect of the process, the method is referred to as the "polymerase chain reaction" (hereinafter "PCR"). Because the desired amplified segments of the target sequence become the predominant sequences (in terms of concentration) in the mixture, they are said to be "PCR amplified."

With PCR, it is possible to amplify a single copy of a specific target sequence in genomic DNA to a level detectable by several different methodologies (*e.g.*, hybridization with a labeled probe; incorporation of biotinylated primers followed by avidin-enzyme conjugate detection; incorporation of <sup>32</sup>P-labeled deoxynucleotide triphosphates, such as dCTP or dATP, into the amplified segment). In addition to genomic DNA, any oligonucleotide or polynucleotide sequence can be amplified with the appropriate set of primer molecules. In particular, the amplified segments created by the PCR process itself are, themselves, efficient templates for subsequent PCR amplifications.

The terms "PCR product," "PCR fragment," and "amplification product" refer to the resultant

mixture of compounds after two or more cycles of the PCR steps of denaturation, annealing and extension are complete. These terms encompass the case where there has been amplification of one or more segments of one or more target sequences.

5 The term "amplification reagents" refers to those reagents (deoxyribonucleotide triphosphates, buffer, etc.), needed for amplification except for primers, nucleic acid template, and the amplification enzyme. Typically, amplification reagents along with other reaction components are placed and contained in a reaction vessel (test tube, microwell, etc.).

10 The term "reverse-transcriptase" or "RT-PCR" refers to a type of PCR where the starting material is mRNA. The starting mRNA is enzymatically converted to complementary DNA or "cDNA" using a reverse transcriptase enzyme. The cDNA is then used as a "template" for a "PCR" reaction

15 The term "gene expression" refers to the process of converting genetic information encoded in a gene into RNA (*e.g.*, mRNA, rRNA, tRNA, or snRNA) through "transcription" of the gene (*i.e.*, via the enzymatic action of an RNA polymerase), and into protein, through "translation" of mRNA. Gene expression can be regulated at many stages in the process. "Up-regulation" or "activation" refers to regulation that increases the production of gene expression products (*i.e.*, RNA or protein), while "down-regulation" or "repression" refers to regulation that decrease production. Molecules (*e.g.*, transcription factors) that are involved in up-regulation or down-regulation are often called "activators" and "repressors," respectively.

20 The terms "in operable combination," "in operable order" and "operably linked" refer to the linkage of nucleic acid sequences in such a manner that a nucleic acid molecule capable of directing the transcription of a given gene and/or the synthesis of a desired protein molecule is produced. The term also refers to the linkage of amino acid sequences in such a manner so that a functional protein is produced.

25 The term "regulatory element" refers to a genetic element which controls some aspect of the expression of nucleic acid sequences. For example, a promoter is a regulatory element which facilitates the initiation of transcription of an operably linked coding region. Other regulatory elements are splicing signals, polyadenylation signals, termination signals, *etc.*

30 Transcriptional control signals in eukaryotes comprise "promoter" and "enhancer" elements. Promoters and enhancers consist of short arrays of DNA sequences that interact specifically with cellular proteins involved in transcription (Maniatis, *et al.*, Science 236:1237, 1987). Promoter and enhancer elements have been isolated from a variety of eukaryotic sources including genes in yeast, insect, mammalian and plant cells. Promoter and enhancer elements have also been isolated from viruses and analogous control elements, such as promoters, are also found in prokaryotes. The selection of a particular promoter and enhancer depends on the cell type used to express the protein of interest. Some eukaryotic promoters and enhancers have a broad host range while others are functional in a limited subset of cell types (*for review, see Voss, et al.*, Trends Biochem. Sci., 11:287, 1986; and Maniatis, *et al.*, *supra* 1987).

The terms "promoter element," "promoter" or "promoter sequence" refer to a DNA sequence

that is located at the 5' end (*i.e.* precedes) of the coding region of a DNA polymer. The location of most promoters known in nature precedes the transcribed region. The promoter functions as a switch, activating the expression of a gene. If the gene is activated, it is said to be transcribed, or participating in transcription. Transcription involves the synthesis of mRNA from the gene. The promoter, therefore, serves as a transcriptional regulatory element and also provides a site for initiation of transcription of the gene into mRNA.

Promoters may be tissue specific or cell specific. The term "tissue specific" as it applies to a promoter refers to a promoter that is capable of directing selective expression of a nucleotide sequence of interest to a specific type of tissue (*e.g.*, petals) in the relative absence of expression of the same nucleotide sequence of interest in a different type of tissue (*e.g.*, roots). Tissue specificity of a promoter may be evaluated by, for example, operably linking a reporter gene to the promoter sequence to generate a reporter construct, introducing the reporter construct into the genome of a plant such that the reporter construct is integrated into every tissue of the resulting transgenic plant, and detecting the expression of the reporter gene (*e.g.*, detecting mRNA, protein, or the activity of a protein encoded by the reporter gene) in different tissues of the transgenic plant. The detection of a greater level of expression of the reporter gene in one or more tissues relative to the level of expression of the reporter gene in other tissues shows that the promoter is specific for the tissues in which greater levels of expression are detected. The term "cell type specific" as applied to a promoter refers to a promoter which is capable of directing selective expression of a nucleotide sequence of interest in a specific type of cell in the relative absence of expression of the same nucleotide sequence of interest in a different type of cell within the same tissue. The term "cell type specific" when applied to a promoter also means a promoter capable of promoting selective expression of a nucleotide sequence of interest in a region within a single tissue. Cell type specificity of a promoter may be assessed using methods well known in the art, *e.g.*, immunohistochemical staining. Briefly, tissue sections are embedded in paraffin, and paraffin sections are reacted with a primary antibody which is specific for the polypeptide product encoded by the nucleotide sequence of interest whose expression is controlled by the promoter. A labeled (*e.g.*, peroxidase conjugated) secondary antibody which is specific for the primary antibody is allowed to bind to the sectioned tissue and specific binding detected (*e.g.*, with avidin/biotin) by microscopy.

Promoters may be constitutive or regulatable. The term "constitutive" when made in reference to a promoter means that the promoter is capable of directing transcription of an operably linked nucleic acid sequence in the absence of a stimulus (*e.g.*, heat shock, chemicals, light, *etc.*). Typically, constitutive promoters are capable of directing expression of a transgene in substantially any cell and any tissue. In contrast, a "regulatable" promoter is one which is capable of directing a level of transcription of an operably linked nucleic acid sequence in the presence of a stimulus (*e.g.*, heat shock, chemicals, light, *etc.*) which is different from the level of transcription of the operably linked nucleic acid sequence in the absence of the stimulus.

The terms "infecting" and "infection" with a bacterium refer to co-incubation of a target biological sample, (*e.g.*, cell, tissue, *etc.*) with the bacterium under conditions such that nucleic acid

sequences contained within the bacterium are introduced into one or more cells of the target biological sample.

The term "*Agrobacterium*" refers to a soil-borne, Gram-negative, rod-shaped phytopathogenic bacterium which causes crown gall. The term "*Agrobacterium*" includes, but is not limited to, the strains *Agrobacterium tumefaciens*, (which typically causes crown gall in infected plants), and *Agrobacterium rhizogens* (which causes hairy root disease in infected host plants). Infection of a plant cell with *Agrobacterium* generally results in the production of opines (e.g., nopaline, agropine, octopine etc.) by the infected cell. Thus, *Agrobacterium* strains which cause production of nopaline (e.g., strain LBA4301, C58, A208) are referred to as "nopaline-type" *Agrobacteria*; *Agrobacterium* strains which cause production of octopine (e.g., strain LBA4404, Ach5, B6) are referred to as "octopine-type" *Agrobacteria*; and *Agrobacterium* strains which cause production of agropine (e.g., strain EHA105, EHA101, A281) are referred to as "agropine-type" *Agrobacteria*.

The term "regulatory region" refers to a gene's 5' transcribed but untranslated regions, located immediately downstream from the promoter and ending just prior to the translational start of the gene.

The term "promoter region" refers to the region immediately upstream of the coding region of a DNA polymer, and is typically between about 500 bp and 4 kb in length, and is preferably about 1 to 1.5 kb in length.

In contrast, an "inducible" promoter is one which is capable of directing a level of transcription of an operably linked nucleic acid sequence in the presence of a stimulus (e.g., heat shock, chemicals, light, etc.) which is different from the level of transcription of the operably linked nucleic acid sequence in the absence of the stimulus.

The term "regulatory element" refers to a genetic element that controls some aspect of the expression of nucleic acid sequence(s). For example, a promoter is a regulatory element that facilitates the initiation of transcription of an operably linked coding region. Other regulatory elements are splicing signals, polyadenylation signals, termination signals, etc.

The enhancer and/or promoter may be "endogenous" or "exogenous" or "heterologous." An "endogenous" enhancer or promoter is one that is naturally linked with a given gene in the genome. An "exogenous" or "heterologous" enhancer or promoter is one that is placed in juxtaposition to a gene by means of genetic manipulation (i.e., molecular biological techniques) such that transcription of the gene is directed by the linked enhancer or promoter. For example, an endogenous promoter in operable combination with a first gene can be isolated, removed, and placed in operable combination with a second gene, thereby making it a "heterologous promoter" in operable combination with the second gene. A variety of such combinations are contemplated (e.g., the first and second genes can be from the same species, or from different species).

The term "naturally linked" or "naturally located" when used in reference to the relative positions of nucleic acid sequences means that the nucleic acid sequences exist in nature in the relative positions.

The presence of "splicing signals" on an expression vector often results in higher levels of expression of the recombinant transcript in eukaryotic host cells. Splicing signals mediate the removal of introns from the primary RNA transcript and consist of a splice donor and acceptor site (Sambrook, *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory Press, New York [1989] pp. 16.7-16.8). A commonly used splice donor and acceptor site is the splice junction from the 16S RNA of SV40.

Efficient expression of recombinant DNA sequences in eukaryotic cells requires expression of signals directing the efficient termination and polyadenylation of the resulting transcript. Transcription termination signals are generally found downstream of the polyadenylation signal and are a few hundred nucleotides in length. The term "poly(A) site" or "poly(A) sequence" as used herein denotes a DNA sequence which directs both the termination and polyadenylation of the nascent RNA transcript. Efficient polyadenylation of the recombinant transcript is desirable, as transcripts lacking a poly(A) tail are unstable and are rapidly degraded. The poly(A) signal utilized in an expression vector may be "heterologous" or "endogenous." An endogenous poly(A) signal is one that is found naturally at the 3' end of the coding region of a given gene in the genome. A heterologous poly(A) signal is one which has been isolated from one gene and positioned 3' to another gene. A commonly used heterologous poly(A) signal is the SV40 poly(A) signal. The SV40 poly(A) signal is contained on a 237 bp *Bam*HI/*Bcl*II restriction fragment and directs both termination and polyadenylation (Sambrook, *supra*, at 16.6-16.7).

The term "vector" refers to any genetic element, such as a plasmid, phage, transposon, cosmid, chromosome, retrovirus, virion, or similar genetic element, which is capable of replication when associated with the proper control elements and which can transfer gene sequences into cells and/or between cells. Thus, this term includes cloning and expression vehicles, as well as viral vectors.

The term "expression vector" as used herein refers to a recombinant DNA molecule containing a desired coding sequence (or coding sequences) - such as the coding sequence(s) for the hybrid enzyme(s) described in more detail below - and appropriate nucleic acid sequences necessary for the expression of the operably linked coding sequence in a particular host cell or organism. Nucleic acid sequences necessary for expression in prokaryotes usually include a promoter, an operator (optional), and a ribosome binding site, often along with other sequences. Eukaryotic cells are known to utilize promoters, enhancers, and termination and polyadenylation signals. It is not intended that the present invention be limited to particular expression vectors or expression vectors with particular elements.

The term "transfection" refers to the introduction of foreign DNA into cells. Transfection may be accomplished by a variety of means known to the art including calcium phosphate-DNA co-precipitation, DEAE-dextran-mediated transfection, polybrene-mediated transfection, glass beads, electroporation, microinjection, liposome fusion, lipofection, protoplast fusion, viral infection, biolistics (*i.e.*, particle bombardment) and the like.

The term "stable transfection" or "stably transfected" refers to the introduction and

integration of foreign DNA into the genome of the transfected cell. The term "stable transfectant" refers to a cell that has stably integrated foreign DNA into the genomic DNA.

The term "transient transfection" or "transiently transfected" refers to the introduction of foreign DNA into a cell where the foreign DNA fails to integrate into the genome of the transfected cell. The foreign DNA persists in the nucleus of the transfected cell for several days. During this time the foreign DNA is subject to the regulatory controls that govern the expression of endogenous genes in the chromosomes. The term "transient transfectant" refers to cells that have taken up foreign DNA but have failed to integrate this DNA.

The term "calcium phosphate co-precipitation" refers to a technique for the introduction of nucleic acids into a cell. The uptake of nucleic acids by cells is enhanced when the nucleic acid is presented as a calcium phosphate-nucleic acid co-precipitate. The original technique of Graham and van der Eb (Graham and van der Eb, *Virology*, 52:456, 1973), has been modified by several groups to optimize conditions for particular types of cells. The art is well aware of these numerous modifications.

The terms "bombarding," "bombardment," and "biolistic bombardment" refer to the process of accelerating particles towards a target biological sample (*e.g.*, cell, tissue, *etc.*) to effect wounding of the cell membrane of a cell in the target biological sample and/or entry of the particles into the target biological sample. Methods for biolistic bombardment are known in the art (*e.g.*, U.S. Patent No. 5,584,807, the contents of which are incorporated herein by reference), and are commercially available (*e.g.*, the helium gas-driven microprojectile accelerator (PDS-1000/He, BioRad).

The term "microwounding" when made in reference to plant tissue refers to the introduction of microscopic wounds in that tissue. Microwounding may be achieved by, for example, particle bombardment as described herein.

The term "plant" as used herein refers to a plurality of plant cells which are largely differentiated into a structure that is present at any stage of a plant's development. Such structures include, but are not limited to, a fruit, shoot, stem, leaf, flower petal, *etc.* The term "plant tissue" includes differentiated and undifferentiated tissues of plants including, but not limited to, roots, shoots, leaves, pollen, seeds, tumor tissue and various types of cells in culture (*e.g.*, single cells, protoplasts, embryos, callus, protocorm-like bodies, *etc.*). Plant tissue may be *in planta*, in organ culture, tissue culture, or cell culture. Similarly, "plant cell(s)" may be cells in culture or may be part of a plant.

The term "transgenic" when used in reference to a cell refers to a cell which contains a transgene, or whose genome has been altered by the introduction of a transgene. The term "transgenic" when used in reference to a cell, tissue or to a plant refers to a cell, tissue or plant, respectively, which comprises a transgene, where one or more cells of the tissue contain a transgene (such as a gene encoding the hybrid enzyme(s) of the present invention), or a plant whose genome has been altered by the introduction of a transgene. Transgenic cells, tissues and plants may be produced by several methods including the introduction of a "transgene" comprising nucleic acid (usually DNA) into a target cell or integration of the transgene into a chromosome of a target cell by

way of human intervention, such as by the methods described herein.

The term "transgene" as used herein refers to any nucleic acid sequence which is introduced into the genome of a cell by experimental manipulations. A transgene may be an "endogenous DNA sequence," or a "heterologous DNA sequence" (i.e., "foreign DNA"). The term "endogenous DNA sequence" refers to a nucleotide sequence which is naturally found in the cell into which it is introduced so long as it does not contain some modification (e.g., a point mutation, the presence of a selectable marker gene, or other like modifications) relative to the naturally-occurring sequence. The term "heterologous DNA sequence" refers to a nucleotide sequence which is ligated to, or is manipulated to become ligated to, a nucleic acid sequence to which it is not ligated in nature, or to which it is ligated at a different location in nature. Heterologous DNA is not endogenous to the cell into which it is introduced, but has been obtained from another cell. Heterologous DNA also includes an endogenous DNA sequence which contains some modification. Generally, although not necessarily, heterologous DNA encodes RNA and proteins that are not normally produced by the cell into which it is expressed. Examples of heterologous DNA include reporter genes, transcriptional and translational regulatory sequences, selectable marker proteins (e.g., proteins which confer drug resistance), or other similar elements.

The term "foreign gene" refers to any nucleic acid (e.g., gene sequence) which is introduced into the genome of a cell by experimental manipulations and may include gene sequences found in that cell so long as the introduced gene contains some modification (e.g., a point mutation, the presence of a selectable marker gene, or other like modifications) relative to the naturally-occurring gene.

The term "transformation" as used herein refers to the introduction of a transgene into a cell. Transformation of a cell may be stable or transient. The term "transient transformation" or "transiently transformed" refers to the introduction of one or more transgenes into a cell in the absence of integration of the transgene into the host cell's genome. Transient transformation may be detected by, for example, enzyme-linked immunosorbent assay (ELISA) which detects the presence of a polypeptide encoded by one or more of the transgenes. Alternatively, transient transformation may be detected by detecting the activity of the protein (e.g.,  $\beta$ -glucuronidase) encoded by the transgene (e.g., the *uid A* gene) as demonstrated herein (e.g., histochemical assay of GUS enzyme activity by staining with X-gluc which gives a blue precipitate in the presence of the GUS enzyme; and a chemiluminescent assay of GUS enzyme activity using the GUS-Light kit (Tropix)). The term "transient transformant" refers to a cell which has transiently incorporated one or more transgenes. In contrast, the term "stable transformation" or "stably transformed" refers to the introduction and integration of one or more transgenes into the genome of a cell. Stable transformation of a cell may be detected by Southern blot hybridization of genomic DNA of the cell with nucleic acid sequences which are capable of binding to one or more of the transgenes. Alternatively, stable transformation of a cell may also be detected by the polymerase chain reaction of genomic DNA of the cell to amplify transgene sequences. The term "stable transformant" refers to a cell which has stably integrated one or more transgenes into the genomic DNA. Thus, a stable transformant is

distinguished from a transient transformant in that, whereas genomic DNA from the stable transformant contains one or more transgenes, genomic DNA from the transient transformant does not contain a transgene.

5 The term "host cell" refers to any cell capable of replicating and/or transcribing and/or translating a heterologous gene. Thus, a "host cell" refers to any eukaryotic or prokaryotic cell (*e.g.*, bacterial cells such as *E. coli*, yeast cells, mammalian cells, avian cells, amphibian cells, plant cells, fish cells, and insect cells), whether located *in vitro* or *in vivo*. For example, host cells may be located in a transgenic animal.

10 The terms "transformants" or "transformed cells" include the primary transformed cell and cultures derived from that cell without regard to the number of transfers. All progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Mutant progeny that have the same functionality as screened for in the originally transformed cell are included in the definition of transformants.

15 The term "selectable marker" refers to a gene which encodes an enzyme having an activity that confers resistance to an antibiotic or drug upon the cell in which the selectable marker is expressed, or which confers expression of a trait which can be detected (*e.g.*, luminescence or fluorescence). Selectable markers may be "positive" or "negative." Examples of positive selectable markers include the neomycin phosphotransferase (NPTII) gene which confers resistance to G418 and to kanamycin, and the bacterial hygromycin phosphotransferase gene (*hyg*), which confers resistance  
20 to the antibiotic hygromycin. Negative selectable markers encode an enzymatic activity whose expression is cytotoxic to the cell when grown in an appropriate selective medium. For example, the HSV-*tk* gene is commonly used as a negative selectable marker. Expression of the HSV-*tk* gene in cells grown in the presence of gancyclovir or acyclovir is cytotoxic; thus, growth of cells in selective medium containing gancyclovir or acyclovir selects against cells capable of expressing a functional  
25 HSV TK enzyme.

The term "reporter gene" refers to a gene encoding a protein that may be assayed. Examples of reporter genes include, but are not limited to, luciferase (*See, e.g., deWet et al., Mol. Cell. Biol.* 7:725, 1987 and U.S. Pat Nos., 6,074,859; 5,976,796; 5,674,713; and 5,618,682; all of which are incorporated herein by reference), green fluorescent protein (*e.g., GenBank Accession Number*  
30 U43284; a number of GFP variants are commercially available from CLONTECH Laboratories, Palo Alto, CA), chloramphenicol acetyltransferase,  $\beta$ -galactosidase, alkaline phosphatase, and horse radish peroxidase.

The term "overexpression" refers to the production of a gene product in transgenic organisms that exceeds levels of production in normal or non-transformed organisms. The term  
35 "cosuppression" refers to the expression of a foreign gene which has substantial homology to an endogenous gene resulting in the suppression of expression of both the foreign and the endogenous gene. As used herein, the term "altered levels" refers to the production of gene product(s) in transgenic organisms in amounts or proportions that differ from that of normal or non-transformed organisms.



The terms "Southern blot analysis" and "Southern blot" and "Southern" refer to the analysis of DNA on agarose or acrylamide gels in which DNA is separated or fragmented according to size followed by transfer of the DNA from the gel to a solid support, such as nitrocellulose or a nylon membrane. The immobilized DNA is then exposed to a labeled probe to detect DNA species complementary to the probe used. The DNA may be cleaved with restriction enzymes prior to electrophoresis. Following electrophoresis, the DNA may be partially depurinated and denatured prior to or during transfer to the solid support. Southern blots are a standard tool of molecular biologists (J. Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, NY, pp 9.31-9.58, 1989).

The term "Northern blot analysis" and "Northern blot" and "Northern" refer to the analysis of RNA by electrophoresis of RNA on agarose gels to fractionate the RNA according to size followed by transfer of the RNA from the gel to a solid support, such as nitrocellulose or a nylon membrane. The immobilized RNA is then probed with a labeled probe to detect RNA species complementary to the probe used. Northern blots are a standard tool of molecular biologists (J. Sambrook, *et al.*, *supra*, pp 7.39-7.52, 1989).

The terms "Western blot analysis" and "Western blot" and "Western" refers to the analysis of protein(s) (or polypeptides) immobilized onto a support such as nitrocellulose or a membrane. A mixture comprising at least one protein is first separated on an acrylamide gel, and the separated proteins are then transferred from the gel to a solid support, such as nitrocellulose or a nylon membrane. The immobilized proteins are exposed to at least one antibody with reactivity against at least one antigen of interest. The bound antibodies may be detected by various methods, including the use of radiolabeled antibodies.

The term "antigenic determinant" refers to that portion of an antigen that makes contact with a particular antibody (*i.e.*, an epitope). When a protein or fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies that bind specifically to a given region or three-dimensional structure on the protein; these regions or structures are referred to as antigenic determinants. An antigenic determinant may compete with the intact antigen (*i.e.*, the "immunogen" used to elicit the immune response) for binding to an antibody.

The term "isolated" when used in relation to a nucleic acid, as in "an isolated nucleic acid sequence" refers to a nucleic acid sequence that is identified and separated from one or more other components (*e.g.*, separated from a cell containing the nucleic acid, or separated from at least one contaminant nucleic acid, or separated from one or more proteins, one or more lipids) with which it is ordinarily associated in its natural source. Isolated nucleic acid is nucleic acid present in a form or setting that is different from that in which it is found in nature. In contrast, non-isolated nucleic acids are nucleic acids such as DNA and RNA which are found in the state they exist in nature. For example, a given DNA sequence (*e.g.*, a gene) is found on the host cell chromosome in proximity to neighboring genes; RNA sequences, such as a specific mRNA sequence encoding a specific protein, are found in the cell as a mixture with numerous other mRNAs which encode a multitude of proteins. However, an isolated nucleic acid sequence comprising, for example, SEQ ID NO:1 includes, by way

of example, such nucleic acid sequences in cells which ordinarily contain, for example, SEQ ID NO:1 where the nucleic acid sequence is in a chromosomal or extrachromosomal location different from that of natural cells, or is otherwise flanked by a different nucleic acid sequence than that found in nature. The isolated nucleic acid sequence may be present in single-stranded or double-stranded form. When an isolated nucleic acid sequence is to be utilized to express a protein, the nucleic acid sequence will contain at a minimum at least a portion of the sense or coding strand (*i.e.*, the nucleic acid sequence may be single-stranded). Alternatively, it may contain both the sense and anti-sense strands (*i.e.*, the nucleic acid sequence may be double-stranded).

The term "purified" refers to molecules, either nucleic or amino acid sequences, that are removed from their natural environment (or components of their natural environment), isolated or separated. An "isolated nucleic acid sequence" may therefore be a purified nucleic acid sequence. "Substantially purified" molecules are at least 60 % free, preferably at least 75 % free, and more preferably at least 90 % free from other components with which they are naturally associated. As used herein, the term "purified" or "to purify" also refer to the removal of contaminants from a sample. The removal of contaminating proteins results in an increase in the percent of polypeptide of interest in the sample. In another example, recombinant polypeptides are expressed in plant, bacterial, yeast, or mammalian host cells and the polypeptides are purified by the removal of host cell proteins; the percent of recombinant polypeptides is thereby increased in the sample. The present invention contemplates both purified (including substantially purified) and unpurified hybrid enzyme(s).

The term "composition comprising" a given polynucleotide sequence or polypeptide refers broadly to any composition containing the given polynucleotide sequence or polypeptide. The composition may comprise an aqueous solution. Compositions comprising polynucleotide sequences encoding GnTIII or fragments thereof may be employed as hybridization probes. In this case, the GnTIII encoding polynucleotide sequences are typically employed in an aqueous solution containing salts (*e.g.*, NaCl), detergents (*e.g.*, SDS), and other components (*e.g.*, Denhardt's solution, dry milk, salmon sperm DNA, etc.).

The term "test compound" refers to any chemical entity, pharmaceutical, drug, and the like that can be used to treat or prevent a disease, illness, sickness, or disorder of bodily function, or otherwise alter the physiological or cellular status of a sample. Test compounds comprise both known and potential therapeutic compounds. A test compound can be determined to be therapeutic by screening using the screening methods of the present invention. A "known therapeutic compound" refers to a therapeutic compound that has been shown (*e.g.*, through animal trials or prior experience with administration to humans) to be effective in such treatment or prevention.

As used herein, the term "response," when used in reference to an assay, refers to the generation of a detectable signal (*e.g.*, accumulation of reporter protein, increase in ion concentration, accumulation of a detectable chemical product).

The term "sample" is used in its broadest sense. In one sense it can refer to a animal cell or tissue. In another sense, it is meant to include a specimen or culture obtained from any source, as

well as biological and environmental samples. Biological samples may be obtained from plants or animals (including humans) and encompass fluids, solids, tissues, and gases. Environmental samples include environmental material such as surface matter, soil, water, and industrial samples. These examples are not to be construed as limiting the sample types applicable to the present invention.

5       The term "fusion protein" refers to a protein wherein at least one part or portion is from a first protein and another part or portion is from a second protein. The term "hybrid enzyme" refers to a fusion protein which is a functional enzyme, wherein at least one part or portion is from a first species and another part or portion is from a second species. Preferred hybrid enzymes of the present invention are functional glycosyltransferases (or portions thereof) wherein at least one part or  
10       portion is from a plant and another part or portion is from a mammal (such as human).

      The term "introduction into a cell" in the context of nucleic acid (*e.g.*, vectors) is intended to include what the art calls "transformation" or "transfection" or "transduction." Transformation of a cell may be stable or transient – and the present invention contemplates introduction of vectors under conditions where, on the one hand, there is stable expression, and on the other hand, where there is  
15       only transient expression. The term "transient transformation" or "transiently transformed" refers to the introduction of one or more transgenes into a cell in the absence of integration of the transgene into the host cell's genome. Transient transformation may be detected by, for example, enzyme-linked immunosorbent assay (ELISA) which detects the presence of a polypeptide encoded by one or more of the transgenes. Alternatively, transient transformation may be detected by detecting the  
20       activity of the protein (*e.g.*, antigen binding of an antibody) encoded by the transgene (*e.g.*, the antibody gene). The term "transient transformant" refers to a cell which has transiently incorporated one or more transgenes. In contrast, the term "stable transformation" or "stably transformed" refers to the introduction and integration of one or more transgenes into the genome of a cell. Stable transformation of a cell may be detected by Southern blot hybridization of genomic DNA of the cell  
25       with nucleic acid sequences which are capable of binding to one or more of the transgenes. Alternatively, stable transformation of a cell may also be detected by the polymerase chain reaction (PCR) of genomic DNA of the cell to amplify transgene sequences. The term "stable transformant" refers to a cell which has stably integrated one or more transgenes into the genomic DNA. Thus, a stable transformant is distinguished from a transient transformant in that, whereas genomic DNA  
30       from the stable transformant contains one or more transgenes, genomic DNA from the transient transformant does not contain a transgene.

      "Bisected oligosaccharide" shall be defined as an oligosaccharide comprising, *e.g.*, two mannose groups and another saccharide moiety attached to a mannose residue of the oligosaccharide. Examples of bisected oligonucleotides are given in Table 1.

35

## DETAILED DESCRIPTION OF THE INVENTION

      The GnTIII (for example, SEQ ID NO: 1, Figure 4A) expressed in the plant host cell of the present invention is a mammalian GnTIII. In a specific embodiment, the GnTIII is a human GnTIII (for example, SEQ ID NO: 2, Figure 4B). The GnTIII may also in a specific embodiment have 80 %

identity with the amino acid sequence of a mammalian GnTIII, more preferably at least about 90 %, even more preferably at least about 95 %, and most preferably at least about 97 % (hereinafter "homologous polypeptides"), which qualitatively retain the activity of said mammalian GnTIII. A polypeptide that has an amino acid sequence at least, for example, 95 % "identical" to a query amino acid sequence is identical to the query sequence except that the subject polypeptide sequence may include on average, up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95 % identical to a query amino acid sequence, up to 5 % of the amino acid residues in the subject sequence may be inserted, deleted or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the referenced sequence or in one or more contiguous groups within the reference sequence.

A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag, *et al.* (*Com. App. Biosci.* 6:237-245, 1990). In a sequence alignment, the query and subject sequence are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score= 1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C- terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C- terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

The GnTIII expressed in the plant host system of the present invention is encoded by a nucleic acid sequence that has at least 80 % identity with the nucleic acid sequence encoding an

amino acid sequence of a mammalian GnTIII, more preferably at least about 90 %, even more preferably at least about 95 %, and most preferably at least about 97 % (hereinafter "homologous polypeptides"), which qualitatively retain the activity of said mammalian GnTIII. The nucleic acid sequence may be an RNA or DNA sequence.

5 A polynucleotide having 95 % "identity" to a reference nucleotide sequence of the present invention, is identical to the reference sequence except that the polynucleotide sequence may include, on average, up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95 % identical to a reference nucleotide sequence, up to 5 % of the nucleotides in the reference  
10 sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5 % of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence, the ORF (open reading frame), or any fragment specified as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least  
15 90 %, 95 %, 96 %, 97 %, 98 % or 99 % identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag, *et al.*, (*Comp. App. Biosci.*, 6:237-  
20 245, 1990). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's (uridine) to T's (thymine). The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch  
Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5,  
25 Gap Size Penalty=0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

The invention also encompasses polynucleotides that hybridize to the nucleic acid sequence encoding said mammalian GnTIII. A polynucleotide "hybridizes" to another polynucleotide, when a single-stranded form of the polynucleotide can anneal to the other polynucleotide under the  
30 appropriate conditions of temperature and solution ionic strength (see, Sambrook, *et al.*, *supra*). The conditions of temperature and ionic strength determine the "stringency" of the hybridization. For preliminary screening for homologous nucleic acids, low stringency hybridization conditions, corresponding to a temperature of 42 °C, can be used, *e.g.*, 5X SSC, 0.1 % SDS, 0.25 % milk, and no formamide; or 40 % formamide, 5X SSC, 0.5 % SDS). Moderate stringency hybridization  
35 conditions correspond to a higher temperature of 55 °C, *e.g.*, 40 % formamide, with 5X or 6X SSC. High stringency hybridization conditions correspond to the highest temperature of 65 °C, *e.g.*, 50 % formamide, 5X or 6X SSC. Hybridization requires that the two nucleic acids contain complementary sequences, although depending on the stringency of the hybridization, mismatches between bases are possible. The appropriate stringency for hybridizing nucleic acids depends on the length of the

nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of similarity or homology between two nucleotide sequences, the greater the value of  $T_m$  (melting temperature) for hybrids of nucleic acids having those sequences. The relative stability (corresponding to higher  $T_m$ ) of nucleic acid hybridizations decreases in the following order:

5 RNA:RNA, DNA:RNA, DNA:DNA.

### Expression of GnTIII and other Heterologous Proteins in Plant Host Systems

In one embodiment, the nucleic acid encoding the mammalian GnTIII or other heterologous proteins, such as a heterologous glycoprotein or mammalian glycosyltransferase may be inserted into  
10 an appropriate expression vector, *i.e.*, a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence, or in the case of an RNA viral vector, the necessary elements for replication and translation, as well as selectable markers. These include but are not limited to a promoter region, a signal sequence, 5' untranslated sequences, initiation codon depending upon whether or not the structural gene comes equipped with one, and transcription  
15 and translation termination sequences. Methods for obtaining such vectors are known in the art (see WO 01/29242 for review).

Promoter sequences suitable for expression in plants are described in the art, *e.g.*, WO 91/198696. These include non-constitutive promoters or constitutive promoters, such as, the nopaline synthetase and octopine synthetase promoters, cauliflower mosaic virus (CaMV) 19S and  
20 35S promoters and the figwort mosaic virus (FMV) 35 promoter (U.S. Pat. No. 6,051,753). Promoters used may also be tissue specific promoters targeted for example to the endosperm, aleurone layer, embryo, pericarp, stem, leaves, kernels, tubers, roots, etc.

A signal sequence allows processing and translocation of a protein where appropriate. The signal can be derived from plants or could be non-plant signal sequences. The signal peptides direct  
25 the nascent polypeptide to the endoplasmic reticulum, where the polypeptide subsequently undergoes post-translational modification. Signal peptides can routinely be identified by those of skill in the art. They typically have a tripartite structure, with positively charged amino acids at the N-terminal end, followed by a hydrophobic region and then the cleavage site within a region of reduced hydrophobicity.

30 The transcription termination is routinely at the opposite end from the transcription initiation regulatory region. It may be associated with the transcriptional initiation region or from a different gene and may be selected to enhance expression. An example is the NOS terminator from *Agrobacterium* Ti plasmid and the rice  $\alpha$ -amylase terminator. Polyadenylation tails may also be added. Examples include but are not limited to *Agrobacterium* octopine synthetase signal, (Gielen, *et al.*, *EMBO J.* 3:835-846, 1984) or nopaline synthase of the same species (Depicker, *et al.*, *Mol. Appl. Genet.* 1:561-573, 1982).  
35

Enhancers may be included to increase and/or maximize transcription of the heterologous protein. These include, but are not limited to peptide export signal sequence, codon usage, introns, polyadenylation, and transcription termination sites (see, WO 01/29242).

Markers include herbicide tolerance and prokaryote selectable markers. Such markers include resistance toward antibiotics such as ampicillin, tetracycline, kanamycin, and spectinomycin. Specific examples include but are not limited to streptomycin phosphotransferase (*spt*) gene coding for streptomycin resistance, neomycin phosphotransferase (*nptII*) gene encoding kanamycin or geneticin resistance, hygromycin phosphotransferase (*hpt*) gene encoding resistance to hygromycin.

The vectors constructed may be introduced into the plant host system using procedures known in the art (reviewed in WO 01/29242 and WO 01/31045). The vectors may be modified to intermediate plant transformation plasmids that contain a region of homology to an *Agrobacterium tumefaciens* vector, a T-DNA border region from *A. tumefaciens*. Alternatively, the vectors used in the methods of the present invention may be *Agrobacterium* vectors. Methods for introducing the vectors include but are not limited to microinjection, velocity ballistic penetration by small particles with the nucleic acid either within the matrix of small beads or particles, or on the surface and electroporation. The vector may be introduced into a plant cell, tissue or organ. In a specific embodiment, once the presence of a heterologous gene is ascertained, a plant may be regenerated using procedures known in the art.

#### Uses of Mammalian GnTIII

The expression of mammalian GnTIII leads to bisected N-glycans on glycoproteins. Bisected N-glycans are important for biological activity of some mammalian glycoproteins. In particular, bisected monoclonal antibodies have enhanced ADCC (antibody-dependent cellular cytotoxicity). Introduction of bisected structures leads to new or optimized functionalities and increased bioavailability of glycoprotein, e.g., increasing the antennary type increases half-life because of reduced clearance by the kidney. Accordingly, the invention is directed to a plant host system comprising said heterologous glycoprotein having bisecting oligosaccharides, particularly bisecting GlcNAc residues and methods for producing said glycoprotein.

Furthermore, expression of GnTIII in plants leads to drastic increase of terminal GlcNAc's compared to wildtype plants (plant N-glycans contain far less GlcNAc residues compared to mammalian N-glycans). More GlcNAc residues on N-glycans of plant glycoproteins or recombinant glycoprotein produced in plants resembles mammalian N-glycans of glycoproteins. The introduction of bisected GlcNAc in plant N-glycans (and in plant-produced recombinant glycoproteins such as Mabs) due to GnTIII expression in plants seems to prevent the N-glycan from degradation by  $\beta$ -N-acetylhexosaminidases. More GlcNAc residues means more acceptor substrate for  $\beta$ (1,4)-galactosyltransferase (GalT) adding terminal galactose. Co-expression of GnTIII and a functional protein such as a transporter or a (mammalian) enzyme or functional fragment thereof providing N-glycan biosynthesis, such as a galactosyltransferase, such as GAIT, or crossing GnTIII plants with GalT plants and vice versa, leads to increased galactosylation of glycoproteins produced in these plants. Accordingly, the invention is directed to a plant host system comprising said mammalian GnTIII and said functional protein; the plant host system may further comprise a heterologous glycoprotein with increased galactosylation relative to a heterologous glycoprotein produced in a

plant host system not comprising said mammalian GnTIII and said functional protein, methods for providing said plant host systems and methods for producing said glycoprotein.

Generating stably transformed plants which produce tailored glycoproteins with commercial interest can be established by inoculating plant cells or tissues with *Agrobacterium* strains containing a vector which comprises both nucleotide sequences encoding GnTIII, optionally N-glycosylation modifying enzymes and nucleotide sequences encoding commercially interesting heterologous glycoproteins or by the procedures described above such as electroporation, microinjection, velocity ballistic penetration by small particles with the nucleic acid either within the matrix of small beads or particles, or on the surface and electroporation. Alternatively, stably transformed plants which produce tailored glycoproteins with commercial interest can be generated by simultaneous inoculation (cotransformation) of two or more *Agrobacterium* strains each carrying a vector comprising either nucleotide sequences encoding GnTIII, optionally, other N-glycosylation modifying enzymes or nucleotide sequences encoding glycoproteins of commercial interest or direct cotransformation of plant cells or tissues with said vectors. Alternatively, stably transformed plants which produce tailored glycoproteins with commercial interest can be generated by (multiple) crossing(s) of plants with modified N-glycosylation with plants which express nucleotide sequences encoding proteins of commercial interest. In all of these procedures, the vector may also comprise a nucleotide sequence which confers resistance against a selection agent.

In order to obtain satisfactory expression of the proteins involved in N-glycosylation, GnTIII and of the glycoproteins or polypeptides of commercial interest, the nucleotide sequences may be adapted to the specific transcription and translation machinery of the host plant as known to people skilled in the art. For example, silent mutations in the coding regions may be introduced to improve codon usage and specific promoters may be used to drive expression of the said genes in the relevant plant tissues. Promoters which are developmentally regulated or which can be induced at will, may be used to ensure expression at the appropriate time, for example, only after plant tissues have been harvested from the field and brought into controlled conditions. In all these cases, choice of expression cassettes of the glycosylation modifying proteins and of the glycoproteins of commercial interest should be such that they express in the same cells to allow desired post translational modifications to the said glycoprotein.

As described above, in a specific embodiment, a plant that can be used in the method of the present invention is a tobacco plant, or at least a plant related to the genus *Nicotiana*, however, use for the invention of other relatively easy transformable plants, such as *Arabidopsis thaliana* or *Zea mays*, or plants related thereto, is also particularly provided. For the production of recombinant glycoproteins, the use of duckweed offers specific advantages. The plants are in general small and reproduce asexually through vegetative budding. Nevertheless, most duckweed species have all the tissues and organs of much larger plants including roots, stems, flowers, seeds and fronds. Duckweed can be grown cheaply and very fast as a free floating plant on the surface of simple liquid solutions from which they can easily be harvested. They can also be grown on nutrient-rich waste water, producing valuable products while simultaneously cleaning wastewater for reuse. Particularly



relevant for pharmaceutical applications, duckweed can be grown indoors under contained and controlled conditions. Stably transformed Duckweed can for example be regenerated from tissues or cells after (co)-inoculating with *Agrobacterium* strains containing each a (binary) vector which comprises one or more nucleotide sequences of interest encoding N-glycosylation modifying enzymes and/or genes encoding commercially interesting heterologous glycoproteins. The duckweed plant may, for example, comprise the genus *Spirodella*, genus *Wolffia*, genus *Wolffiella*, or the genus *Lemna*, *Lemna minor*, *Lemna miniscula* and *Lemna gibba*. Also mosses such as *Physcomitrella patens* offer advantages in that it can be grown cheaply under contained conditions. In addition the haploid genome of *Physcomitrella patens* is relatively easy to manipulate.

Expression in tomato fruits also offers specific advantages. Tomatoes can be easily grown in greenhouses under contained and controlled conditions and tomato fruit biomass can be harvested continuously throughout the year in enormous quantities. The watery fraction containing the glycoproteins of interest can be readily separated from the rest of the tomato fruit which allows easier purification of the glycoprotein. Expression in storage organs of other crops including but not limited to the kernels of corn, the tubers of potato and the seeds of rape seed or sunflower are also attractive alternatives which provide huge biomass in organs for which harvesting and processing technology is in place. Expression in nectar offers specific advantages with respect to purity and homogeneity of the glycoprotein secreted in the nectar.

Alternatively, a plant comprising a heterologous glycoprotein is crossed with a plant according to the invention comprising GnTIII and optionally at least one functional mammalian protein, e.g., a transporter or an enzyme providing N-glycan biosynthesis that is normally not present in plants, harvesting progeny from said crossing and selecting a desired progeny plant expressing said heterologous glycoprotein and expressing GnTIII and optionally a functional (mammalian) enzyme involved in mammalian-like N-glycan biosynthesis that is normally not present in plants. This process is known as crosspollination. In a preferred embodiment, the invention provides a method according to the invention further comprising selecting a desired progeny plant expressing said recombinant protein comprising bisecting oligosaccharide, particularly galactose residues and/or increased galactosylation. Now that such a plant is provided, the invention also provides use of a transgenic plant to produce a desired glycoprotein or functional fragment thereof, in particular wherein said glycoprotein or functional fragment thereof comprises bisecting oligosaccharide and/or increased galactosylation.

The invention additionally provides a method for obtaining a desired glycoprotein or functional fragment thereof comprising cultivating a plant according to the invention until said plant has reached a harvestable stage, for example when sufficient biomass has grown to allow profitable harvesting, followed by harvesting said plant with established techniques known in the art and fractionating said plant with established techniques known in the art to obtain fractionated plant material and at least partly isolating said glycoprotein from said fractionated plant material. The presence of desired proteins may be screened using methods known in the art, preferably using screening assays where the biologically active site is detected in such a way as to produce a

detectable signal. This signal may be produced directly or indirectly. Examples of such assays include ELISA or a radioimmunoassay.

The introduction of bisected GlcNAc residues due to expression of GnTIII can also be used for the prevention of removal (degradation) of saccharides from N-glycan by "blocking" activity glycosidases, *e.g.*,  $\beta$ -N-acetylhexosaminidases and preventing the addition of other saccharides (driven by "other" subsequent glycosyltransferase genes) to N-linked glycan, *e.g.*, fucosylation, xylosylation. By controlling localization (*e.g.*, by providing other subcellular targeting signals) and/or controlling expression levels (*e.g.*, varying levels in independent transgenic plants or using different promoter) glycoform composition could be modulated. Hence introduction of bisecting GlcNAc residues in glycoproteins in plants including recombinant glycoproteins, inhibits incorporation  $\alpha$ -1,3-fucose by blocking activity  $\alpha$  1,3fucosyltransferase,  $\alpha$ -1,4-fucose by blocking  $\alpha$ -1,4-fucosyltransferase,  $\beta$ -1,2-xylose by blocking  $\beta$ -1,2-xylosyltransferase,  $\beta$ -1,3-galactose by blocking  $\beta$ -1,3-galactosyltransferase and removal/degradation of saccharides added to the N-glycan especially terminal GlcNAc residues by blocking activity of  $\beta$ -N-acetylhexosaminidases and terminal  $\beta$ -1,4-galactose (added by expression of  $\beta$ -1,4-galactosyltransferase as provided by patent application WO 01/31045) by blocking  $\beta$ -1,4galactosidase. Thus in this way, controlled expression of GnTIII and controlled introduction of bisecting GlcNAc residues can be used to steer glycoform composition and/or limit glycoform heterogeneity.

## 20 **Modified GnTIII andGnTIII Hybrid proteins**

The invention is further directed to an isolated hybrid protein comprising a catalytic portion of mammalian GnTIII and a transmembrane portion of a protein, said protein residing in endoplasmic reticulum or Golgi apparatus of a eukaryotic cell. The invention is also directed to a modified mammalian GnTIII, wherein the transmembrane domain is removed but comprising a retention signal such as KDEL for retention of said GnTIII in the ER.

A nucleic acid sequence encoding a hybrid enzyme comprising a transmembrane portion of a first enzyme and a catalytic portion of a second enzyme may be obtained as follows. The sequence encoding the transmembrane portion is removed from the second enzyme, leaving a nucleic acid sequence comprising a nucleic acid sequence encoding the C-terminal portion of the second enzyme, which encompasses the catalytic site. The sequence encoding the transmembrane portion of the first enzyme is isolated or obtained via PCR and ligated to the sequence encoding a sequence comprising the C-terminal portion of the second enzyme.

A nucleic acid sequence encoding a protein, particularly enzymes such as galactosyltransferases, mannosidases and N-acetylglucosamine transferases that are retained in the ER may be obtained by removing the sequence encoding the transmembrane fragment and substituting it for a methionine (initiation of translation) codon and by inserting between the last codon and the stop codon of galactosyltransferase the nucleic acid sequence encoding an ER retention signal such as the sequence encoding KDEL (amino acid residue sequence: lysine-aspartic acid-glutamic acid-leucine) (Rothman, 1987).

Besides controlling expression, relocalization of GnTIII activity may also be controlled by making a fusion of the gene sequence coding for the enzymatic part of GnTIII with a transmembrane domain of other glycosyltransferases or enzymes/proteins residing in the endoplasmic reticulum (ER) or Golgi apparatus membrane, or by adding so-called retention signal such as but not limited to KDEL for retention in the ER. Such relocalization modulates the addition of specific saccharides to the N-linked glycan of glycoproteins including recombinant glycoprotein and the prevention of removal of these.

The exchange of transmembrane domain of GnTIII with that of, for example, GnTI (TmGnTI), mannosidase II (TmManII) xylosyltransferase (TmXyl) or  $\alpha$ -1,3 fucosyltransferase (TmFuc) but not limited to these, enables earlier expression of GnTIII and introduction of bisecting GlcNAc at positions 20 to 22 in Figure 2. This prevents the action of subsequent glycosyltransferases such as xylosyltransferase and fucosyltransferase to act on the substrate leading to glycoforms lacking Xyl and Fuc. Importantly, the additional of terminal galactose by the action of  $\beta$ -1,4-galactosyltransferase (GalT) is not inhibited by the bisecting GlcNAc. Co-expression of GalT (Bakker, *et al.*, "Galactose-extended glycans of antibodies produced by transgenic plants" *Proc. Nat. Acad. Sci. USA* 98:2899-2904, 2001) results in structures similar as indicated to the right of the arrows annotated with 20, 21 and 22 in Figure 2. Although devoid of immunogenic xylose and fucose residues, these structures have only one arm processed to complex type glycans. To allow conversion of also the other arm, in addition to relocating GnTIII, also Mannosidase II (ManII) and GnTII are relocated in the Golgi to act earlier in the glycan processing sequence. This can be established in several ways. For example, by exchanging their respective transmembrane domains by that of GnTI (TmGnTI), which results in relocation to position indicated 5 in Figure 2. Alternatively, both ManII and GnTII can be relocalised to the ER by removing the transmembrane Golgi targeting domain and supplying the remaining enzyme fragments with a C-terminal ER retention signal (*e.g.*, the amino acid residues KDEL). A plant expressing GalT (Bakker, *et al.*, "Galactose-extended glycans of antibodies produced by transgenic plants" *Proc. Nat. Acad. Sci. USA* 98:2899-2904, 2001) as well as the relocated versions of GnTIII (*e.g.*, TmXyl-GnTIII), ManII (*e.g.*, TmGnTI-ManII) and GnTII (*e.g.*, TmGnTI-GnTII) can then be crossed with plants expressing the recombinant glycoprotein of interest (Figure 3) or can be retransformed with the gene encoding the glycoprotein of interest such as the genes encoding an antibody. This allows the production of recombinant glycoproteins having bisected glycans with terminal galactose residues which are devoid of xylose and fucose. Transformation procedures and crossing (co-pollination) procedures are described above.

In another embodiment, GnTIII with transmembrane domain of Mannosidase II (TmManII-GnTIII) or xylosyltransferase (TmXyl-GnTIII) combined with TmXyl-GalT, TmGnTI-GnTII, TmGnTI-ManII. This combination could either be obtained by coexpression or by combining through cross-pollination of the genes involved and leads to glycoproteins including recombinant glycoproteins, lacking xylose and fucose on the core sequence but having bisected GlcNAc residues on the trimannosyl core and terminal galactose.

## EXAMPLES

The effect of the introduction of GnTIII in plants on the occurrence of bisected oligosaccharides on the glycans of plant glycoproteins has been evaluated. The human gene for GnTIII has been cloned, and a C-terminal c-myc tag for analysis of expression of the tagged fusion protein has been provided and the whole has been placed under control of plant regulatory elements for introduction in tobacco. It is shown that GnTIII is expressed in plants and that expression results in bisected oligosaccharide structures on endogenous plant glycoproteins. The amount of N-glycans containing at least two GlcNAc residues more than doubled compared to those found in normal tobacco plants. Remarkably, the expression of GnTIII also resulted in a significant reduction of complex type N-glycan degradation products as apparent from matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) analyses of the isolated glycans of endogenous plant glycoproteins. These data suggest that expression of GnTIII in tobacco resulting in the introduction of bisected structures on N-glycans protects the glycans from degradation by  $\beta$ -N-acetylhexosaminidases.  $\beta$ -N-acetylhexosaminidases have broad specificity for non-reducing terminal GlcNAc and  $\beta$ -N-acetylglucosamine (GlcNAc) cleaving amongst others GlcNAc- $\beta$ 1-2 linkages typically present on the trimannosyl core (Man- $\alpha$ -1-3 and Man- $\alpha$ -1-6).

### Example 1

**Plasmids and plant transformation.** PAC clone RP5-1104E15 GnTIII (SEQ ID NO: 1, Figure 4A) was obtained from Pieter J. de Jong, Children's Hospital Oakland Research Institute (CHORI) and is available on request through Sanger Center being part of clone set HBRC\_1.sc. The clone originates from Homo sapiens, male, blood and can be requested through <http://www.sanger.ac.uk/Teams/Team63/CloneRequest/> (from Human chromosome 22q12.3-13.1; The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SA, UK; [www.sanger.ac.uk](http://www.sanger.ac.uk))

The human gene for GnTIII was cloned from said PAC clone by PCR using AccuTaq LA DNA polymerase (SigmaAldrich) and primers GNT3F (5'-atactcgagttaacaatgaagatgagacgct-3'; SEQ ID NO: 3) and GNT3Rmyc (5'-tatggatcctaattcagatcctctctgagatgag-3'; SEQ ID NO: 4). Oligos were from Eurogentec (Belgium). PCR was performed on a PerkinElmerCetus 480 thermal cycler (ABI/PE) using optimal conditions for the AccuTaq polymerase according to the manufacturer. The resulting fragment was cloned in EcoRV site of pBluescribe SK+ (Stratagene, Inc., La Jolla, CA USA) and sequence verified. Sequencing was performed using fluorescently labelled dideoxynucleotides essentially as described (Sanger, *et al.*, "DNA sequencing with the dideoxy chain-terminating inhibitors" *Proc. Nat. Acad. Sci. USA* 74:5463-5467, 1977) and reaction mixtures were run on an Applied Biosystems 370A or 380 automated DNA sequencer. Data were analysed using different software modules freely available on the web and compared with the DNA sequence of human GnTIII present in the database.

A 1.6 kb HpaI/BamHI fragment containing the GnTIII gene with C-terminal c-myc tag was

subsequently cloned into the Sma/BglIII site of pUCAP35S (Van Engelen, *et al.*, "Coordinate expression of antibody subunit genes yields high levels of functional antibodies in roots of transgenic tobacco" *Plant Molecular Biology* 26:1701-1710, 1994) and named pAMV-GnTIII. The cauliflower mosaic virus 35S (CaMV35S) 20 promoter expression cassette with modified GnTIII gene was  
5 subsequently cloned as a AscI/PacI fragment in the binary vector pBINPLUS (Van Engelen, *et al.*, "Coordinate expression of antibody subunit genes yields high levels of functional antibodies in roots of transgenic tobacco" *Plant Molecular Biology* 26:1701-1710, 1994) resulting in pBINPLUSGnTIII and introduced in *Agrobacterium tumefaciens* strain Ag10 by electroporation. Transformation of  
10 *Nicotiana tabacum* variety Samsun NN was as described before (Horsch, *et al.*, "A simple and general method for transferring genes into plants" *Science* 227:1229-1231, 1985). Sixteen independent transgenic plants were selected and grown to maturity in the greenhouse as described. Leaf material was analysed for expression of GnTIII (SEQ ID NO: 2, Figure 4B) and glycan composition of endogenous cellular glycoproteins.

## 15 Example 2

**Analysis of expression.** Total protein extracts of tobacco leaves were prepared as described before (Bakker, *et al.*, "Galactose-extended glycans of antibodies produced by transgenic plants" *Proc. Nat. Acad. Sci. USA* 98:2899-2904, 2001). The amount of protein present in samples was  
20 estimated by the Bradford method (Bradford, M.M., "A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding" *Anal Biochem* 72:248-254, 1976) using bovine serum albumin as standard. Fixed amounts of protein samples were run on precast 10 or 12 % SDS-PAGE gels (Bio-Rad) under reduced conditions. Rainbow coloured molecular weight protein markers were from Amersham. Western blot analysis was performed essentially as described (Bakker, *et al.*, "Galactose-extended glycans of antibodies  
25 produced by transgenic plants" *Proc. Nat. Acad. Sci. USA* 98:2899-2904, 2001). Separated proteins were transferred to nitrocellulose (BA85, Schleicher and Schuell or Trans-Blot Transfer Medium, Bio-Rad) using a Bio-Rad Mini Trans-blot Electrophoretic Transfer Cell in 3[cyclohexylamino]-1-propanesulfonic acid (CAPS) buffer for 60 min. Expression of the GnTIII-c-myc fusion protein was analysed by affino blotting using a peroxidase labelled c-myc antibody. Introduction of bisecting  
30 oligosaccharides in endogenous tobacco glycoproteins was visualized by incubation with biotinylated erythroagglutinating phytohemagglutinin (E-PHA; Vector Laboratories). Detection was performed by enhanced chemiluminescence using Lumi-Light Western Blotting Substrate from Roche (Roche Diagnostics GmbH, Mannheim, Germany) on a Lumi-Imager F 1 apparatus (Boehringer Mannheim GmbH, Mannheim, Germany) using LumiAnalyst software (version 3.0).

35

## Example 3

**Matrix-assisted Laser Desorption Ionization Time-of-Flight (MALDI-TOF) Mass Spectrometry.** For the analysis of glycan structure cellular proteins were isolated from tobacco leaves of a selected plant transformed with human GnTIII (GnTIII-17). Protein isolation and N-

glycan preparation were performed as described (Elbers, *et al.*, 2001). The N-glycans were desalted on a nonporous, graphitized carbon-black column (Carbograph Ultra Clean Tubes, Alltech Associates) before mass spectrometry analysis as described. MALDI-TOF spectra were measured on a Micromass (Manchester, U.K.) ToF spec E MALDI-TOF mass spectrometer. Mass spectra were performed in positive mode by using 2,5-dihydroxybenzoic acid as the matrix essentially as described (Elbers, *et al.*, 2001).

Expression of human GnTIII introduces bisecting N-glycans on endogenous glycoproteins in *N. tabacum*. Human GnTIII was introduced in tobacco plants by *Agrobacterium*-mediated transformation of binary vector pBINPLUSGnTIII containing a cDNA harbouring the complete coding sequence fused to a C-terminal c-myc tag under control of the constitutive CaMV35S promoter. Sixty independent transgenic shoots selected for kanamycin resistance were obtained which were analysed for expression of the GnTIII-c-myc fusion protein using the c-myc antibody. Analysis revealed that all expressed the gene at various levels. Fourteen were selected, rooted and transferred to the greenhouse. One plant (GnTIII-17) selected for high expression of the GnTIII-c-myc fusion protein using the c-myc antibody was analysed for the occurrence of bisected GlcNAc residues on N-glycans of endogenous tobacco glycoproteins using a specific binding assay with the biotinylated lectin E-PHA. SDS-PAGE of protein extracts followed by transfer to nitrocellulose and analysis using the specific binding assay with the biotinylated E-PHA lectin revealed that endogenous tobacco glycoproteins of GnTIII-17 contained bisected oligosaccharides whereas those of control tobacco did not. GnTIII-17 was multiplied in the greenhouse for further detailed analysis of glycan structure by MALDI-TOF.

#### Example 4

**Oligosaccharide distributions and level of bisected complex oligosaccharides in wildtype and selected transgenic GnTIII-17 tobacco plant.** Endogenous glycoproteins were isolated from young leaves of control tobacco plant and the selected GnTIII-17 plant to investigate in detail the effect of expression of human GnTIII on the structure of glycans N-linked to glycoproteins. A comparison of the structures of the N-glycans isolated from glycoproteins present in leaves of control wild-type tobacco plants with those from plant GnTIII-17 using MALDI-TOF is represented in Figure 1. MALDI-TOF allows for the detection of different molecular species in the pool of the N-glycans (glycoforms) and shows a mixture of ions that were assigned to (M+Na)<sup>+</sup> adducts of high-mannose (Man)-type N-glycans ranging from d, Mans to n, Man<sub>9</sub> and of mature N-glycans from the truncated structure a, XM<sub>3</sub>GN<sub>2</sub> to m, GN<sub>3</sub>FXM<sub>3</sub>GN<sub>2</sub> (for structure see Table 1; for a summary of the data see, Table 2). In addition to the N-glycans characterized in the control plants (Figure 1A), the MALDI-TOF MS of the glycan mixture from plant GnTIII-17 (Figure 1B) showed at least two ions assigned to N-linked glycans that result from the action of the human GnTIII enzyme (for a comparison see Table 1 and Table 2). These oligosaccharides, GN<sub>3</sub>XM<sub>3</sub>GN<sub>2</sub> (i) and GN<sub>3</sub>FXM<sub>3</sub>GN<sub>2</sub> (k) representing 8 % and 31 % respectively of the population, contain three GlcNAc residues each linked to one of the three mannoses of the trimannosyl core structure of the

N-linked glycan.

Analysis of glycan structure through MALDI-TOF as performed here cannot distinguish between GlcNAc residues  $\beta(1,2)$ - or  $\beta(1,4)$ -linked to mannose. Hence, it was not clear if or to what extent the structures GN2XM3GN2 and GN2FXM3GN2 have bisecting oligosaccharides.

- 5 Additional experiments are required to reveal that these structures are a mix of normal and bisected oligosaccharides or a single compound.

In the light of the observed lethality of CHO cell that overexpress GnTIII (Umana, *et al.*, "Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity" *Nature Biotechnology* 17:176-180, 1999), remarkably transgenic plants having  
10 significant amounts of bisected glycans look phenotypically normal and are completely fertile (can be cross-pollinated and self-pollinated).

### Example 5

**Expression of human GnTIII in tobacco seems to protect N-glycans from degradation by D-Nacetylhexosaminidases and more than doubles terminal N-glucosaminylation.** MALDI-TOF analysis of extracts clearly showed that at least 40 % of the population of glycoforms now has a bisecting GlcNAc in complex-type N-linked glycans of cellular tobacco proteins through the action of the GnTIII enzyme. Moreover 70 % of the population of complex-type N-linked glycans of endogenous glycoproteins of GnTIII-17 has two or three terminal GlcNAc residues compared to  
20 about 30 % for wildtype tobacco (Table 1). The observed *de novo* synthesis of at least 40 % bisected complex-type N-linked glycans upon expression of GnTIII in tobacco (Figure 1B, Table 1 and Table 2) coincides with the disappearance of mainly FXM3GN2 (b, from 30 % to 4 %) and GNFXM3GN2 (f, from 10 to 2%) and to a minor degree GN2FXM3GN2 (j, from 29 % to 19 %). In addition it also coincides with a significant increase in GN2XM3GN2 (h) from 4 % in wildtype tobacco to 14 % in  
25 GnTIII-17. Whether the latter GN2XM3GN2 (h) in GnTIII plants has the second GlcNAc linked to the ( $\beta$ -linked mannose of the trimannosyl core of the N-linked glycan and hence is the result of GnTIII activity, or to the second  $\alpha$ -linked mannose of the trimannosyl core remains to be investigated (see above).

Saccharides a, b and c accounting for 40 % of the N-linked glycans in wildtype tobacco  
30 plants, are degradation products expected to have arisen from mature glycans of endogenous tobacco glycoproteins after GnTI activity since an Arabidopsis thaliana mutant lacking GnTI activity did not contain xylose and fucose residues in the N-glycans of endogenous glycoproteins (Von Schaewen, *et al.*, "Isolation of a mutant Arabidopsis plant that lacks N-Acetylglucosaminyl transferase I and is unable to synthesize golgi-modified complex N-linked glycans" *Plant Physiology* 102:1109-1118,  
35 1993). The 7-fold decrease (40 % > 6 %) in these structures in GnTIII-17 together with the threefold reduction of GNXM3GN2 and XM3GN2 (12 % > 4 %) suggests that the introduction of a bisected GlcNAc protects the mature N-linked glycan from degradation by endogenous glycosidases especially  $\beta$ -Nacetylhexosaminidases that removes terminal GlcNAc. The total amount of N-linked glycans expected to have arisen from degradation of mature, full-length N-linked glycans has hence

decreased fivefold (from 52 % to 10 %).

### Example 6

**Vector construction and DNA preparation for maize transformation.** The human GNTIII gene along with its 3' c-myc immunodetection tag was obtained by PCR from plasmid pAMV-GNTIII by the following method. Primers MS20 and MS19 homologous to the 5' and 3' ends of the hGNTIII gene respectively, were designed and synthesized to add a PmeI site and a stop codon to the 3' end of the gene.

- MS20 (5' NcoI site): 5'-CCATGGTGATGAGACGCTAC-3' (SEQ ID NO: 5)  
 MS19 (adds stop and PmeI site 3'): 5'-GTTTAAACCTAGGATCCTAATTCAGATCCTCT-3' (SEQ ID NO: 6)

Following gel electrophoresis to identify the correct sized PCR product, the 1.6 kbp PCR product was recovered from the gel with a QIAquick Gel Extraction Kit (Qiagen, Valencia, CA). Plasmid 4005 (see, SEQ ID NO: 8) (Figures 5A and 5B), which contains a Zmubi /GUS /per5 cassette (Christensen, *et al.*, *Plant Molec. Biol.* 18:675-689, 1992), was digested with NcoI and PmeI to release the GUS gene and the vector fragment was recovered from a gel with a QIAquick Gel Extraction Kit (Qiagen, Valencia, CA).

Following digestion with NcoI and PmeI, the PCR-derived hGNTIII fragment was ligated to the vector fragment left after digestion of pDAB4005 with NcoI and PmeI, to create the intermediate plasmid pDAB7119 (see, SEQ ID NO: 9) (Figures 6A and 6B). Intermediate plasmid pDAB7119 was cut with SpeI and SphI to release the hGNTIII plant expression cassette, which was treated with T4 DNA polymerase to create blunt ends.

Plasmid pDAB8504 (SEQ ID NO: 10) (see, Figures 7A and 7B), which contains the RB7 MAR sequences, was digested with SrfI and blunt ended with T4 DNA polymerase. Following treatment with calf intestinal phosphatase, the treated 8504 fragment and the hGNTIII plant expression cassette were ligated to create plasmid pDAB 7113 (SEQ ID NO: 10) (see, Figures 8A and 8B), which contains RB7 MAR sequences flanking the gene of interest and the selectable marker cassette as follows: RB7 MAR // Zmubi promoter/hGNTIII/per5 3'UTR // Rice actin promoter (D. McElroy, *et al.*, "Isolation of an efficient actin promoter for use in rice transformation" *The Plant Cell* 2:163-171, 1990) /PAT/ Zm lipase 3'UTR // RB7 MAR.

The integrity of the GNTIII sequence was checked by sequencing (Big Dye Terminator Cycle Sequencing Ready Reaction, Applied Biosystems, Foster City, CA) and was confirmed to encode the human GNTIII enzyme. One base change, G384 → 384, was found but this substitution does not affect the encoded amino acid, proline 128.

Plasmid pDAB7113 was grown up in 2 L of medium (LB + amp) and purified with Qiagen plasmid Giga kit to produce 5 milligrams of purified plasmid for plant cell transformation.



**Example 7**

**Transformation of maize cells.** Plasmid pDAB7113 was introduced into maize cells with WHISKERS-mediated DNA transfer essentially as described in these citations, and as follows (Frame, B., *et al.*, "Production of fertile transgenic maize plants by silicon carbide whisker-mediated transformation" *Plant J.* 6:941-948, 1994; Thompson, J., *et al.*, "Maize transformation utilizing silicon carbide whiskers: a review" *Euphytica* 85:75-80, 1995; P. Song, C. Q. Cai, M. Skokut, B. Kosegi, and J. Petolino, "Quantitative real-time PCR as a screening tool for estimating transgene copy number in Whiskers-derived transgenic maize" *Plant Cell Rep.* 20:948-954, 2002; both of which are incorporated herein by reference).

- Embryogenic maize suspension cell cultures were subcultured on medium G-N6 (N6 medium containing 30 gm/L sucrose, 100 mg/L inositol, and 2 mg/L 2,4-D) the day before whisker mediated transformation. On the day of the experiment, cells were pretreated with osmoticum by shaking with medium G-N6 containing 0.2 Molar each mannitol and sorbitol for 30 minutes. Thirty six mls of cells were transferred to a 250 ml centrifuge bottle in 50 ml of medium G-N6, to which was added 8.1 ml of a 5 % (w/v) silicon carbide whiskers suspension (Silar SC-9, Advanced Composite Materials, Greer, S.C.) in medium, plus 170  $\mu$ l of 1 mg/ml plasmid solution (in TE buffer). The centrifuge bottle containing cells, whiskers and DNA was agitated vigorously on a modified Red Devil brand paint mixer for 10 seconds. Whiskered cells were then shaken for two hours in medium with half the level of added osmoticum. Whiskered cells were recovered by filtration on a sterile Buchner funnel and the filter papers were placed on semisolid G-N6 medium for 1 week. After 1 week the filters were moved to semisolid G-N6 medium containing 1 mg/L Herbiace (a commercial formulation of 20% bialaphos, Meiji Seika, Tokyo, Japan). Two weeks later, the cells were removed from the filter paper, mixed with melted G-N6 + 1 mg/L Herbiace (G-N6 +1H) medium also containing 7 gm/L Seaplaque agarose (BioWhittaker, Rockland, Maine), and spread on top of G-N6 + 1H solid medium. Plates were cultured in the dark at 30 °C. Colonies resistant to the selective agent were recovered 5-7 weeks post embedding, and individually moved to fresh G-N6+1H medium for further increase of tissue mass.

**Example 8**

- Molecular analysis for copy number of inserted DNA.** Tissue from each transgenic isolate was individually freeze-dried in a lyophilizer and DNA was extracted by a standard method (DNAeasy 96 Plant Kit, Qiagen). The copy number of inserted transgenic DNA was estimated by the Invader Operating System, available from Third Wave Technologies (Third Wave Technologies, Madison, Wisconsin, twt.com). Primers were designed by the Third Wave Technologies company specifically for the PAT selectable marker and its copy number was estimated relative to genomic DNA copy number for the endogenous maize alpha-tubulin gene.

**Example 9**

**Test transgenic maize callus for altered lectin binding due to expression of the GntIII**

gene. Callus samples from 100 individually isolated unique transgenic events were extracted as follows. Samples from each event were fresh frozen in 96-well cluster tube boxes (Costar 1.2 ml polypropylene, with lid) along with a steel and a tungsten bead in each well. 450  $\mu$ l of extraction buffer (25 mM sodium phosphate pH6.6, 100 mM NaCl, 30 mM sodium bisulfate, 1 % v/v Triton X-100) was added per well and the box of samples was pulverized for 3 minutes full speed on a Kleco Bead Mill. The plate was centrifuged (4 °C) at 2500 rpm for 10 minutes. Extracts were removed to a 96-well deep well plate and frozen for storage. All screening assays were performed on these extracts of individual events.

Protein analyses (microtiter plate protocol, BioRad 500-0006) were made to determine the total protein for each extract. 25  $\mu$ g protein per sample were loaded in 20  $\mu$ l loading buffer (Laemmli, U.K. Nature 277:680 (1970)). Gels (4-20 % Criterion PAGE gels, 12+2 wells, BioRad 345-0032) were electrophoresed at 65 mA in Tris/glycine /SDS running buffer (BioRad 161-077). After soaking in transfer buffer (running buffer plus 20 % v/v methanol) for 10 minutes, the gels were transferred to nitrocellulose membranes using a semi-dry blotter (150 mA/1.5 hrs). The membranes were incubated for 30 minutes in blocking buffer (20 mM Tris, 144 mM NaCl, 0.5 % v/v Tween 20, 10 % w/v nonfat powdered milk) at room temperature, then the blocking buffer was removed and replaced with the primary detection lectin (Phaseolus hemagglutinin E, biotinylated, Vector Laboratories B-1125) 2.5  $\mu$ g/ml in blocking buffer. The primary detection lectin was incubated on the membrane for 1 hour at room temperature. The primary detection solution was removed, the membrane was rinsed once with blocking buffer and the secondary detection solution was added (avidin-HRP, BioRad 170-6528, at 1:5000, plus molecular weight marker detection agent, StrepTactin-HRP, BioRad 161-0380 at 1:10,000 in blocking buffer. The secondary detection reagent was incubated on the membrane for 1 hour at room temperature. During the blocking, primary, and secondary reagent steps the solutions were mixed on the blots. The secondary detection reagent was then removed and the membrane was rinsed with Tris buffered saline (20 mM Tris, 144 mM NaCl) containing 0.5 % Tween 20 three times at 10 minutes each and once more for 5 minutes. After dripping off the excess rinse solution, the blot was soaked in substrate ECL (Pierce 34080) for 1 minute, excess ECL solution was drained off, and the membrane was exposed to film. Negative controls were included in each gel to discriminate new glycoprotein bands now visible with this bisecting glycan -detecting lectin reagent on the transgenic callus extracts.

Positive test results (Table 5) for the E-PHA binding were rated as 0 (negative), 1 (one plus, weak) 2 (two pluses, moderately strong) or 3 (three pluses, strongest rating). Callus of events rated 2 or 3 were selected to produce sample for mass analysis. Samples 25, 26, 33, 48, 55, 56 and 59 were pooled to produce the protein extract for MALDI-TOF analysis of glycan substructures. A gel blot example (Figure 12) shows samples 19 through 27.

### Example 10

**Test transgenic maize callus for c-myc epitope expression.** Callus samples from 100 individually isolated unique transgenic events were extracted as follows. Samples from each event

were fresh frozen in 96-well cluster tube boxes (Costar 1.2 ml polypropylene, with lid) along with a steel and a tungsten bead in each well. 450  $\mu$ l of extraction buffer (25 mM sodium phosphate pH6.6, 100 mM NaCl, 30 mM sodium bisulfate, 1 % v/v Triton X-100) was added per well and the box of samples was pulverized for 3 minutes full speed on a Kleco Bead Mill. The plate was centrifuged (4 °C) at 2500 rpm for 10 minutes. Extracts were removed to a 96-well deep well plate and frozen for storage. All screening assays were performed on these extracts of individual events.

Protein analyses (microtiter plate protocol, BioRad 500-0006) were made to determine the total protein for each extract. 25  $\mu$ g protein per sample were loaded in 20  $\mu$ l loading buffer (Laemmli, U.K. Nature 277:680, 1970)). Gels (4-20 % Criterion PAGE gels, 12+2 wells per gel, BioRad 345-0032) were electrophoresed at 65 mA in Tris\_/glycine /SDS running buffer (BioRad 161-0772). After soaking in transfer buffer (running buffer plus 20 % methanol) for 10 minutes, the gels were transferred to nitrocellulose membranes using a semi-dry blotter (150 mA/1.5 hrs). The membranes were incubated for 30 minutes in blocking buffer (20 mM Tris, 144 mM NaCl 0.5 % v/v Tween 20, 10 % w/v dry milk) at room temperature, then the blocking buffer was removed and replaced with the primary detection reagent, Mouse anti-c-myc clone 9E10 (sigma M5546) at 1  $\mu$ g/ml in blocking buffer. After 1 hour of incubation at room temperature, the primary detection reagent was removed and the membrane was rinsed with blocking buffer. The secondary detection reagent, anti-mouse - HRP (BioRad 170-6516) at 1:10,000 plus a molecular weight marker detection reagent (StrepTactin - HRP, BioRad 161-0380) at 1:10,000 in blocking buffer, was then added and incubated on the membrane for 1 hour at room temperature. During the blocking, primary, and secondary reagent steps the solutions were mixed on the blots. The secondary detection agent was removed, and the membrane was rinsed three times with Tris buffered saline (20 mM Tris, 144 mM NaCl) containing 0.5 % Tween 20 for 10 minutes each, plus another 5 minute rinse. After draining off the excess rinse solution the membrane was soaked in ECL reagent (Pierce 34080) for 1 minute, drained, and then exposed to film.

As detailed above, callus samples from independent events 1-100 were screened for expression of the c-myc epitope. Then, samples 3, 11, 12, 26, 31, 55 and 64 were analysed and showed the presence of a band in the predicted molecular weight range of 50-55 kilodaltons. These callus samples were pooled to produce a protein sample for glycan analysis by MALDI-TOF. A representative blot is shown in Figure 13.

### Example 11

**Preparation of extract for mass spec analysis of glycans.** The samples were prepared from combined calluses of several maize callus events which tested positive for GnTIII transgene expression based on lectin blotting using E-PHA. Callus tissue was collected fresh and stored frozen at -80 °C, then ground to a fine powder in liquid nitrogen. Weighed sample was added to extraction buffer (5 mM EDTA, 0.5 mM PMSF, 20 mM sodium bisulfite, 150 mM sodium phosphate buffer pH 7.4, and 0.4 mM PVPP soluble MW 40,000) and stirred for 30 minutes at 4 °C. After centrifugation at 5000 x G at 4 °C, the supernatant was collected. Ammonium sulfate and wash buffer (5 mM

EDTA, 150 mM sodium phosphate buffer, pH 7.4) were added to the supernatant to achieve a final concentration of 20 % (w/v) ammonium sulfate. After centrifugation 5 minutes at 5000 x G at 4 °C, the supernatant was transferred to a fresh tube and additional ammonium sulfate plus wash buffer were added to achieve 60 % (w/v) ammonium sulfate. This preparation was stirred overnight at 4 °C, then centrifuged 20 minutes at 10,000 x G. The pellet was recovered in 5 ml of wash buffer and frozen at -80 °C, then lyophilized at 4 °C until dry. Samples were sent to the lab for glycan analysis.

### Example 12

**Maize plant regeneration from transgenic callus tissue.** For plant regeneration from transformed callus, tissue was placed onto regeneration media containing MS basal salts and vitamins (Murashige T. and F. Skoog, *Physiol Plant* 15:473-497, 1962), 30 g/l sucrose, 5 mg/l 6-benzylaminopurine (BA), 0.025 mg/l 2, 4-dichlorophenoxyacetic acid (2,4-D), 1 mg/l Herbiace (a commercial formulation of 20 % bialaphos, Meiji Seika, Tokyo, Japan), and 2.5 g/l Gelrite, pH 5.7. Cultures were grown in the light. When shoots reached 1-3 cm in length, they were transferred into vessels containing SH basal salts and vitamins (Schenk R. and A.C. Hildebrandt, *Can J Bot* 50:199-204, 1972), 10 g/l sucrose, 1 g/l myo-inositol, and 2.5 g/l Gelrite, pH 5.8.

Plants were screened for expression of GNTIII by altered binding of the lectin E-PHA to endogenous proteins. Samples were then screened for E-PHA binding as described in Example 9, *supra*. The protein extract and 20 % / 60 % ammonium sulfate precipitate was prepared exactly as for the callus samples as described in Example 13, *infra*. One plant each from plants regenerated from 23 independent events were screened by lectin blotting for the results of expression of the GNTIII gene. Four of these events gave positive signals for E-PHA binding. These four events had also tested positive at the callus stage. Plants regenerated from those four events were pooled to produce a protein extract for glycan analysis by MALDI-TOF.

### Example 13

**Oligosaccharide distributions and level of bisected complex oligosaccharides in wildtype and selected transgenic corn calli.** Endogenous glycoproteins were isolated from control corn calli and selected corn calli expressing GnTIII based on lectin blotting using E-PHA. In addition, the present invention also contemplates the extraction of c-myc tagged samples. E-PHA and c-myc tagged samples may be callus, plant cells, plant tissues or entire plants as defined in the definitions section *supra*. A comparison of the structures of the N-glycans isolated from glycoproteins present in calli is presented in Figures 9A and 9B. MALDI-TOF allowed for the detection of different molecular species in the pool of the N-glycans (glycoforms) and showed a mixture of ions that were assigned to (M+Na)<sup>+</sup> adducts of high-mannose (Man)- type N-glycans ranging from **d**, Man5 to **l**, Man8 and of mature N-glycans from the truncated structure **a**, XM3GN2 to **m**, bGN3FXM3GN2 (see, Table 3). In addition to the N-glycans characterized in the control callus (Figure 9A), the MALDI-TOF MS of the glycan mixture from selected corn calli expressing GnTIII (Figure 9B) showed at least one ion assigned to N-linked glycans that result from the action of the human GnTIII

enzyme (for a comparison see, Table 3). This oligosaccharide, GN3XM3GN2 (**m**) represents 20 % of the population and contains three GlcNAc residues each linked to one of the three mannoses of the trimannosyl core structure of the N-linked glycan. Analysis of glycan structure through MALDI-TOF as performed here cannot distinguish between GlcNAc residues  $\beta(1,2)$ - or  $\beta(1,4)$ -linked to mannose.

Hence it is not clear if or to what extent the structures GN2XM3GN2 (**h**) and GN2FXM3GN2 (**k**) have bisecting oligosaccharides. Both had increased numbers in GnTIII corn cells compared to untransformed control corn cells. Additional experiments are required to reveal that these structures are a mix of normal and bisected oligosaccharides or a single compound.

Besides the new appearance of saccharide structure **m** (bGN3FXM3GN2) in GnTIII corn, it is apparent from the comparison of the glycoforms of control and GnTIII corn, as shown in Table 3, that the amount of structures harbouring high-mannose type N-glycans (M4 and higher) is reduced more than twofold (from 19 % to 7 %) which can be attributed mostly to the reduction of M4-containing N-glycans (from 10 % to 1 % of total) in GnTIII corn versus control corn. In addition the amount of glycoforms having two or more GlcNAc residues has increased from 16 % to 42 % (control versus GnTIII).

In a follow-up experiment, endogenous glycoproteins were isolated from control corn calli and selected corn calli expressing GnTIII based on analysis for the presence of c-myc tag sequence by Western blotting. A comparison of the structures of the N-glycans isolated from glycoproteins present in calli is presented in Table 4. MALDI-TOF allows for the detection of different molecular species in the pool of the N-glycans (glycoforms) and shows a mixture of ions that were assigned to (M+Na)<sup>+</sup> adducts of high-mannose (Man)- type N-glycans ranging from **d**, Man5 to **l**, Man8 and of mature N-glycans from the truncated structure **a**, XM3GN2 to **k**, GN2FXM3GN2 in control corn.

Remarkably, in transgenic corn expressing GnTIII (Table 4, GnTIII-2), only three isoforms could be detected: FXM3GN2 (**b**; accounting for 9 % of total), GN2FXM3GN2/bGN2FXM3GN2 (**k**; 38 %) and bGN3FXM3GN2 (**m**; 54 %). It is not clear if or to what extent the structure depicted as **k** (GN2FXM3GN2/bGN2FXM3GN2) has bisecting oligosaccharides. Its presence is significantly increased in GnTIII corn compared to control corn. Additional experiments are required to reveal that these structures are a mix of normal and bisected oligosaccharides or a single compound.

Besides the new appearance of saccharide structure **m** (bGN3FXM3GN2) in GnTIII corn (54 %), it is apparent from the comparison of the glycoforms of control and GnTIII corn, as summarized in Table 4, that the amount of structures harbouring high-mannose type N-glycans (M4 and higher) is reduced to nil in GnTIII corn versus control corn. Furthermore, the total amount of N-glycans bearing 2 or more (3) GlcNAc residues has increased from 16 to 92% (control versus GnTIII) suggesting that the introduction of bisected GlcNAc residue protects the glycan from degradation by endogenous hexosaminidases as observed before for transgenic GnTIII tobacco.

Additionally, MALDI-TOF mass spectroscopy data (Figure 11) demonstrate the bisected GlcNAc structure.

**Example 14**

**Oligosaccharide distributions and level of bisected complex oligosaccharides in wildtype and selected transgenic corn plants.** Endogenous glycoproteins were isolated from control corn plant leaves and selected corn plant leaves expressing GnTIII based on analysis for the presence of c-myc tag sequence by Western blotting or lectin blotting using E-PHA. A comparison of the structures of the N-glycans isolated from glycoproteins present in leaves is presented in Table 6. MALDI-TOF allows for the detection of different molecular species in the pool of the N-glycans (glycoforms) and shows a mixture of ions that were assigned to (M+Na)<sup>+</sup> or (M+K)<sup>+</sup> adducts of high-mannose (Man)-type N-glycans ranging from f, Man6 to h, Man8 and of mature N-glycans from the truncated structure a, XM3GN2 to g, GN2FXM3GN2 in control corn plant and to i, bGN3FXM3GN2 in transgenic GnTIII corn plant.

In addition to the N-glycans characterized in the control plants (Figure A), the MALDI-TOF MS of the glycan mixture from selected corn plant expressing GnTIII (Figure B) showed at least one ion assigned to N-linked glycans that result from the action of the human GnTIII enzyme (for a comparison see Table 6). This oligosaccharide, GN3XM3GN2 (i) represents 15% of the population and contains three GlcNAc residues each linked to one of the three mannoses of the trimannosyl core structure of the N-linked glycan. Analysis of glycan structure through MALDI-TOF as performed here cannot distinguish between GlcNAc residues  $\beta$ (1,2)- or  $\beta$ (1,4)-linked to mannose. Hence it is not clear if or to what extent the structure GN2FXM3GN2 (g) has bisecting oligosaccharides. It has increased in GnTIII corn compared to control corn plant (23 % versus 5 % in control). Additional experiments are required to reveal that these structures are a mix of normal and bisected oligosaccharides or a single compound. Besides this it is apparent from the comparison of the glycoforms of control and GnTIII corn plants, as depicted in Table 6, that the amount of structures harbouring FXM3GN2 is reduced twofold (from 59 to 30) and the amount of glycoforms having two or more GlcNAc residues has increased from 5 to 38 % (control versus GnTIII).

Additionally, Figure 14 shows a comparison of MALDI-TOF mass spectra of N-glycans of glycoproteins isolated from leaves of control corn (A) and of selected GnTIII-corn plants. GnTIII corn plant was obtained through transformation with human GnTIII gene sequence and selection was performed by Western blotting using either c-myc tag or E-PHA lectin. See Table 6 for structures and abbreviations.

It is understood that the present invention is not limited to the particular methodology, protocols, cell lines, vectors, and reagent, etc., described herein, as these may vary. It is also to be understood that the terminology used herein is used for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention. It must be noted that as used herein and in the appended claims, the singular forms "a," "an" and "the" include plural reference unless the context clearly dictates otherwise.

Unless defined otherwise, all technical and scientific terms used herein have the same

meanings as commonly understood by one of ordinary skill in the art to which this invention belongs.

The invention described and claimed herein is not to be limited in scope by the specific embodiments herein disclosed, since these embodiments are intended as illustrations of several aspects of the invention. Any equivalent embodiments are intended to be within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

Various references are cited herein, the disclosures of which are incorporated by reference in their entireties.

**Table 1.** Structure, molecular weight and percentage of total pool of N-glycans isolated from control and selected GnTIII-17 plants.

Structure	Abbreviation	Name	Mol. Wt.	%	
				Wildtype	GnTIII-17
	XM3GN2	A	1065	8	4
	FM3GN2	B	1079	3	0
	FXM3GN2	C	1211	30	4
	Man5	D	1257	2	3
	GNXM3GN2	E	1268	4	0
	GNFXM3GN2	F	1414	10	2
	Man6	G	1419	3	5
	GN2XM3GN2	H	1471	- 4 -	14
	Man7	I	1581	3	4
	GN2FXM3GN2	J	1617	- 29 -	19
	GN3XM3GN2	K	1674	-	8



	Man8	L	1743	2	4
	GN3FXM3GN2	M	1820	-	31
	Man9	N	1905	1	2

- 5 **Table 2.** Comparison of the results of mass spec (MALDI-TOF) analysis of N-glycans of endogenous glycoproteins isolated from control tobacco and selected GnTIII-17 plant. See also Table 1.

m/z	Type	Wildtype endo	GnTIII-17 endo
1065	XM3	8	4
1079	FM3	3	0
1211	FXM3	30	4
1257	M5	2	3
1268	GNXM3	4	0
1414	GNFXM3	10	2
1419	M6	3	5
1471	GNbGNXM3		14
1471	GN2XM3	4	
1581	M7	3	4
1617	GN2FXM3	29	19
1617	GNbGNXM3		
1674	GN2bGNXM3	0	8
1743	M8	2	4
1820	GN2bGNFXM3	0	31
1905	M9	1	2
TOTAL		99	100

**Table 3. Overview N-glycans observed in control and transgenic GnTIII corn.**

Comparison of N-glycan structures (% of total) found on endogenous glycoproteins of control, untransformed corn and transgenic corn callus expressing GnTIII that could be annotated.

Corresponding mass spectra obtained through MALDI-TOF analyses are given below and

5 saccharides are indicated under column "name." Bisecting GlcNAc residues are depicted as bGN.

Structure abbreviation	m/z	name	Corn callus	
			control	GnTIII
XM3GN2	1065	a	1	5
FXM3GN2	1211	b	37	36
XM4GN2	1227	c	6	1
M5GN2	1257	d	1	1
GNFXM3GN2	1414	e	12	3
M6GN2	1419	f	5	4
GNXM4GN2	1430	g	3	
GN2XM3GN2	1471	h		3
bGN2XM3GN2				
GNFXM4GN2	1576	i	1	
M7GN2	1581	j	1	1
GN2FXM3GN2	1617	k	16	19
bGN2FXM3GN2				
M8GN2	1743	l	1	
bGN3FXM3GN2	1820	m		20
		<b>Total</b>	<b>84</b>	<b>93</b>

**Table 4. Schematic overview N-glycans observed in control and transgenic GnTIII corn-2.**

Comparison of N-glycan structures (% of total) found on endogenous glycoproteins of control, untransformed corn and transgenic corn callus expressing GnTIII that could be annotated.

Transgenic corn was selected using c-myc tag. Corresponding mass spectra obtained through

5 MALDI-TOF analyses are given below and saccharides are indicated under column "name".

Bisecting GlcNAc residues are depicted as bGN.

Structure abbreviation	m/z	name	Corn callus	
			control	GnTIII-2
XM3GN2	1065	a	1	
FXM3GN2	1211	b	37	9
XM4GN2	1227	c	6	
M5GN2	1257	d	1	
GNFXM3GN2	1414	e	12	
M6GN2	1419	f	5	
GNXM4GN2	1430	g	3	
GN2XM3GN2	1471	h		
bGN2XM3GN2				
GNFXM4GN2	1576	i	1	
M7GN2	1581	j	1	
GN2FXM3GN2	1617	k	16	38
bGN2FXM3GN2				
M8GN2	1743	l	1	
bGN3FXM3GN2	1820	m		54
		<b>Total</b>	<b>84</b>	<b>101</b>

Table 5. Positive test results for E-PHA binding.

Sample ID number	Rating for E-PHA Binding	Included in Pooled positive sample
1.	Unclear	
2.	Unclear	
3.	1	
4.	0	
5.	0	
6.	0	
7.	0	
8.	0	
9.	0	
10.	Unclear	
11.	Unclear	
12.	1	
13.	1	
14.	0	
15.	0	
16.	0	
17.	0	
18.	0	
19.	0	
20.	0	
21.	0	
22.	0	
23.	1	
24.	1	
25.	3	Yes
26.	3	Yes
27.	0	
28.	0	
29.	0	
30.	0	
31.	0	
32.	0	
33.	2	Yes
34.	1	
35.	0	
36.	0	
37.	Unclear	
38.	1	
39.	0	
40.	1	
41.	1	
42.	0	
43.	0	
44.	Unclear	
45.	0	
46.	0	

-59-

47.	0	
48.	2	Yes
49.	0	
50.	0	
51.	0	
52.	0	
53.	0	
54.	1	
55.	2	Yes
56.	2	Yes
57.	2	Yes
58.	1	
59.	2	Yes
60.	0	
61.	0	
62.	0	
63.	0	
64.	0	
65.	0	
66.	0	
67.	0	
68.	0	
69.	Negative control	

**Table 6. Schematic overview N-glycans observed in control and transgenic GnTIII corn plants.**

Structure abbreviation	m/z	name	Corn plant	
			control	GnTIII
XM3GN2	1065	a	4	14
FM3GN2	1079	b	2	
FXM3GN2	1211	c	59	30
XM4GN2	1227	d	3	12
GNFXM3GN2	1414	e	10	6
M6GN2	1419	f	2	
GN2FXM3GN2	1617	g	5	23
bGN2FXM3GN2				
M8GN2	1743	h	1	
bGN3FXM3GN2	1820	i		15
Total			86	100

**CLAIMS**

What is Claimed is:

- 5 1. A plant host cell system, comprising a mammalian UDP-N-acetylglucosamine:  $\beta$ -D mannoside  $\beta(1,4)$ -N-acetylglucosaminyltransferase (GnTIII) enzyme.
2. The plant host system according to Claim 1, wherein said GnTIII is a human GnTIII.
- 10 3. The plant host system according to Claim 1, wherein said system is a portion of a plant.
4. The plant host system according to Claim 1, wherein said system is a portion of a plant selected from the group consisting of a cell, leaf, embryo, callus, stem, pericarp, protoplast, root, tuber, kernel, endosperm and embryo.
- 15 5. The plant host system according to Claim 1, wherein said system is a whole plant.
6. The plant host system according to Claim 1, further comprising a heterologous glycoprotein.
- 20 7. The plant host system according to Claim 5, wherein said heterologous glycoprotein protein comprises an antibody or fragment thereof.
8. The plant host system according to Claim 5, wherein said heterologous glycoprotein or functional fragment thereof comprises bisected oligosaccharides.
- 25 9. The plant host system according to Claim 5, wherein said heterologous glycoprotein comprises bisected glycans with galactose residues.
10. The plant host system according to Claim 1, wherein said plant is a tobacco plant.
- 30 11. The plant host system according to Claim 1, which further comprises a functional protein selected from the group consisting of a transporter and an enzyme providing N-glycan biosynthesis.
- 35 12. The plant host system according to Claim 11, wherein said enzyme is a (human)  $\beta$ -1,4 galactosyltransferase.
13. The plant host system according to Claim 11, which further comprises a heterologous glycoprotein, having an increased number of galactose residues.

14. A plant host system comprising a nucleic acid sequence encoding a mammalian GnTIII protein.
15. A plant host system comprising a vector comprising a nucleic acid sequence encoding a  
5 mammalian GnTIII protein.
16. The plant host system according to Claim 15, which further comprises a nucleic acid sequence  
encoding a functional protein selected from a group consisting of a transporter and an enzyme  
providing N-glycan biosynthesis.  
10
17. A method comprising a) crossing a plant expressing a heterologous glycoprotein with a plant  
according to Claim 5, b) harvesting progeny from said crossing and c) selecting a desired  
progeny plant.
- 15 18. The method according to Claim 17, wherein said desired progeny plant expressing said  
heterologous glycoprotein protein having bisected oligosaccharides.
19. The method according to Claim 17, wherein said plant host system is a transgenic plant.
- 20 20. A method for obtaining a heterologous glycoprotein having bisected oligosaccharides  
comprising introducing a nucleic acid sequence encoding GnTIII that is normally not present in  
plant into a plant host system and a nucleic acid sequence encoding a heterologous glycoprotein  
and isolating said heterologous glycoprotein.
- 25 21. The method according to Claim 20, wherein said nucleic acid sequences are introduced into a  
plant cell and said plant cell is regenerated into a plant.
22. The method according to Claim 20, wherein said nucleic acid sequences are introduced into a  
plant host system by transforming said plant host system with a vector comprising a acid  
30 sequence encoding GnTIII that is normally not present in plant into a plant and a nucleic acid  
sequence encoding a heterologous glycoprotein.
23. The method according to Claim 20, wherein said nucleic acid sequences are introduced into a  
plant host system by transforming said plant host system with a vector comprising a nucleic acid  
35 sequence encoding GnTIII that is normally not present in plant into a plant and a nucleic acid  
sequence encoding a heterologous glycoprotein.
24. The method according to Claim 20, wherein said nucleic acid sequences are introduced into a  
plant host system by transforming said plant with a vector comprising a nucleic acid sequence

encoding GnTIII that is normally not present in plant into a plant host system and vector comprising a nucleic acid sequence encoding a heterologous glycoprotein.

- 5 25. A method for obtaining a heterologous glycoprotein having bisected oligosaccharides comprising cultivating the regenerated plant obtained in claim 21.
26. A method for obtaining a desired glycoprotein comprising a) cultivating the plant host system of Claim 6 and b) harvesting and fractionating said plant.
- 10 27. A plant obtainable by a method according to Claim 19.
28. A method for obtaining a plant host system comprising a) crossing a plant comprising a functional protein selected from a group consisting of a transporter or an enzyme providing N-glycan biosynthesis with a plant according to Claim 5, b) harvesting progeny from said crossing  
15 and c) selecting a desired progeny.
29. A transgenic plant obtained according to the method of Claim 28.
30. A method for increasing galactosylation of a heterologous glycoprotein expressed in a plant host  
20 system comprising a) introducing a nucleic acid sequence encoding GnTIII and a sequence selected from a group consisting of a transporter or an enzyme not normally present in a plant into said plant host system expressing said heterologous glycoprotein and b) isolating said glycoprotein.
- 25 31. A plant derived glycoprotein comprising bisected oligosaccharides.
32. Use of a plant host system according to Claims 1-16 to produce a desired glycoprotein or functional fragment thereof.
- 30 33. Use according to Claim 32 wherein a said glycoprotein or functional fragment thereof comprises bisected oligosaccharides.
34. A plant-derived glycoprotein or functional fragment thereof obtained by a method according to Claim 19.
- 35 35. Use of a glycoprotein or functional fragment thereof according to Claim 31 for the production of a pharmaceutical composition.
36. A composition comprising a glycoprotein or functional fragment thereof according to Claim 31.



37. An isolated hybrid protein comprising an active site of GnTIII and a transmembrane region of a protein, said protein residing in endoplasmic reticulum or Golgi apparatus of a eukaryotic cell.
- 5 38. The protein according to Claim 37, wherein said protein residing in endoplasmic reticulum or Golgi apparatus of a eukaryotic cell is an enzyme.
39. The protein according to Claim 37, wherein said protein residing in endoplasmic reticulum or Golgi apparatus of a eukaryotic cell is a glycosyltransferase.
- 10 40. The protein according to Claim 37, wherein said protein residing in endoplasmic reticulum or Golgi apparatus of a eukaryotic cell is a glycosyltransferase selected from the group consisting of a mannosidaseI, mannosidaseII, GnTI, GnTII, XylT and FucT,
- 15 41. The protein according to Claim 37, wherein said protein residing in endoplasmic reticulum or Golgi apparatus of a eukaryotic cell is a plant protein.
42. An isolated nucleic acid sequence encoding the protein of Claim 31.
- 20 43. A vector comprising the isolated nucleic acid sequence of Claim 42.
44. A plant comprising the isolated nucleic acid sequence of Claim 42.
45. The plant according to Claim 44 which further comprises a nucleic acid sequence encoding a heterologous glycoprotein.
- 25 46. A method for providing a transgenic plant capable of expressing a heterologous glycoprotein with the capacity to extend an N-linked glycan with galactose comprising crossing a transgenic plant with a plant according to Claim 44, harvesting progeny from said crossing and selecting a desired progeny plant expressing said recombinant protein and expressing a functional (mammalian) enzyme involved in (mammalian) N-glycan biosynthesis that is normally not present in plants.
- 30 47. A method for providing a transgenic plant capable of expressing a heterologous glycoprotein with the capacity to extend an N-linked glycan with galactose comprising introducing the nucleic acid sequence of Claim 42 and a nucleic acid sequence encoding said heterologous glycoprotein.
- 35 48. A method, comprising:

- a. providing: i) a plant cell, and ii) an expression vector comprising nucleic acid encoding a GNTIII enzyme; and
- b. introducing said expression vector into said plant cell under conditions such that said enzyme is expressed.

5

49. The method of Claim 22, wherein said nucleic acid encoding a GNTIII comprises the nucleic acid sequence of SEQ ID NO:1.

50. A method, comprising:

10

- a. providing: i) a plant cell, ii) a first expression vector comprising nucleic acid encoding a GNTIII enzyme, and iii) a second expression vector comprising nucleic acid encoding a heterologous glycoprotein; and
- b. introducing said first and second expression vectors into said plant cell under conditions such that said hybrid enzyme and said heterologous protein are expressed.

15

51. The method of Claim 50, wherein said heterologous protein is an antibody or antibody fragment.

52. A method, comprising:

20

- a) providing: i) a first plant comprising a first expression vector, said first vector comprising nucleic acid encoding a GNTIII enzyme, and ii) a second plant comprising a second expression vector, said second vector comprising nucleic acid encoding a heterologous protein; and
- b) crossing said first plant and said second plant to produce progeny expressing said hybrid enzyme and said heterologous protein.

25

53. A plant, comprising first and second expression vectors, said first vector comprising nucleic acid encoding a GNTIII enzyme, said second vector comprising nucleic acid encoding a heterologous protein.

30

54. The plant of Claim 53, wherein said heterologous protein is an antibody or antibody fragment.

FIG. 1A





FIG. 1B






FIG. 2



X



Antibody Construct

FIG. 3

**Nucleotide sequence (incl. myc-tag)**

CCATGGTGATGAGACGCTACAAGCTCTTTCTCATGTTCTGTATGGCCGGCCTG  
TGCCTCATCTCCTTCTGCACTTCTTCAAGACCTGTCTATGTCACCTTCCCC  
CGAGAACTGGCCTCCCTCAGCCCTAACCTGGTGTCCAGCTTTTCTGGAACAA  
TGCCCCGGTCACGCCCCAGGCCAGCCCCGAGCCAGGAGGCCCTGACCTGCTG  
CGTACCCCACTCTACTCCCACTCGCCCCGCTGCAGCCGCTGCCGCCAGCAA  
GGCGGCCGAGGAGCTCCACCGGGTGGACTTGGTGTGCTGCCGAGGACACCACC  
GAGTATTTTCGTGCGCACCAAGGCCGGCGGCGTCTGCTTCAAACCCGGCACCA  
AGATGCTGGAGAGGCCGCCCCCGGGACGGCCGGAGGAGAAGCCTGAGGGGG  
CCAACGGCTCCTCGGCCCCGGCGGCCACCCCGGTACCTCCTGAGCGCCCCGGA  
GCGCACGGGGGGCCGAGGCGCCCGGCGCAAGTGGGTGGAGTGCGTGTGCCT  
GCCCCGGCTGGCACGGACCCAGCTGCGGCGTGCCCACTGTGGTGCAGTACTCC  
AACCTGCCCCACCAAGGAGCGGCTGGTGCCAGGGAGGTGCCGCGCCGCGTCA  
TCAACGCCATCAACGTCAACCACGAGTTCGACCTGCTGGACGTGCGCTTCCA  
CGAGCTGGGCGACGTGGTGGACGCCTTTGTGGTGTGCGAGTCCAACCTTCAG  
GCTTATGGGGAGCCGCGGCCGCTCAAGTTCCGGGAGATGCTGACCAATGGCA  
CCTTCGAGTACATCCGCCACAAGGTGCTCTATGTCTTCTGGACCACTTCCCG  
CCCCGCGGCCGGCAGGACGGCTGGATCGCCGACGACTACCTGCGCACCTTCC  
TCACCCAGGACGGCGTCTCGCGGCTGCGCAACCTGCGGCCCGACGACGTCTT  
CATCATTTGACGATGCGGACGAGATCCCGGCCCGTGACGGCGTCCTTTTCCTCA  
AGCTCTACGATGGCTGGACCGAGCCCTTCGCCTTCCACATGCGCAAGTCGCTC  
TACGGCTTCTTCTGGAAGCAGCCGGGCACCCTGGAGGTGGTGTGAGGCTGCA  
CGGTGGACATGCTGCAGGCAGTGTATGGGCTGGACGGCATCCGCCTGCGCCG  
CCGCCAGTACTACACCATGCCCAACTTCAGACAGTATGAGAACCGCACCGGC  
CACATCCTGGTGCAGTGGTCTGCTGGGCAGCCCCCTGCACTTCGCCGGCTGGC  
ACTGCTCCTGGTGTCTTACGCCCCGAGGGCATCTACTTCAAGCTCGTGTCCGCC  
CAGAATGGCGACTTCCCACGCTGGGGTGACTACGAGGACAAGCGGGACCTGA  
ACTACATCCGCGGCCTGATCCGCACCGGGGGCTGGTTCGACGGCACGCAGCA  
GGAGTACCCGCCTGCAGACCCAGCGAGCACATGTATGCGCCCAAGTACCTG  
CTGAAGAACTACGACCGGTTCCTACTACCTGCTGGACAACCCCTACCAGGAGC  
CCAGGAGCACGGCGGGCGGGCGGGTGGCGCCACAGGGGTCCCGAGGGAAGGC  
CGCCCGCCCGGGGCAAACTGGACGAGGCGGAAGTCGAACAAAACTCATCT  
CAGAAGAGGATCTGAATTAGGATCC

**FIG. 4A**

**PROTEIN SEQUENCE**

MVMRRYKLFL MFCMAGLCLI SFLHFFKTLS YVTFPRELAS LSPNLVSSFF  
WNNAPVTPOA SPEPGGPDLL RTPLYSHSPL LOPLPPSKAA EELHRVDLVL  
PEDTTEYFVR TKAGGVCFKP GTKMLERPPP GRPEEKPEGA NGSSARRPPR  
YLLSARERTG GRGARRKWVE CVCLPGWHGP SCGVPTVVQY SNLPTKERLV  
PREVPRRVIN AINVNHEFDL LDVRFHELGD VVDAFVVCES NFTAYGEPRP  
LKFREMLTNG TFEYIRHKVL YVFLDHFPFG GRODGWIADD YLRTFLTODG  
VSRLRNLRPD DVFIIDDADE IPARDGVLEFL KLYDGWTEPF AFHMRKSLYG  
FFWKOPGTLE VVSGCTVDML OAVYGLDGIR LRRROYTMP NFROYENRTG  
HILVOWSLGS PLHFAGWHCS WCFTPEGIYF KLVSAONGDF PRWGDYEDKR  
DLNYIRGLIR TGGWFDGTOO EYPPADPSEH MYAPKYLLKN YDRFHYLLDN  
PYOEPRSTAA GGWRHRGPEG RPPARGKLDE AEVEQKLISE EDLN

**FIG. 4B**




FIG. 5A



Plasmid pDAB4005 (7027 bp)  
Description: ZmUbilpromoter + intron/GUS/Per5 3'UTR

Nucleotide start	Nucleotide end	Sequence Feature
1	115	Linker sequence with multiple cloning site: CATGATTACGCCAAGCTAGCGGCCGCATTCCTCCGGGAAGCTA GGCCACCGTGGCCCGCCTGTCAGGGGAAGCTTGCATGCTGTC AGATCCCCGGGGATCCTCTAGAGTCGACCTGCA
116	2105	Maize ubiquitin promoter + intron
1093	2105	Maize ubiquitin intron
2106	2125	Linker sequence: GGGTACCCCGGGGTCGAC
2126	3967	GUS coding region
3968	3985	Linker sequence: TAATGAGCTCGTTTAAA
3986	4350	Maize peroxidase-5' 3' UTR
4351	4405	Linker sequence: CGGCCGGCCTAGCTAGCCACGGTGGCCAGATCCACTAGTTC TAGAGCGGCCGCTT
4406	7027	Puc19
5006	5856	Ampicillin resistance gene

Sequence

1 CATGATTACG CCAAGCTAGC GGCCGCAATTC CCGGGAAGCT AGGCCACCGT  
51 GGCCCGCCTG CAGGGGAAGC TTGCATGCCT GCAGATCCCC GGGGATCCTC  
101 TAGAGTCGAC CTGCAGTGCA GCGTGACCCG GTCGTGCCCC TCTCTAGAGA

FIG 5B

```

151 TAATGAGCAT TGCATGCTA AGTTATAAAA AATTACCACA TATTTTTTTT
201 GTCACACTTG TTTGAAGTGC AGTTTATCTA TCTTTATACA TATATTTAAA
251 CTTTAATCTA CGAATAAAT ATCTATAGT ACTACAATAA TATCAGTGT
301 TTAGAGAATC ATATAAATGA ACAGTTAGAC ATGGTCTAAA GGACAATTGA
351 GTATTTTGAC AACAGGACTC TACAGTTTAA TCTTTTTTAGT GTGCATGTGT
401 TCTCTTTTTT TTTTGCAAT AGCTTCACCT ATATAATACT TCATCCATTT
451 TATTAGTACA TCCATTTAGG GTTTAGGGTT AATGGTTTTT ATAGACTAAT
501 TTTTATTAGT CATCTATTTT ATTCTATTTT AGCCTCTAAA TTAAGAAAAA
551 TAAACTCTA TTTTAGTTTT TTTTATTAAAT AATTIAGATA TAAAAATAGAA
601 TAAATAAAG TGACTAAAAA TTAACAAAT ACCCTTTAAG AAATTAATAA
651 AACTAAGGAA ACATTTTTCT TGTTCGAGT AGATAATGCC AGCTGTATA
701 AGCCGTCGA CGAGTCTAAC GGACACCAAC CAGCGAACCA GCAGCGTCGC
751 GTCGGGCCAA GCGAAGCAGA CCGCACGGCA TCTCTGTCCG TGCCCTGGA
801 CCCCTCTCGA GAGTCCGCT CCACCGTTGG ACTTGCTCCG CTGTGGCAT
851 CCAGAAATTG CGTGGCGGAG CCGCAGACGT GAGCCGGCAC GGCAGCGGC
901 CTCCTCTCC TCTCAGGCA CCGCAGCTAC GGGGATTCC TTTCCACCG
951 CTCCTTCGCT TTCCCTTCCT CGCCGCGCGT AATAAATAGA CACCCCTCC
1001 ACACCTCTTT TCCCAACCT CGTGTGTTT GAGCGCAC CACACACAAC
1051 CAGATCTCCC CCAATCCAC CCGTCGGCAC CTCGGCTTCA AGGTACGCCG
1101 CTCGTCTCC CCCCCCCCC CTCTCTACCT TCTCTAGATC GCGTTCCGG
1151 TCCATGCATG GTTAGGGCCC GGTAGTTCTA CTTCTGTTCA TGTGTGT
1201 AGATCCGTTG TTGTGTTAGA TCCGTGCTGC TAGCGTTCGT ACACGGAIGC
1251 GACCTGTACG TCAGACACGT TCTGATTGCT AACTTGCCAG TGTTCCTT
1301 TGGGGAATCC TGGGATGGCT CTAGCCGTTT CCGACACGGG ATCGATTCA
1351 TGATTTTTTT TGTTCGTTG CATAGGGTTT GGTTCGCCCT TTTCCCTTAT
1401 TTCAATATAT GCCGTGCACT TGTTCGTTG GTCATCTTTT CATGCTTTTT
1451 TTTGTCTTGG TTGTGATGAT GTGGTCTGGT TGGGCGGTCC TTCTAGATCG
1501 GAGTAGAATT CTGTTTCAAA CTACCTGGTG GATTATATA TTTTGGATCT
1551 GTATGTGTGT GCCATACATA TTCATAGTTA CGAATTGAAG ATGATGGATG
1601 GAAATATCGA TCTAGGATAG GTATACATGT TGATCGGGT TTTACTGATG
1651 CATATACAGA GATGCTTTTT GTTCGCTTGG TTGTGATGAT GTGGTGTGGT

```

FIG 5B CONT.

1701 TGGGCGGTG TTTATTCGTT CTAGATCGGA GTAGATACT GTTCAAACT  
1751 ACCTGGTGTA TTTATTAATT TTGAACTGT ATGTGTGTGT CATACATCTT  
1801 CATAGTTACG AGTTAAGAT GGATGGAAT ATCGATCTAG GATAGGTATA  
1851 CATGTTGATG TGGGTTTAC TGATGCATAT ACATGATGGC ATATGCAGCA  
1901 TCTATTTCATA TGCTCTAACC TTGAGTACCT ATCTATTATA ATAAACAAGT  
1951 ATGTTTATATA ATTATTTTGA TCTTGATATA CTTGGATGAT GGCATATGCA  
2001 GCAGCTATAT GTGGATTTT TTAGCCCTGC CTTCATACGC TATTTATTTG  
2051 CTTGGTACTG TTTCTTTTGT CGATGCTCAC CCTGTTGTTT GGTGTTACTT  
2101 CTGCAGGTA CCCCAGGCT CGACCATGGT AAGGGCAGC CACCACCACC  
2151 ACCACCACAT GGTCCGTCCT GTAGAAACCC CAACCCGTGA AATCAAAAAA  
2201 CTCGACGGCC TGTGGGCATT CAGTCTGGAT CGCGAAAACT GTGGAATTGA  
2251 TCAGCGTTGG TGGGAAAGCG CGTTACAAGA AAGCCGGGCA ATTGCTGTGC  
2301 CAGGCAGTTT TAACGATCAG TTCGCCGATG CAGATATTCT TAATTATGCG  
2351 GGCAACGCTT GGTATCAGCG CGAAGTCTTT ATACCGAAAG GTTGGGCAGG  
2401 CCAGCGTATC GTGCTGCGTT TCGATGCGGT CACTCATTAC GGCAAAAGTGT  
2451 GGTCAATAA TCAGGAAGTG ATGGAGCATC AGGGCGGCTA TACGCCATTT  
2501 GAAGCCGATG TCACGCCGTA TGTATTGCC GGGAAAAAGTG TACGTATCAC  
2551 CGTTTGTGTG AACAAACGAA TGAACCTGGCA GACTATCCCG CCGGGAATGG  
2601 TGATTACCGA CGAAACGGC AAGAAAAAGC AGTCTTACTT CCATGATTTC  
2651 TTTAACTATG CCGGAATCCA TCGCAGCGTA ATGCTCTACA CCACGCCGAA  
2701 CACCTGGGTG GACGATATCA CCGTGGTGAC GCATGTGCGG CAAGACTGTA  
2751 ACCACGCGTC TGTTGACTGG CAGGTGGTGG CCAATGGTGA TGTACGCGTT  
2801 GAACTGCGTG ATGCGGATCA ACAGGTGGTT GCAACTGGAC AAGGCACCTAG  
2851 CGGCACTTTG CAAGTGGTGA ATCCGCACCT CTGGCAACCG GGTGAAGTTT  
2901 ATCTCTATGA ACTGTGCGTC ACAGCCAAA GCCAGACAGA GTGTGATATC  
2951 TACCCGCTTC GGTCTGGCAT CCGTCACTG GCAGTGAAGG GCGAACAGTT  
3001 CCTGATTAA CACAAACCGT TCTACTTTAC TGGCTTTGGT CGTCATGAAG  
3051 ATGCGGACTT ACGTGGCAAA GGATTCGATA ACGTCTGAT GGTGCACGAC  
3101 CACGCATTAA TGGACTGGAT TGGGGCCAAC TCCTACCGTA CCTCGCATTA  
3151 CCCTTACGCT GAAGAGATGC TCGACTGGGC AGATGAACAT GGCATCGTGG  
3201 TGATTGATGA AACTGCTGCT GTCGGCTTTA ACCTCTCTTT AGGCATTGGT

FIG 5B CONT.

3251 TTCGAAGCGG GCAACAAGCC GAAAGAACTG TACAGCGAAG AGGCAGTCAA  
3301 CGGGGAAACT CAGCAAGCGC ACTTACAGGC GATTAAAGAG CTGATAGCGC  
3351 GTGACAAAAA CCACCCAAGC GTGGTGATGT GGAGTATTGC CAACGAACCG  
3401 GATACCCGTC CGCAAGTGCA CGGGAATATT TCGCCACTGG CGGAAGCAAC  
3451 GCGTAAACTC GACCCGACGC GTCCGATCAC CTGCGTCAAT GTAATGTTCT  
3501 GCGACGCTCA CACCGATACC ATCAGCGATC TCTTTGATGT GCTGTGCCTG  
3551 AACCGTTATT ACGGATGGTA TGTCCAAAGC GCGGATTGG AAACGGCAGA  
3601 GAAGTACTG GAAAAAGAAC TTCTGGCCCTG GCAGGAGAAA CTGCATCAGC  
3651 CGATTATCAT CACCGAATAC GCGTGGATA CGTTAGCCGG GCTGCACTCA  
3701 ATGTACACCG ACATGTGGAG TGAAGAGTAT CAGTGTGCAT GGCTGGATAT  
3751 GTATCACCGC GTCTTTGATC GCGTCAGCGC CGTCGTCGGT GAACAGGTAT  
3801 GGAATTTCGC CGATTTTGGC ACCTCGCAAG GCATATTGCG CGTTGGCGGT  
3851 AACAAAGAAAG GGATCTTCAC TCGCGACCGC AAACCGAAGT CGGCGGCTTT  
3901 TCTGCTGCAA AAACGCTGGA CTGGCATGAA CTTCCGGTGAA AAACCGCAGC  
3951 AGGGAGGCAA ACAATGATAA TGAGCTCGTT TAAACTGAGG GCACCTGAAGT  
4001 CGCTTGATGT GCTGAATTGT TTGTGATGTT GGTGGCGTAT TTTGTTTAAA  
4051 TAAAGTAAGCA TGGCTGTGAT TTTATCATAT GATCGATCTT TGGGGTTTTA  
4101 TTAAACACAT TGTAAAATGT GTATCTATTA ATAACTCAAT GTATAAGATG  
4151 TGTTCAATTCT TCGGTTGCCA TAGATCTGCT TATTTGACCT GTGATGTTTT  
4201 GACTCCAAAA ACCAAAATCA CAACCTCAATA AACTCATGGA ATATGTCCAC  
4251 CTGTTTCTTG AAGAGTTTCA CTACCATTC AGTTGGCATT TATCAGTGTT  
4301 GCAGCGGCGC TGTGCTTTGT AACATAACAA TTGTTACGGC ATATATCCAA  
4351 CGGCCGGCCT AGCTAGCCAC GGTGGCCAGA TCCACTAGTT CTAGAGCGGC  
4401 CGCTTAATTC ACTGGCCGTC GTTTTACAAC GTCGTGACTG GGAAAACCCCT  
4451 GCGGTTACCC AACTTAAATCG CCTTGCAGCA CATCCCCCTT TCGCCAGCTG  
4501 GCGTAATAGC GAAGAGGCCCC GCACCGATCG CCCTTCCCAA CAGTTGCGCA  
4551 GCCTGAATGG CGAATGGCGC CTGATGCGGT ATTTTCTCCT TACGCATCTG  
4601 TCGGTAATTT CACACCCGAT ATGGTGCACT CTCAGTACAA TCTGCTCTGA  
4651 TGCCGCATAG TTAAGCCAGC CCCGACACCC GCCAACACCC GCTGACGCGC  
4701 CCTGACGGGC TTGTCGTGTC CCGGCATCCG CTTACAGACA AGCTGTGACC  
4751 GTCTCCGGGA GCTGCAATGT TCAGAGGTTT TCACCGTCAT CACCGAAAACG

FIG 5B CONT.

4801 CGCGAGACGA AAGGCCTCG TGATACGCCT ATTTTATAG GTTAATGTCA  
 4851 TGATAATAAT GGTTCCTTAG ACGTCAGGTG GCACTTTTCG GGGAAATGTG  
 4901 CGCGGAACCC CTATTTGTTT ATTTTCTAA ATACATTCAA ATATGTATCC  
 4951 GCTCATGAGA CAATAACCTT GATAAATGCT TCAATAATAT TGA AAAAGGA  
 5001 AGAGTATGAG TATCAACAT TTCCGTGTCG CCTTATTTCC CTTTTTTGCG  
 5051 GCATTTTGCC TTCCTGTTTT TGCTCACCCA GAAACGCTGG TGA AAGTAAA  
 5101 AGATGCTGAA GATCAGTTGG GTGCACGAGT GGTGTACATC GAAC TGGATC  
 5151 TCAACAGCGG TAAGATCCTT GAGAGTTTTC GCCCCGAAGA ACGTTTTCOA  
 5201 ATGATGAGCA CTTTTAAAGT TCTGCTATGT GCGCGGTAT TATCCCGTAT  
 5251 TGACGCCCGG CAAGAGCAAC TCGGTCGCCG CATACTAT TCTCAGAATG  
 5301 ACTTGGTTGA GTACTCACCA GTCACAGAA AGCATCTTAC GGATGGCATG  
 5351 ACAGTAAGAG AATTATGCAG TGCTGCCATA ACCATGAGTG ATAACACTGC  
 5401 GGCCAACTTA CTTCTGACAA CGATCGGAG ACCGAAGGAG CTAACCCGCTT  
 5451 TTTTGACAAA CATGGGGGAT CATGTAACTC GCCTTGATCG TTGGGAACCG  
 5501 GAGCTGAATG AAGCCATACC AAACGACGAG CGTGACACCA CGATGCCCTGT  
 5551 AGCAATGGCA ACAACGTTGC GCAAACTATT AACTGGCGAA CTACTTACTC  
 5601 TAGCTTCCCG GCAACAATTA ATAGACTGGA TGGAGGCGGA TAAAGTTGCA  
 5651 GGACCACTTC TCGCTCGGC CCTTCCGGCT GGCTGGTTTA TTGCTGATAA  
 5701 ATCTGGAGCC GGTGAGCGTG GGTCTCGCG TATCATTGCA GCACTGGGGC  
 5751 CAGATGGTAA GCCCTCCCGT ATCGTAGTTA TCTACACGAC GGGGAGTCAG  
 5801 GCAACTATGG ATGAACGAAA TAGACAGATC GCTGAGATAG GTGCCTCACT  
 5851 GATTAAGCAT TGGTAACTGT CAGACCAAGT TTACTCATAT ATACTTTAGA  
 5901 TTGATTTAAA ACTTCATTTT TAAATTTAAA GGATCTAGGT GAAGATCCTT  
 5951 TTTGATAATC TCATGACCAA AATCCCTTAA CGTGAGTTTT CGTTCCACTG  
 6001 AGCGTCAGAC CCCGTAGAAA AGATCA AAGG ATCTTCTTGA GATCCTTTTT  
 6051 TTCTGCGCGT AATCTGCTGC TTGCA AACA AAAAACCACC GCTACACGCG  
 6101 GTGGTTTGTG TGCCGGATCA AGAGCTACCA ACTCTTTTTC CGAAGGTAAC  
 6151 TGGCTTCAGC AGAGCGCAGA TACCA AATAC TGTCCTTCTA GTGTAGCCGT  
 6201 AGTTAGGCCA CCACTTCAAG AACTCTGTAG CACCGCCTAC ATACCTCGCT  
 6251 CTGCTAATCC TGTACCAGT GGTGCTGCC AGTGGCGATA AGTCGTGTCT  
 6301 TACCGGGTTG GACTCAAGAC GATAGTTACC GGATAAGGCG CAGCGGTCCG

FIG 5B CONT.

6351 GCTGAACGGG GGGTTCGTGC ACACAGCCCA GCTTGGAGCG AACGACCTAC  
6401 ACCGAACCTGA GATACCTACA GCGTGAGCAT TGAGAAAGCG CCACGCTTCC  
6451 CGAAGGGAGA AAGGCGGACA GGTATCCGGT AAGCGGCAGG GTCGGAACAG  
6501 GAGAGCGCAC GAGGGAGCTT CCAGGGGGA ACGCCTGGTA TCTTTATAGT  
6551 CCTGTCCGGT TTCGCCACCT CTGACTTGAG CGTCGATTTT TGTGATGCTC  
6601 GTCAGGGGGG CGGAGCCTAT GGAAAAACGC CAGCAACGCG GCCTTTTAC  
6651 GGTTCCTGGC CTTTTCCTGG CTTTTCGCTG CTTTTCGCTC ACATGTTCTT TCCTGCGTTA  
6701 TCCCCTGATT CTGTGGATAA CCGTATTACC GCCTTTGAGT GAGCTGATAC  
6751 CGCTCGCCG AGCCGAACGA CCGAGCGCAG CGAGTCAGTG AGCGAGGAAG  
6801 CGGAAGAGCG CCCAATACGC AAACCGCCTC TCCCCGCGCG TTGGCCGATT  
6851 CATTAAATGCA GCTGGCACGA CAGTTTCCC GACTGGAAG CGGGCAGTGA  
6901 GCGCAACGCA ATTAATGTA GTTAGCTCAC TCATTAGGCA CCCCAGGCTT  
6951 TACACTTTAT GCTTCCGGCT CGTATGTTGT GTGGAATTGT GAGCGGATAA  
7001 CAATTTCACA CAGGAAACAG CTATGAC

FIG 5B CONT.




FIG. 6A

## pDAB7119 6818bp

Sequence	Feature
1-38 Linker	CCTGCAGATCCCCGGGGATCCTCTAGAGTCGACCTGCA
39-2028	Maize Ubiquitin 1 promoter
2029-2047 Linker	GGGTACCCCCGGGGTCGAC
2048-3695	GNT III v.2 plus TAGGTTT
2462	C to replace G as reported in original sequence
3696-3699 PmeI	AAAC
3700-4064	Maize Per 5 3'UTR
4065-6818	pUC19 backbone
4259-4264	TGCGCA FspI
4720-5580	Ampicillin Resistance gene
5282-5287	TGCGCA FspI

BamHI

~~~~~

```

1  CCTGCAGATC CCCGGGGATC CTCTAGAGTC GACCTGCAGT
   GCAGCGTGAC CCGGTCGTGC CCCTCTCTAG AGATAATGAG
   CATTGCATGT CTAAGTTATA
101 AAAAATTACC ACATATTTTT TTTGTCACAC TTGTTTGAAG
    TGCAGTTTAT CTATCTTTAT ACATATATTT AAACTTTAAT
    CTACGAATAA TATAATCTAT
201 AGTACTACAA TAATATCAGT GTTTTAGAGA ATCATATAAA
    TGAACAGTTA GACATGGTCT AAAGGACAAT TGAGTATTTT
    GACAACAGGA CTCTACAGTT
301 TTATCTTTTT AGTGTGCATG TGTTCTCCTT TTTTTTTGCA
    AATAGCTTCA CCTATATAAT ACTTCATCCA TTTTATTAGT
    ACATCCATTT AGGGTTTAGG
401 GTTAATGGTT TTTATAGACT AATTTTTTTT GTACATCTAT
    TTTATTCTAT TTTAGCCTCT AAATTAAGAA AACTAAAAC
    CTATTTTAGT TTTTATTATT
501 AATAATTTAG ATATAAAATA GAATAAAATA AAGTGACTAA
    AAATTAAACA AATACCCTTT AAGAAATTAA AAAAATAAG
    GAAACATTTT TCTTGTTTCG
601 AGTAGATAAT GCCAGCCTGT TAAACGCCGT CGACGAGTCT
    AACGGACACC AACCAGCGAA CCAGCAGCGT CGCGTCGGGC
    CAAGCGAAGC AGACGGCAGC
701 GCATCTCTGT CGCTGCCTCT GGACCCCTCT CGAGAGTTCC
    GCTCCACCGT TGGACTTGCT CCGCTGTCGG CATCCAGAAA
    TTGCGTGCGG GAGCGGCAGA
801 CGTGAGCCGG CACGGCAGGC GGCCTCCTCC TCCTCTCACG
    GCACGGCAGC TACGGGGGAT TCCTTTCCCA CCGCTCCTTC
    GCTTCCCTT CCTCGCCCGC

```

FIG 6B



```

901  CGTAATAAAT AGACACCCCC TCCACACCCT CTTTCCCCAA
      CCTCGTGTTG TTCGGAGCGC ACACACACAC AACCAGATCT
      CCCCCAAATC CACCCGTCGG
1001  CACCTCCGCT TCAAGGTACG CCGCTCGTCC TCCCCCCCCC
      CCCCTCTCTA CCTTCTCTAG ATCGGCGTTC CGGTCCATGC
      ATGGTTAGGG CCCGGTAGTT
1101  CTACTTCTGT TCATGTTTGT GTTAGATCCG TGTTTGTGTT
      AGATCCGTGC TGCTAGCGTT CGTACACGGA TGCGACCTGT
      ACGTCAGACA CGTTCTGATT
1201  GCTAACTTGC CAGTGTTTCT CTTTGGGGAA TCCTGGGATG
      GCTCTAGCCG TTCCGCAGAC GGGATCGATT TCATGATTTT
      TTTTGTTTCG TTGCATAGGG
1301  TTTGGTTTGC CCTTTTCCTT TATTTCAATA TATGCCGTGC
      ACTTGTTTGT CGGGTCATCT TTTCATGCTT TTTTGTGTCT
      TGGTTGTGAT GATGTGGTCT
1401  GGTGCGGCGG TCGTTCTAGA TCGGAGTAGA ATTCTGTTTC
      AAACCTACCTG GTGGATTAT TAATTTTGA TCTGTATGTG
      TGTGCCATAC ATATTCATAG
1501  TTACGAATTG AAGATGATGG ATGGAAATAT CGATCTAGGA
      TAGGTATACA TGTTGATGCG GGTTTTACTG ATGCATATAC
      AGAGATGCTT TTTGTTTCGCT
1601  TGGTTGTGAT GATGTGGTGT GGTTGGGCGG TCGTTCATTC
      GTTCTAGATC GGAGTAGAAT ACTGTTTCAA ACTACCTGGT
      GTATTTATTA ATTTTGAAC
1701  TGTATGTGTG TGTCATACAT CTTCATAGTT ACGAGTTTAA
      GATGGATGGA AATATCGATC TAGGATAGGT ATACATGTTG
      ATGTGGGTTT TACTGATGCA
1801  TATACATGAT GGCATATGCA GCATCTATTC ATATGCTCTA
      ACCTTGAGTA CCTATCTATT ATAATAAACA AGTATGTTTT
      ATAATTATTT TGATCTTGAT
1901  ATACTTGGAT GATGGCATAT GCAGCAGCTA TATGTGGATT
      TTTTGTAGCCC TGCCTTCATA CGCTATTTAT TTGCTTGGTA
      CTGTTTCTTT TGTCGATGCT

```

NcoI

FseI

```

~~~~~
~~~~~

```

```

2001  CACCCTGTTG TTTGGTGTTA CTTCTGCAGG GTACCCCGG
      GGTCGACCAT GGTGATGAGA CGCTACAAGC TCTTTCTCAT
      GTTCTGTATG GCCGGCCTGT
2101  GCCTCATCTC CTTCTGCAC TTCTTCAAGA CCCTGTCCTA
      TGTACCTTC CCCCAGAGAAC TGGCCTCCCT CAGCCCTAAC
      CTGGTGTCCA GCTTTTCTG
2201  GAACAATGCC CCGGTCACGC CCCAGGCCAG CCCCAGCCA
      GGAGGCCCTG ACCTGCTGCG TACCCCACTC TACTCCCACT
      CGCCCCTGCT GCAGCCGCTG

```

FIG 6B CONT.

16/41

SacI

FspI

~~~~~

~~~~~

2301 CCGCCCAGCA AGGCGGCCGA GGAGCTCCAC CGGGTGGACT  
 TGGTGCTGCC CGAGGACACC ACCGAGTATT TCGTGCGCAC  
 CAAGGCCGGC GGCGTCTGCT  
 2401 TCAAACCCGG CACCAAGATG CTGGAGAGGC CCCCCCGGG  
 ACGGCCGGAG GAGAAGCCTG AGGGGGCCAA CGGCTCCTCG  
 GCGCGGCGGC CACCCCGGTA  
 2501 CCTCCTGAGC GCGCGGGAGC GCACGGGGGG CCGAGGCGCC  
 CGGCGCAAGT GGGTGGAGTG CGTGTGCCTG CCCGGCTGGC  
 ACGGACCCAG CTGCGGCGTG  
 2601 CCCACTGTGG TGCAGTACTC CAACCTGCCC ACCAAGGAGC  
 GGCTGGTGCC CAGGGAGGTG CCGCGCCGCG TCATCAACGC  
 CATCAACGTC AACCACGAGT

NotI

~~~~~

2701 TCGACCTGCT GGACGTGCGC TTCCACGAGC TGGGCGACGT  
 GGTGGACGCC TTTGTGGTGT GCGAGTCCAA CTTCACGGCT  
 TATGGGGAGC CGCGGCCGCT  
 2801 CAAGTTCCGG GAGATGCTGA CCAATGGCAC CTTGAGTAC  
 ATCCGCCACA AGGTGCTCTA TGTCTTCCTG GACCACTTCC  
 CGCCCGGCGG CCGGCAGGAC

FspI

FspI

~~~~~

~~~~~

2901 GGCTGGATCG CCGACGACTA CCTGCGCACC TTCCTACCC  
 AGGACGGCGT CTCGCGGCTG CGCAACCTGC GGCCCGACGA  
 CGTCTTCATC ATTGACGATG

FspI

~~~~~

3001 CGGACGAGAT CCCGGCCCGT GACGGCGTCC TTTTCCTCAA  
 GCTCTACGAT GGCTGGACCG AGCCCTTCGC CTTCCACATG  
 CGCAAGTCGC TCTACGGCTT  
 3101 CTTCTGGAAG CAGCCGGGCA CCCTGGAGGT GGTGTCAGGC  
 TGCACGGTGG ACATGCTGCA GGCAGTGTAT GGGCTGGACG  
 GCATCCGCCT GCGCCGCCGC  
 3201 CAGTACTACA CCATGCCCAA CTTGAGACAG TATGAGAACC  
 GCACCGGCCA CATCCTGGTG CAGTGGTCGC TGGGCAGCCC  
 CCTGCACTTC GCCGGCTGGC

FIG 6B CONT.

3301 ACTGCTCCTG GTGCTTCACG CCCGAGGGCA TCTACTTCAA  
 GCTCGTGTCC GCCCAGAATG GCGACTTCCC ACGCTGGGGT  
 GACTACGAGG ACAAGCGGGA  
 3401 CCTGAACTAC ATCCGCGGCC TGATCCGCAC CGGGGGCTGG  
 TTCGACGGCA CGCAGCAGGA GTACCCGCCT GCAGACCCCA  
 GCGAGCACAT GTATGCGCCC  
 3501 AAGTACCTGC TGAAGAACTA CGACCGGTTC CACTACCTGC  
 TGGACAACCC CTACCAGGAG CCCAGGAGCA CGGCGGCGGG  
 CGGGTGGCGC CACAGGGGTC

BamHI

PmeI

~~~~~

~~~~~

3601 CCGAGGGAAG GCCGCCCCGCC CGGGGCAAAC TGGACGAGGC  
 GGAAGTCGAA CAAAACTCA TCTCAGAAGA GGATCTGAAT  
 TAGGATCCTA GGTTTAAACT  
 3701 GAGGGCACTG AAGTCGCTTG ATGTGCTGAA TTGTTTGTGA  
 TGTTGGTGGC GTATTTTGT TAAATAAGTA AGCATGGCTG  
 TGATTTTATC ATATGATCGA  
 3801 TCTTTGGGGT TTTATTTAAC ACATTGTAAA ATGTGTATCT  
 ATTAATAACT CAATGTATAA GATGTGTTCA TTCTTCGGTT  
 GCCATAGATC TGCTTATTTG  
 3901 ACCTGTGATG TTTTGACTCC AAAAACC AAA ATCACAACTC  
 AATAAACTCA TGGAATATGT CCACCTGTTT CTTGAAGAGT  
 TCATCTACCA TTCCAGTTGG

FseI

~~~~~

4001 CATTTATCAG TGTTGCAGCG GCGCTGTGCT TTGTAACATA  
 ACAATTGTTC ACGGCATATA TCCACGGCCG GCCTAGCTAG  
 CCACGGTGGC CAGATCCACT

NotI

~~~~~

4101 AGTTCTAGAG CGGCCGCTTA ATTCACTGGC CGTCGTTTTA  
 CAACGTCGTG ACTGGGAAAA CCCTGGCGTT ACCCAACTTA  
 ATCGCCTTGC AGCACATCCC

FspI

~~~~~

4201 CCTTTCGCCA GCTGGCGTAA TAGCGAAGAG GCCCGCACCG  
 ATCGCCCTTC CCAACAGTTG CGCAGCCTGA ATGGCGAATG  
 GCGCCTGATG CGGTATTTTC  
 4301 TCCTTACGCA TCTGTGCGGT ATTTACACACC GCATATGGTG  
 CACTCTCAGT ACAATCTGCT CTGATGCCGC ATAGTTAAGC  
 CAGCCCCGAC ACCCGCCAAC

FIG 6B CONT.

4401 ACCCGCTGAC GCGCCCTGAC GGGCTTGTCT GCTCCCGGCA  
 TCCGCTTACA GACAAGCTGT GACCGTCTCC GGGAGCTGCA  
 TGTGTCAGAG GTTTTACACG  
 4501 TCATCACCGA AACGCGCGAG ACGAAAGGGC CTCGTGATAC  
 GCCTATTTTT ATAGGTTAAT GTCATGATAA TAATGGTTTC  
 TTAGACGTCA GGTGGCACTT  
 4601 TTCGGGGAAA TGTGCGCGGA ACCCCTATTT GTTTATTTTT  
 CTAAATACAT TCAAATATGT ATCCGCTCAT GAGACAATAA  
 CCCTGATAAA TGCTTCAATA  
 4701 ATATTGAAAA AGGAAGAGTA TGAGTATTCA ACATTTCCGT  
 GTCGCCCTTA TTCCCTTTTT TGCGGCATTT TGCCTTCCTG  
 TTTTGTCTCA CCCAGAAACG  
 4801 CTGGTGAAAG TAAAAGATGC TGAAGATCAG TTGGGTGCAC  
 GAGTGGGTTA CATCGAACTG GATCTCAACA GCGGTAAGAT  
 CCTTGAGAGT TTTCGCCCCG  
 4901 AAGAACGTTT TCCAATGATG AGCACTTTTA AAGTTCTGCT  
 ATGTGGCGCG GTATTATCCC GTATTGACGC CGGGCAAGAG  
 CAACTCGGTC GCCGCATACA  
 5001 CTATTCTCAG AATGACTTGG TTGAGTACTC ACCAGTCACA  
 GAAAAGCATC TTACGGATGG CATGACAGTA AGAGAATTAT  
 GCAGTGCTGC CATAACCATG  
 5101 AGTGATAACA CTGCGGCCAA CTTACTTCTG ACAACGATCG  
 GAGGACCGAA GGAGCTAACC GCTTTTTTGC ACAACATGGG  
 GGATCATGTA ACTCGCCTTG

FspI

~~~~~

5201 ATCGTTGGGA ACCGGAGCTG AATGAAGCCA TACCAAACGA  
 CGAGCGTGAC ACCACGATGC CTGTAGCAAT GGCAACAACG  
 TTGCGCAAAC TATTAAGTGG  
 5301 CGAACTACTT ACTCTAGCTT CCCGGCAACA ATTAATAGAC  
 TGGATGGAGG CGGATAAAGT TGCAGGACCA CTTCTGCGCT  
 CGGCCCTTCC GGCTGGCTGG  
 5401 TTTATTGCTG ATAAATCTGG AGCCGGTGAG CGTGGGTCTC  
 GCGGTATCAT TGCAGCACTG GGGCCAGATG GTAAGCCCTC  
 CCGTATCGTA GTTATCTACA  
 5501 CGACGGGGAG TCAGGCAACT ATGGATGAAC GAAATAGACA  
 GATCGCTGAG ATAGGTGCCT CACTGATTAA GCATTGGTAA  
 CTGTCAGACC AAGTTTACTC  
 5601 ATATATACTT TAGATTGATT TAAAACTTCA TTTTAAATTT  
 AAAAGGATCT AGGTGAAGAT CCTTTTTTGAT AATCTCATGA  
 CCAAAATCCC TTAACGTGAG  
 5701 TTTTCGTTCC ACTGAGCGTC AGACCCCGTA GAAAAGATCA  
 AAGGATCTTC TTGAGATCCT TTTTCTCTGC GCGTAATCTG  
 CTGCTTGCAA ACAAAAAAAC

FIG 6B CONT.

5801 CACCGCTACC AGCGGTGGTT TGTTTGCCGG ATCAAGAGCT  
ACCAACTCTT TTTCCGAAGG TAACTGGCTT CAGCAGAGCG  
CAGATACCAA ATACTGTCCT  
5901 TCTAGTGTAG CCGTAGTTAG GCCACCACTT CAAGAACTCT  
GTAGCACCGC CTACATACCT CGCTCTGCTA ATCCTGTTAC  
CAGTGGCTGC TGCCAGTGGC  
6001 GATAAGTCGT GTCTTACCGG GTTGGACTCA AGACGATAGT  
TACCGGATAA GGCGCAGCGG TCGGGCTGAA CGGGGGGTTT  
GTGCACACAG CCCAGCTTGG  
6101 AGCGAACGAC CTACACCGAA CTGAGATACC TACAGCGTGA  
GCATTGAGAA AGCGCCACGC TTCCCGAAGG GAGAAAGGCG  
GACAGGTATC CGGTAAGCGG  
6201 CAGGGTCGGA ACAGGAGAGC GCACGAGGGA GCTTCCAGGG  
GGAAACGCCT GGTATCTTTA TAGTCCTGTC GGGTTTCGCC  
ACCTCTGACT TGAGCGTCGA  
6301 TTTTGTGTGAT GCTCGTCAGG GGGGCGGAGC CTATGGAAAA  
ACGCCAGCAA CGCGGCCTTT TTACGGTTCC TGGCCTTTTG  
CTGGCCTTTT GCTCATGT  
6401 TCTTTCCTGC GTTATCCCT GATTCTGTGG ATAACCGTAT  
TACCGCCTTT GAGTGAGCTG ATACCGCTCG CCGCAGCCGA  
ACGACCGAGC GCAGCGAGTC  
6501 AGTGAGCGAG GAAGCGGAAG AGCGCCCAAT ACGCAAACCG  
CCTCTCCCCG CGCGTTGGCC GATTCATTAA TGCAGCTGGC  
ACGACAGGTT TCCCGACTGG  
6601 AAAGCGGGCA GTGAGCGCAA CGCAATTAAT GTGAGTTAGC  
TCACTCATTA GGCACCCAG GCTTTACACT TTATGCTTCC  
GGCTCGTATG TTGTGTGGAA

NotI

~~~~~

6701 TTGTGAGCGG ATAACAATTT CACACAGGAA ACAGCTATGA  
CCATGATTAC GCCAAGCTAG CGGCCGCATT CCCGGGAAGC  
TAGGCCACCG TGGCCGCCT

HindIII

~~~~~

6801 GCAGGGGAAG CTTGCATG

FIG 6B CONT.




FIG. 7A

Plasmid pDAB8504 (7545 bp)

Description: Cloning vector with Rb7 MARs (inverted orientation) flanking a multiple cloning site and the rice actin/PAT/lipase selectable marker cassette

| Nucleotide start | Nucleotide end | Sequence Feature                                                                                                                                                                                     |
|------------------|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1                | 1166           | Tobacco Rb7 MARs                                                                                                                                                                                     |
| 1167             | 1304           | Linker Sequence with multiple cloning site:<br>TGGCCACCGCTTAATTAAGGCGCGCCATGCCCGGGCAAGCG<br>GCCGCTTAATTAAATTTAAATGTTTAACTAGGAAATCCAA<br>GCTTGGGCTGCAGGTCAATCCCATTGCTTTTGAAGCAGCTC<br>AACATTGATCTCTTT |
| 1305             | 2701           | Rice actin promoter with intron                                                                                                                                                                      |
| 2235             | 2696           | Rice actin intron                                                                                                                                                                                    |
| 2702             | 2703           | CC                                                                                                                                                                                                   |
| 2704             | 3258           | PAT gene (phosphinothricin acyl transferase)                                                                                                                                                         |
| 3259             | 3272           | Linker sequence: GGTACCCTGAGCTC                                                                                                                                                                      |
| 3273             | 3629           | Maize lipase 3' UTR                                                                                                                                                                                  |
| 3630             | 3670           | Linker sequence:<br>GAATTCATATTTCTCCTGCAGGGTTTAACTTGCCGTGGC                                                                                                                                          |
| 3671             | 4836           | Tobacco Rb7 MAR (complementary)                                                                                                                                                                      |
| 4837             | 4857           | Linker sequence: CGGCCCACTAGTCACCGGTGT                                                                                                                                                               |
| 4858             | 5103           | Puc19                                                                                                                                                                                                |
| 5104             | 5130           | Linker sequence:<br>GCGCACGCTGCGCACGCTGCGCACGCT                                                                                                                                                      |
| 5130             | 7523           | Puc19                                                                                                                                                                                                |
| 7524             | 7545           | Linker sequence: ACACCGGTGTGATCATGGGCCG                                                                                                                                                              |

#### Sequence

```

1      CGATTAAAAA TCTCAATTAT ATTTGGTCTA ATTTAGTTTG GTATTGAGTA
51     AAACAAATTC GAACCAAACC AAAATATAAA TATATAGTTT TTATATATAT
101    GCCTTTAAGA CTTTTTATAG AATTTTCCTT AAAAAATATC TAGAAATATT
151    TGCGACTCTT CTGGCATGTA ATATTTCTGT AAATATGAAG TGCTCCATTT
201    TTATTAACCT TAAATAATTG GTTGTACGAT CACTTTCTTA TCAAGTGTTA
251    CTAAAATGCG TCAATCTCTT TGTTCTTCCA TATTCATATG TCAAAACCTA
301    TCAAAATTCCT TATATATCTT TTTCGAATTT GAAGTGAAAT TTCGATAATT
351    TAAAATTAAA TAGAACATAT CATTATTTAG GTATCATATT GATTTTTATA
401    CTTAATTACT AAATTTGGTT AACTTTGAAA GTGTACATCA ACGAAAAATT
451    AGTCAAACGA CTAAAATAAA TAAATATCAT GTGTTATTAA GAAAATTCTC
501    CTATAAGAAT ATTTTAATAG ATCATATGTT TGTAACAAAA ATTAATTTTT
551    ACTAACACAT ATATTTACTT ATCAAAAATT TGACAAAGTA AGATTAAAAAT
601    AATATTCATC TAACAAAAAA AAAACCAGAA AATGCTGAAA ACCCGGCAAA
651    ACCGAACCAA TCCAAACCGA TATAGTTGGT TTGGTTTGAT TTTGATATAA
701    ACCGAACCAA CTCGGTCCAT TTGCACCCCT AATCATAATA GCTTTAATAT
751    TTCAAGATAT TATTAAGTTA ACGTTGTCAA TATCCTGGAA ATTTTGCAAA
801    ATGAATCAAG CCTATATGGC TGTAATATGA ATTTAAAAGC AGCTCGATGT
851    GGTGGTAATA TGTAATTTAC TTGATTCTAA AAAAATATCC CAAGTATTAA

```

FIG 7B

```

901 TAATTTCTGC TAGGAAGAAG GTTAGCTACG ATTTACAGCA AAGCCAGAAT
951 ACAATGAACC ATAAAGTGAT TGAAGCTCGA AATATACGAA GGAACAAATA
1001 TTTTAAAAA AATACGCAAT GACTTGGAAC AAAAGAAAGT GATATATTTT
1051 TTGTTCTTAA ACAAGCATCC CCTCTAAAGA ATGGCAGTTT TCCTTTGCAT
1101 GTAACATTA TGCTCCCTTC GTTACAAAAA TTTTGGACTA CTATTGGGAA
1151 CTTCTTCTGA AAATAGTGGC CACCGCTTAA TTAAGGCGCG CCATGCCCCG
1201 GCAAGCGGCC GCTTAATTAA ATTTAAATGT TTAAACTAGG AAATCCAAGC
1251 TTGGGCTGCA GGTCAATCCC ATTGCTTTTG AAGCAGCTCA ACATTGATCT
1301 CTTTCTCGAG GTCATTCATA TGCTTGAGAA GAGAGTCGGG ATAGTCCAAA
1351 ATAAAAACAAA GGTAAGATTA CCTGGTCAAA AGTGAAAACA TCAGTTAAAA
1401 GGTGGTATAA AGTAAAATAT CGGTAATAAA AGGTGGCCCA AAGTGAAATT
1451 TACTCTTTTC TACTATTATA AAAATTGAGG ATGTTTTTGT CGGTACTTTG
1501 ATACGTCATT TTTGTATGAA TTGGTTTTTA AGTTTATTCG CTTTTGGAAA
1551 TGCATATCTG TATTTGAGTC GGGTTTTAAG TTCGTTTGCT TTTGTAAATA
1601 CAGAGGGATT TGTATAAGAA ATATCTTTAA AAAAACCCAT ATGCTAATTT
1651 GACATAATTT TTGAGAAAAA TATATATTCA GGCGAATTCT CACAATGAAC
1701 AATAATAAGA TTAAAATAGC TTTCCCCCGT TGCAGCGCAT GGGTATTTTT
1751 TCTAGTAAAA ATAAAAGATA AACTTAGACT CAAAACATTT AAAAAACAA
1801 CCCCTAAAGT TCCTAAAGCC CAAAGTGCTA TCCACGATCC ATAGCAAGCC
1851 CAGCCCAACC CAACCCAACC CAACCCACCC CAGTCCAGCC AACTGGACAA
1901 TAGTCTCCAC ACCCCCCCAC TATCACCGTG AGTTGTCCGC ACGCACCGCA
1951 CGTCTCGCAG CCAAAAAAAA AAAAAGAAAG AAAAAAAGA AAAAGAAAAA
2001 ACAGCAGGTG GGTCCGGGTC GTGGGGGCCG GAAACGCGAG GAGGATCGCG
2051 AGCCAGCGAC GAGGCCGGCC CTCCCTCCGC TTCCAAAGAA ACGCCCCCA
2101 TCGCCACTAT ATACATACCC CCCCCTCTCC TCCCATCCCC CCAACCCTAC
2151 CACCACCACC ACCACCACCT CCACCTCCTC CCCCCTCGCT GCCGGACGAC
2201 GCCTCCCCCC TCCCCCTCCG CCGCCGCGCG GCCGTAACC ACCCCGCCCC
2251 TCTCCTCTTT CTTTCTCCGT TTTTTTTTTC CGTCTCGGTC TCGATCTTTG
2301 GCCTTGGTAG TTTGGGTGGG CGAGAGGCGG CTCGTGCGC GCCCAGATCG
2351 GTGCGCGGGA GGGGCGGGAT CTCGCGGCTG GGGCTCTCGC CGGCGTGGAT
2401 CCGGCCCCGA TCTCGCGGGG AATGGGGCTC TCGGATGTAG ATCTGCGATC
2451 CGCCGTTGTT GGGGGAGATG ATGGGGGTT TAAATTTCC GCCATGCTAA
2501 ACAAGATCAG GAAGAGGGGA AAAGGGCACT ATGGTTTATA TTTTATATA
2551 TTTCTGCTGC TTCGTCAGGC TTAGATGTGC TAGATCTTTC TTTCTTCTTT
2601 TTGTGGGTAG AATTTGAATC CCTCAGCAT GTTCATCGGT AGTTTTTCTT
2651 TTCATGATTT GTGACAAATG CAGCCTCGTG CGGAGCTTTT TTGTAGGTAG
2701 ACCATGGCTT CTCCGGAGAG GAGACCAGTT GAGATTAGGC CAGCTACAGC
2751 AGCTGATATG GCCGCGGTTT GTGATATCGT TAACCATTAC ATTGAGACGT
2801 CTACAGTGAA CTTTAGGACA GAGCCACAAA CACCACAAGA GTGGATTGAT
2851 GATCTAGAGA GGTTGCAAGA TAGATACCCT TGGTTGGTTG CTGAGGTTGA
2901 GGGTGTGTG GCTGGTATTG CTTACGCTGG GCCCTGGAAG GCTAGGAACG
2951 CTTACGATTG GACAGTTGAG AGTACTGTTT ACGTGTCACT TAGGCATCAA
3001 AGGTTGGGCC TAGGATCCAC ATTTGACACA CATTTGCTTA AGTCTATGGA
3051 GGCACAAGGT TTTAAGTCTG TGGTTGCTGT TATAGGCCTT CCAAACGATC
3101 CATCTGTTAG GTTGCATGAG GCTTTGGGAT ACACAGCCCC GGGTACATTG
3151 CGCGCAGCTG GATACAAGCA TGGTGGATGG CATGATGTTG GTTTTTGGCA
3201 AAGGGATTTT GAGTTGCCAG CTCTCCAAG GCCAGTTAGG CCAGTTACCC
3251 AGATCTGAGG TACCCTGAGC TCGGTCGCAG CGTGTGCGTG TCCGTCGTAC
3301 GTTCTGGCCG GCCGGGCTT GGGCGCGCGA TCAGAAGCGT TCGGTTGGCG
3351 TGTGTGTGCT TCTGGTTTGC TTTAATTTTA CCAAGTTTGT TTCAAGGTGG
3401 ATCGCGTGGT CAAGGCCCGT GTGCTTTAAA GACCCACCGG CACTGGCAGT
3451 GAGTGTGCT GCTTGTGTAG GCTTTGGTAC GTATGGGCTT TATTTGCTTC

```

FIG 7B CONT.



```

3501  TGGATGTTGT GTACTACTTG GGTTTGTTGA ATTATTATGA GCAGTTGCGT
3551  ATTGTAATTC AGCTGGGCTA CCTGGACATT GTTATGTATT AATAAATGCT
3601  TTGCTTTCTT CTAAAGATCT TTAAGTGCTG AATTCATATT TCCTCCTGCA
3651  GGGTTTAAAC TTGCCGTGGC CTATTTTCAG AAGAAGTTCC CAATAGTAGT
3701  CCAAAATTTT TGTAAACGAAG GGAGCATAAT AGTTACATGC AAAGGAAAAC
3751  TGCCATTCTT TAGAGGGGAT GCTTGTTTAA GAACAAAAAA TATATCACTT
3801  TCTTTTGTTT CAAGTCATTG CGTATTTTTT TAAAAATATT TGTTCCCTCG
3851  TATATTTCTG GCTTCAATCA CTTTATGGTT CTTTGTATTG TGGCTTTGCT
3901  GTAAATCGTA GCTAACCTTC TTCCTAGCAG AAATTATTAA TACTTGGGAT
3951  ATTTTTTTAG AATCAAGTAA ATTACATATT ACCACCACAT CGAGCTGCTT
4001  TTAAATTCAT ATTACAGCCA TATAGGCTTG ATTCATTTTG CAAAATTTCC
4051  AGGATATTGA CAACGTTAAC TTAATAATAT CTTGAAATAT TAAAGCTATT
4101  ATGATTAGGG GTGCAAATGG ACCGAGTTGG TTCGGTTTAT ATCAAAATCA
4151  AACCAAACCA ACTATATCGG TTTGGATTGG TTCGGTTTTG CCGGGTTTTT
4201  AGCATTTTCT GGTTTTTTTT TTGTTAGATG AATATTATTT TAATCTTACT
4251  TTGTCAAATT TTTGATAAGT AAATATATGT GTTAGTAAAA ATTAATTTTT
4301  TTTACAAACA TATGATCTAT TAAAATATTC TTATAGGAGA ATTTTCTTAA
4351  TAACACATGA TATTTATTTA TTTTAGTCGT TTGACTAATT TTTTCGTTGAT
4401  GTACACTTTC AAAGTTAACC AAATTTAGTA ATTAAGTATA AAAATCAATA
4451  TGATACCTAA ATAATGATAT GTTCTATTTA ATTTTAAATT ATCGAAATTT
4501  CACTTCAAAT TCGAAAAAGA TATATAAGAA TTTTGATAGA TTTTGACATA
4551  TGAATATGGA AGAACAAAGA GATTGACGCA TTTTAGTAAC ACTTGATAAG
4601  AAAGTGATCG TACAACCAAT TATTTAAAGT TAATAAAAAAT GGAGCACTTC
4651  ATATTTAACG AAATATTACA TGCCAGAAGA GTCGCAAATA TTTCTAGATA
4701  TTTTTTAAAG AAAATTCCTAT AAAAAGTCTT AAAGGCATAT ATATAAAAAAC
4751  TATATATTTA TATTTTGGTT TGGTTCGAAT TTGTTTTACT CAATACCAAA
4801  CTAAATTAGA CCAATATATA TTGGGATTTT TAATCGCGGC CCACTAGTCA
4851  CCGGTGTAGC TTGGCGTAAT CATGGTCATA GCTGTTTCCT GTGTGAAATT
4901  GTTATCCGCT CACAATTCCA CACAACATAC GAGCCGGAAG CATAAAGTGT
4951  AAAGCCTGGG GTGCCTAATG AGTGAGCTAA CTCACATTAA TTGCGTTGCG
5001  CTCACTGCCC GCTTTCCAGT CGGGAAACCT GTCGTGCCAG CTGCATTAAT
5051  GAATCGGCCA ACGCGCGGGG AGAGGCGGTT TGCCTATTGG GCGCTCTTCC
5101  GCTGCGCACG CTGCGCACGC TGCGCACGCT TCCTCGCTCA CTGACTCGCT
5151  GCGCTCGGTC GTTCGGCTGC GGCGAGCGGT ATCAGCTCAC TCAAAGGCGG
5201  TAATACGGTT ATCCACAGAA TCAGGGGATA ACGCAGGAAA GAACATGTGA
5251  GCAAAAGGCC AGCAAAAGGC CAGGAACCGT AAAAAGGCCG CGTTGCTGGC
5301  GTTTTTCCAT AGGCTCCGCC CCCCTGACGA GCATCACAAA AATCGACGCT
5351  CAAGTCAGAG GTGGCGAAAC CCGACAGGAC TATAAAGATA CCAGGCGTTT
5401  CCCCCTGGAA GCTCCCTCGT GCGCTCTCCT GTTCCGACCC TGCCGCTTAC
5451  CGGATACCTG TCCGCCTTTC TCCCTTCGGG AAGCGTGGCG CTTTCTCATA
5501  GCTCACGCTG TAGGTATCTC AGTTCGGTGT AGGTCGTTCT CTCCAAGCTG
5551  GGCTGTGTGC ACGAACCCCC CGTTCAGCCC GACCGCTGCG CTTTATCCGG
5601  TAACTATCGT CTTGAGTCCA ACCCGGTAAG ACACGACTTA TCGCCACTGG
5651  CAGCAGCCAC TGGTAACAGG ATTAGCAGAG CGAGGTATGT AGGCGGTGCT
5701  ACAGAGTTCT TGAAGTGGTG GCCTAACTAC GGCTACACTA GAAGGACAGT
5751  ATTTGGTATC TGCGCTCTGC TGAAGCCAGT TACCTTCGGA AAAAGAGTTG
5801  GTAGCTCTTG ATCCGGCAAA CAAACCACCG CTGGTAGCGG TGGTTTTTTT
5851  GTTTGCAAGC AGCAGATTAC GCGCAGAAAA AAAGGATCTC AAGAAGATCC
5901  TTTGATCTTT TCTACGGGGT CTGACGCTCA GTGGAACGAA AACTCACGTT
5951  AAGGGATTTT GGTCAATGAGA TTATCAAAAA GGATCTTCAC CTAGATCCTT
6001  TTAAATTAAA AATGAAGTTT TAAATCAATC TAAAGTATAT ATGAGTAAAC
6051  TTGGTCTGAC AGTTACCAAT GCTTAATCAG TGAGGCACCT ATCTCAGCGA

```

FIG 7B CONT.

```
6101 TCTGTCTATT TCGTTCATCC ATAGTTGCCT GACTCCCCGT CGTGTAGATA
6151 ACTACGATAC GGGAGGGCTT ACCATCTGGC CCCAGTGCTG CAATGATACC
6201 GCGAGACCCA CGCTCACCGG CTCCAGATTT ATCAGCAATA AACCAGCCAG
6251 CCGGAAGGGC CGAGCGCAGA AGTGGTCCTG CAACTTTATC CGCCTCCATC
6301 CAGTCTATTA ATTGTTGCCG GGAAGCTAGA GTAAGTAGTT CGCCAGTTAA
6351 TAGTTTGCGC AACGTTGTTG CCATTGCTAC AGGCATCGTG GTGTCACGCT
6401 CGTCGTTTGG TATGGCTTCA TTCAGCTCCG GTCCCAACG ATCAAGGCGA
6451 GTTACATGAT CCCCCATGTT GTGCAAAAAA GCGGTTAGCT CCTTCGGTCC
6501 TCCGATCGTT GTCAGAAGTA AGTTGGCCGC AGTGTTATCA CTCATGGTTA
6551 TGGCAGCACT GCATAATTCT CTTACTGTCA TGCCATCCGT AAGATGCTTT
6601 TCTGTGACTG GTGAGTACTC AACCAAGTCA TTCTGAGAAT AGTGTATGCG
6651 GCGACCGAGT TGCTCTTGCC CGGCGTCAAT ACGGGATAAT ACCGCGCCAC
6701 ATAGCAGAAC TTTAAAGTG CTCATCATTG GAAAACGTTT TCGGGGCGA
6751 AAACCTCTCA GGATCTTACC GCTGTTGAGA TCCAGTTCGA TGTAACCCAC
6801 TCGTGCACCC AACTGATCTT CAGCATCTTT TACTTTCACC AGCGTTTCTG
6851 GGTGAGCAAA AACAGGAAGG CAAAATGCCG CAAAAAAGGG AATAAGGGCG
6901 ACACGGAAAT GTTGAATACT CATACTCTTC CTTTTTCAAT ATTATTGAAG
6951 CATTTATCAG GGTTATTGTC TCATGAGCGG ATACATATTT GAATGTATTT
7001 AGAAAAATAA ACAAATAGGG GTTCCGCGCA CATTTCCCCG AAAAGTGCCA
7051 CCTGACGTCT AAGAAACCAT TATTATCATG ACATTAACCT ATAAAAATAG
7101 GCGTATCACG AGGCCCTTTC GTCTCGCGCG TTTCGGTGAT GACGGTGAAA
7151 ACCTCTGACA CATGCAGCTC CCGGAGACGG TCACAGCTTG TCTGTAAGCG
7201 GATGCCGGGA GCAGACAAGC CCGTCAGGGC GCGTCAGCGG GTGTTGGCGG
7251 GTGTCGGGGC TGGCTTAACT ATGCGGCATC AGAGCAGATT GTACTGAGAG
7301 TGCACCATAT GCGGTGTGAA ATACCGCACA GATGCGTAAG GAGAAAATAC
7351 CGCATCAGGC GCCATTGCGC ATTCAGGCTG CGCAACTGTT GGGGAAGGGCG
7401 ATCGGTGCGG GCCTCTTCGC TATTACGCCA GCTGGCGAAA GGGGGATGTG
7451 CTGCAAGGCG ATTAAGTTGG GTAACGCCAG GTTTTTCCCA GTCACGACGT
7501 TGTAACGCA CGGCCAGTGA ATTACACCGG TGTGATCATG GGCCG
```

FIG 7B CONT.




FIG. 8A

## pDAB7113 11643bp

| Sequence                               | Feature                                                                                                                                                     |
|----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1-1164bp                               | RB7 MAR v3                                                                                                                                                  |
| 1165-1233<br>Linker                    | TGGCCACCGCTTAATTAAGGCGCGCCATGCCCCCTGCAG<br>ATCCCCGGGGATCCTCTAGAGTCGACCTGC                                                                                   |
| 1234-3224                              | Maize Ubiquitin 1 promoter                                                                                                                                  |
| 3224-4891                              | GNT III v.2                                                                                                                                                 |
| 3627                                   | C to replace G as reported in original<br>sequence                                                                                                          |
| 4892-4895<br>Linker                    | TAGGTTT                                                                                                                                                     |
| 4896-5260                              | Maize Per5 3'UTR v2                                                                                                                                         |
| 5261-5404<br>multiple<br>cloning sites | CGGCCGGCCTAGCTAGCCACGGTGGCCAGATCCACTAGG<br>GGCAAGCGGCCGCTTAATTAAATTTAAATGTTTAACTA<br>GGAAATCCAAGCTTGGGCTGCAGGTCAATCCCATTGCTT<br>TTGAAGCAGCTCAACATTGATCTCTTT |
| 5405-6802                              | Rice Actin 1 Promoter v2                                                                                                                                    |
| 6803-7358                              | PAT v3                                                                                                                                                      |
| 7359-7372<br>Linker                    | GGTACCCTGAGCTC                                                                                                                                              |
| 7373-7729                              | Maize Lipase 3' UTR v1                                                                                                                                      |
| 7730-7770<br>Linker                    | GAATTCATATTTCTCCTGCGAGGGTTTAACTTGCCGTG<br>GC                                                                                                                |
| 7771-8934                              | RB7 MAR v3                                                                                                                                                  |
| 8935-11643                             | PUC19                                                                                                                                                       |
| 9201-9225                              | 3 FspI sites (TGCGCAA) with CG in<br>between sites                                                                                                          |
| 10164-11021                            | Ampicillin resistance gene                                                                                                                                  |
| 10454-10459                            | TGCGCAA FspI                                                                                                                                                |
| 11477-11482                            | TGCGCAA FspI                                                                                                                                                |

```

1  CGATTAAAAA  CCCAATTATA  TTTGGTCTAA  TTTAGTTTGG
   TATTGAGTAA  AACAAATTCG  AACCAAACCA  AAATATAAAT
   ATATAGTTTT  TATATATATG
101 CCTTTAAGAC  TTTTATAGA  ATTTTCTTTA  AAAAATATCT
   AGAAATATTT  GCGACTCTTC  TGGCATGTAA  TATTTGTTA
   AATATGAAGT  GCTCCATTTT
201 TATTAACTTT  AAATAATTGG  TTGTACGATC  ACTTTCTTAT
   CAAGTGTTAC  TAAAATGCGT  CAATCTCTTT  GTTCTTCCAT
   ATTCATATGT  CAAAATCTAT
301 CAAAATTCTT  ATATATCTTT  TTCGAATTG  AAGTGAAATT
   TCGATAATTT  AAAATTAAAT  AGAACATATC  ATTATTTAGG
   TATCATATTG  ATTTTATAC

```

FIG 8B

```

401  TTAATTACTA AATTTGGTTA ACTTTGAAAG TGTACATCAA
      CGAAAAATTA GTCAAACGAC TAAAATAAAT AAATATCATG
      TGTTATTAAG AAAATTCTCC
501  TATAAGAATA TTTTAATAGA TCATATGTTT GTAAAAAATA
      TTAATTTTTA CTAACACATA TATTTACTTA TCAAAAATTT
      GACAAAGTAA GATTAATAAATA
601  ATATTCATCT AACAAAAAATA AAACCAGAAA ATGCTGAAAA
      CCCGGCAAAA CCGAACCAAT CCAAACCGAT ATAGTTGGTT
      TGGTTTGATT TTGATATAAA
701  CCGAACCAAC TCGGTCCATT TGCACCCCTA ATCATAATAG
      CTTTAATATT TCAAGATATT ATTAAGTTAA CGTTGTCAAT
      ATCCTGGAAA TTTTGCAAAA
801  TGAATCAAGC CTATATGGCT GTAATATGAA TTTAAAAGCA
      GCTCGATGTG GTGGTAATAT GTAATTTACT TGATTCTAAA
      AAAATATCCC AAGTATTAAT
901  AATTTCTGCT AGGAAGAAGG TTAGCTACGA TTTACAGCAA
      AGCCAGAATA CAAAGAACCA TAAAGTGATT GAAGCTCGAA
      ATATACGAAG GAACAAATAT
1001 TTTTAAAAAA ATACGCAATG ACTTGGAACA AAAGAAAGTG
      ATATATTTTT TGTTCTTAAA CAAGCATCCC CTCTAAAGAA
      TGGCAGTTTT CCTTTGCATG

```

PacI

~~~~~

AscI

~~~~~

```

1101 TAACTATTAT GCTCCCTTCG TTACAAAAAT TTTGGACTAC
      TATTGGGAAT TCTTCTGAAA ATAGTGGCCA CCGCTTAATT
      AAGGCGCGCC ATGCCCCCTG

```

BamHI

~~~~~

```

1201 CAGATCCCCG GGGATCCTCT AGAGTCGACC TGCAGTGCAG
      CGTGACCCGG TCGTGCCCCCT CTCTAGAGAT AATGAGCATT
      GCATGTCTAA GTTATAAAAA
1301 ATTACCACAT ATTTTTTTTG TCACACTTGT TTGAAGTGCA
      GTTTATCTAT CTTTATACAT ATATTTAAAC TTTAATCTAC
      GAATAATATA ATCTATAGTA
1401 CTACAATAAT ATCAGTGTTT TAGAGAATCA TATAAATGAA
      CAGTTAGACA TGGTCTAAAG GACAATTGAG TATTTTGACA
      ACAGGACTCT ACAGTTTTAT
1501 CTTTTTAGTG TGCATGTGTT CTCCTTTTTT TTTGCAAATA
      GCTTCACCTA TATAATACTT CATCCATTTT ATTAGTACAT
      CCATTTAGGG TTTAGGGTTA

```

FIG 8B CONT.

1601 ATGGTTTTTA TAGACTAATT TTTT TAGTAC ATCTATTTTA  
TTCTATTTTA GCCTCTAAAT TAAGAAAAC T AAAACTCTAT  
TTTAGTTTTT TTATTTAATA  
1701 ATTTAGATAT AAAATAGAAT AAAATAAAGT GACTAAAAAT  
TAAACAAATA CCCTTTAAGA AATTAAAAA ACTAAGGAAA  
CATTTTTCTT GTTTCGAGTA  
1801 GATAATGCCA GCCTGTTAAA CGCCGTCGAC GAGTCTAACG  
GACACCAACC AGCGAACCAG CAGCGTCGCG TCGGGCCAAG  
CGAAGCAGAC GGCACGGCAT  
1901 CTCTGTCGCT GCCTCTGGAC CCCTCTCGAG AGTTCCGCTC  
CACCGTTGGA CTTGCTCCGC TGTCCGCATC CAGAAATTGC  
GTGGCGGAGC GGCAGACGTG  
2001 AGCCGGCAGC GCAGGCGGCC TCCTCCTCCT CTCACGGCAC  
GGCAGCTACG GGGGATTCCT TTCCACCGC TCCTTCGCTT  
TCCCTTCCTC GCCCGCCGTA  
2101 ATAAATAGAC ACCCCCTCCA CACCCTCTTT CCCCAACCTC  
GTGTTGTTCG GAGCGCACAC ACACACAACC AGATCTCCCC  
CAAATCCACC CGTCGGCACC  
2201 TCCGCTTCAA GGTACGCCGC TCGTCCTCCC CCCCCCCCCC  
TCTCTACCTT CTCTAGATCG GCGTTCGGT CCATGCATGG  
TTAGGGCCCG GTAGTTCTAC  
2301 TTCTGTTTAT GTTTGTGTTA GATCCGTGTT TGTGTTAGAT  
CCGTGCTGCT AGCGTTCGTA CACGGATGCG ACCTGTACGT  
CAGACACGTT CTGATTGCTA  
2401 ACTTGCCAGT GTTTCCTCTT GGGGAATCCT GGGATGGCTC  
TAGCCGTTCC GCAGACGGGA TCGATTTTAT GATTTTTTTT  
GTTTCGTTGC ATAGGGTTTG  
2501 GTTTGCCCTT TTCCTTTATT TCAATATATG CCGTGCACCT  
GTTTGTCCGG TCATCTTTTC ATGCTTTTTT TTGTCTTGGT  
TGTGATGATG TGGTCTGGTT  
2601 GGGCGGTCGT TCTAGATCGG AGTAGAATTC TGTTTCAAAC  
TACCTGGTGG ATTTATTAAT TTTGGATCTG TATGTGTGTG  
CCATACATAT TCATAGTTAC  
2701 GAATTGAAGA TGATGGATGG AAATATCGAT CTAGGATAGG  
TATACATGTT GATGCGGGTT TTAGTATGAT ATATACAGAG  
ATGCTTTTTT TTCGCTTGGT  
2801 TGTGATGATG TGGTGTGTT GGGCGGTCGT TCATTCGTTT  
TAGATCGGAG TAGAATACTG TTTCAAATA CCTGGTGTAT  
TTATTAATTT TGGAACTGTA  
2901 TGTGTGTGTC ATACATCTTC ATAGTTACGA GTTTAAGATG  
GATGGAAATA TCGATCTAGG ATAGGTATAC ATGTTGATGT  
GGGTTTTTACT GATGCATATA  
3001 CATGATGGCA TATGCAGCAT CTATTCATAT GCTCTAACCT  
TGAGTACCTA TCTATTATAA TAAACAAGTA TGTTTTATAA  
TTATTTTGAT CTTGATATAC  
3101 TTGGATGATG GCATATGCAG CAGCTATATG TGGATTTTTT  
TAGCCCTGCC TTCATACGCT ATTTATTTGC TTGGTACTGT  
TTCTTTTGTC GATGCTCACC

FIG 8B CONT.

NcoI  
 FseI  
 ~~~~~  
 ~~~~~  
 3201 CTGTTGTTTG GTGTTACTTC TGCAGGGTAC CCCCAGGGTC  
 GACCATGGTG ATGAGACGCT ACAAGCTCTT TCTCATGTTC  
 TGTATGGCCG GCCTGTGCCT  
 3301 CATCTCCTTC CTGCACTTCT TCAAGACCCT GTCCTATGTC  
 ACCTTCCCCC GAGAACTGGC CTCCCTCAGC CCTAACCTGG  
 TGTCCAGCTT TTTCTGGAAC  
 3401 AATGCCCCGG TCACGCCCCA GGCCAGCCCC GAGCCAGGAG  
 GCCCTGACCT GCTGCGTACC CCACTCTACT CCCACTCGCC  
 CCTGCTGCAG CCGCTGCCGC  
 SacI  
 ~~~~~  
 3501 CCAGCAAGGC GGCCGAGGAG CTCCACCGGG TGGACTTGGT  
 GCTGCCCCGAG GACACCACCG AGTATTTCTG GCGCACCAAG  
 GCCGGCGGGC TCTGCTTCAA  
 3601 ACCCGGCACC AAGATGCTGG AGAGGCCCCC CCCGGGACGG  
 CCGGAGGAGA AGCCTGAGGG GGCCAACGGC TCCTCGGCCC  
 GGCGGCCACC CCGGTACCTC  
 3701 CTGAGCGCCC GGGAGCGCAC GGGGGGCCGA GGCGCCCGGC  
 GCAAGTGGGT GGAGTGCGTG TGCCTGCCCC GCTGGCACGG  
 ACCCAGCTGC GGCCTGCCCA  
 3801 CTGTGGTGCA GTA CTCCAAC CTGCCCACCA AGGAGCGGCT  
 GGTGCCCAGG GAGGTGCCGC GCCGCGTCAT CAACGCCATC  
 AACGTCAACC ACGAGTTCGA  
 NotI  
 ~~~~~  
 3901 CCTGCTGGAC GTGCGCTTCC ACGAGCTGGG CGACGTGGTG  
 GACGCCTTTG TGGTGTGCGA GTCCAACCTC ACGGCTTATG  
 GGGAGCCGCG GCCGCTCAAG  
 4001 TTCCGGGAGA TGCTGACCAA TGGCACCTTC GAGTACATCC  
 GCCACAAGGT GCTCTATGTC TTCCTGGACC ACTTCCCGCC  
 CGGCGGCCCG CAGGACGGCT  
 4101 GGATCGCCGA CGACTACCTG CGCACCTTCC TCACCCAGGA  
 CGGCGTCTCG CGGCTGCGCA ACCTGCGGCC CGACGACGTC  
 TTCATCATTG ACGATGCGGA  
 4201 CGAGATCCCG GCCCGTGACG GCGTCCTTTT CCTCAAGCTC  
 TACGATGGCT GGACCGAGCC CTTGCGCTTC CACATGCGCA  
 AGTCGCTCTA CGGCTTCTTC  
 4301 TGGAAGCAGC CGGGCACCTT GGAGGTGGTG TCAGGCTGCA  
 CGGTGGACAT GCTGCAGGCA GTGTATGGGC TGGACGGCAT  
 CCGCCTGCGC CGCCGCCAGT

FIG 8B CONT.

4401 ACTACACCAT GCCCAACTTC AGACAGTATG AGAACCGCAC  
 CGGCCACATC CTGGTGCAGT GGTCGCTGGG CAGCCCCCTG  
 CACTTCGCCG GCTGGCACTG  
 4501 CTCCTGGTGC TTCACGCCCC AGGGCATCTA CTTCAAGCTC  
 GTGTCCGCCC AGAATGGCGA CTTCCCACGC TGGGGTGACT  
 ACGAGGACAA GCGGGACCTG  
 4601 AACTACATCC GCGGCCTGAT CCGCACCGGG GGCTGGTTCCG  
 ACGGCACGCA GCAGGAGTAC CCGCCTGCAG ACCCCAGCGA  
 GCACATGTAT GCGCCCAAGT  
 4701 ACCTGCTGAA GAACTACGAC CGGTTCCACT ACCTGCTGGA  
 CAACCCCTAC CAGGAGCCCA GGAGCACGGC GCGGGGCGGG  
 TGGCGCCACA GGGGTCCCGA

BamHI

PmeI

~~~~~

~~~~~

4801 GGGAAGGCCG CCCGCCCGGG GCAAACCTGGA CGAGGCGGAA  
 GTCGAACAAA AACTCATCTC AGAAGAGGAT CTGAATTAGG  
 ATCCTAGGTT TAAACTGAGG  
 4901 GCACTGAAGT CGCTTGATGT GCTGAATTGT TTGTGATGTT  
 GGTGGCGTAT TTTGTTTAAA TAAGTAAGCA TGGCTGTGAT  
 TTTATCATAT GATCGATCTT  
 5001 TGGGGTTTTTA TTAAACACAT TGTAATATGT GTATCTATTA  
 ATAACCTCAAT GTATAAGATG TGTTCAATTCT TCGGTTGCCA  
 TAGATCTGCT TATTTGACCT  
 5101 GTGATGTTTT GACTCCAAAA ACCAAAATCA CAACTCAATA  
 AACTCATGGA ATATGTCCAC CTGTTTCTTG AAGAGTTCAT  
 CTACCATTC AGTTGGCATT

FseI

~~~~~

5201 TATCAGTGTT GCAGCGGCGC TGTGCTTTGT AACATAACAA  
 TTGTTACGG CATATATCCA CGGCCGGCCT AGCTAGCCAC  
 GGTGGCCAGA TCCACTAGGG

PacI

~~~~~

SwaI

~~~~~

NotI

PmeI

HindIII

~~~~~

~~~~~

~~~~~

5301 GCAAGCGGCC GCTTAATTAA ATTTAAATGT TTAAACTAGG  
 AAATCCAAGC TTGGGCTGCA GGTCAATCCC ATTGCTTTTG  
 AAGCAGCTCA ACATTGATCT

FIG 8B CONT.



5401 CTTTCTCGAG GTCATTGATA TGCTTGAGAA GAGAGTCGGG  
 ATAGTCCAAA ATAAAACAAA GGTAAGATTA CCTGGTCAAA  
 AGTGAAAACA TCAGTTAAAA  
 5501 GGTGGTATAA AGTAAAATAT CGGTAATAAA AGGTGGCCCA  
 AAGTGAAATT TACTCTTTTC TACTATTATA AAAATTGAGG  
 ATGTTTTTGT CGGTACTTTG  
 5601 ATACGTCATT TTTGTATGAA TTGGTTTTTA AGTTTATTCG  
 CTTTTGGAAA TGCATATCTG TATTTGAGTC GGGTTTTAAG  
 TTCGTTTGCT TTTGTAAATA  
 5701 CAGAGGGATT TGTATAAGAA ATATCTTTAA AAAAACCCAT  
 ATGCTAATTT GACATAATTT TTGAGAAAAA TATATATTCA  
 GGCGAATTCT CACAATGAAC  
 5801 AATAATAAGA TTAAAATAGC TTTCCCCCGT TGCAGCGCAT  
 GGGTATTTTT TCTAGTAAAA ATAAAAGATA AACTTAGACT  
 CAAAACATTT ACAAAAACAA  
 5901 CCCCTAAAGT TCCTAAAGCC CAAAGTGCTA TCCACGATCC  
 ATAGCAAGCC CAGCCCAACC CAACCCAACC CAACCCACCC  
 CAGTCCAGCC AACTGGACAA  
 6001 TAGTCTCCAC ACCCCCCCAC TATCACCGTG AGTTGTCCGC  
 ACGCACCGCA CGTCTCGCAG CCAAAAAAAA AAAAAGAAAG  
 AAAAAAAGA AAAAGAAAAA

FseI

~~~~~

6101 ACAGCAGGTG GGTCCGGGTC GTGGGGGCCG GAAACGCGAG  
 GAGGATCGCG AGCCAGCGAC GAGGCCGGCC CTCCCTCCGC  
 TTCCAAAGAA ACGCCCCCA  
 6201 TCGCCACTAT ATACATACCC CCCCCTCTCC TCCCATCCCC  
 CCAACCCCTAC CACCACCACC ACCACCACCT CCACCTCCTC  
 CCCCCTCGCT GCCGGACGAC  
 6301 GCCTCCCCC TCCCCCTCCG CCGCCGCCGC GCCGGTAACC  
 ACCCCGCCCC TCTCCTCTTT CTTTCTCCGT TTTTTTTTTC  
 CGTCTCGGTC TCGATCTTTG

BamHI

~~~~

6401 GCCTTGGTAG TTTGGGTGGG CGAGAGGCGG CTTCGTGCGC  
 GCCCAGATCG GTGCGCGGGA GGGGCGGGAT CTCGCGGCTG  
 GGGCTCTCGC CGGCGTGGAT

BamHI

~~

6501 CCGGCCCGGA TCTCGCGGGG AATGGGGCTC TCGGATGTAG  
 ATCTGCGATC CGCCGTTGTT GGGGGAGATG ATGGGGGGTT  
 TAAAATTTCC GCCATGCTAA

```

6601 ACAAGATCAG GAAGAGGGGA AAAGGGCACT ATGGTTTATA
      TTTTATATA TTTCTGCTGC TTCGTCAGGC TTAGATGTGC
      TAGATCTTTC TTTCTTCTTT
6701 TTGTGGGTAG AATTTGAATC CCTCAGCATT GTTCATCGGT
      AGTTTTTCTT TTCATGATTT GTGACAAATG CAGCCTCGTG
      CGGAGCTTTT TTGTAGGTAG
      NcoI
      ~~~~~~
6801 ACCATGGCTT CTCCGGAGAG GAGACCAATT GAGATTAGGC
      CAGCTACAGC AGCTGATATG GCCGCGGTTT GTGATATCGT
      TAACCATTAC ATTGAGACGT
6901 CTACAGTGAA CTTTAGGACA GAGCCACAAA CACCACAAGA
      GTGGATTGAT GATCTAGAGA GGTTGCAAGA TAGATACCCT
      TGGTTGGTTG CTGAGGTTGA
7001 GGGTGTGTGT GCTGGTATTG CTTACGCTGG GCCCTGGAAG
      GCTAGGAACG CTTACGATTG GACAGTTGAG AGTACTGTTT
      ACGTGTCA CA TAGGCATCAA
      BamHI
      ~~~~~~
7101 AGGTTGGGCC TAGGATCCAC ATTGTACACA CATTTGCTTA
      AGTCTATGGA GGCGCAAGGT TTTAAGTCTG TGGTTGCTGT
      TATAGGCCTT CCAAACGATC
7201 CATCTGTTAG GTTGCATGAG GCTTTGGGAT ACACAGCCCCG
      GGGTACATTG CGCGCAGCTG GATACAAGCA TGGTGGATGG
      CATGATGTTG GTTTTTGGCA

      SacI
      ~~~~~~
7301 AAGGGATTTT GAGTTGCCAG CTCCTCCAAG GCCAGTTAGG
      CCAGTTACCC AGATCTGAGG TACCCTGAGC TCGGTCGCAG
      CGTGTGCGTG TCCGTCGTAC
      FseI
      ~~~~~~
7401 GTTCTGGCCG GCCGGGCCTT GGGCGCGCGA TCAGAAGCGT
      TGCGTTGGCG TGTGTGTGCT TCTGGTTTGC TTTAATTTTA
      CCAAGTTTGT TTCAAGGTGG
7501 ATCGCGTGGT CAAGGCCCGT GTGCTTTAAA GACCCACCGG
      CACTGGCAGT GAGTGTGCT GCTTGTGTAG GCTTTGGTAC
      GTATGGGCTT TATTTGCTTC
7601 TGGATGTTGT GTACTACTTG GGTTTGTGTA ATTATTATGA
      GCAGTTGCGT ATTGTAATTC AGCTGGGCTA CCTGGACATT
      GTTATGTATT AATAAATGCT

```

PmeI

~~~~~

FIG 8B CONT.

```

7701 TTGCTTTCTT CTAAAGATCT TTAAGTGCTG AATTCATATT
    TCCTCCTGCA GGGTTTAAAC TTGCCGTGGC CTATTTTCAG
    AAGAATTCCC AATAGTAGTC
7801 CAAAAATTTT GTAACGAAGG GAGCATAATA GTTACATGCA
    AAGGAAAAC T GCCATTCTTT AGAGGGGATG CTTGTTTAAG
    AACAAAAAAT ATATCACTTT
7901 CTTTTGTTCC AAGTCATTGC GTATTTTTTTT AAAAATATTT
    GTTCCTTCGT ATATTTTCGAG CTCAATCAC TTTATGGTTC
    TTTGTATTCT GGCTTTGCTG
8001 TAAATCGTAG CTAACCTTCT TCCTAGCAGA AATTATTAAT
    ACTTGGGATA TTTTTTTAGA ATCAAGTAA TTACATATTA
    CCACCACATC GAGCTGCTTT
8101 TAAATTCATA TTACAGCCAT ATAGGCTTGA TTCATTTTGC
    AAAATTTCCA GGATATTGAC AACGTAACT TAATAATATC
    TTGAAATATT AAAGCTATTA
8201 TGATTAGGGG TGCAAATGGA CCGAGTTGGT TCGGTTTATA
    TCAAAATCAA ACCAAACCAA CTATATCGGT TTGGATTGGT
    TCGGTTTTGC CGGGTTTTCA
8301 GCATTTTCTG GTTTTTTTTT TGTTAGATGA ATATTATTTT
    AATCTTACTT TGTCAAATTT TTGATAAGTA AATATATGTG
    TTAGTAAAAA TTAATTTTTT
8401 TTACAAACAT ATGATCTATT AAAATATTCT TATAGGAGAA
    TTTTCTTAAT AACACATGAT ATTATTTAT TTTAGTCGTT
    TGACTAATTT TTCGTTGATG
8501 TACACTTTCA AAGTTAACCA AATTTAGTAA TTAAGTATAA
    AAATCAATAT GATACCTAAA TAATGATATG TTCTATTTAA
    TTTTAAATTA TCGAAATTC
8601 ACTTCAAATT CGAAAAAGAT ATATAAGAAT TTTGATAGAT
    TTTGACATAT GAATATGGAA GAACAAAGAG ATTGACGCAT
    TTTAGTAACA CTTGATAAGA
8701 AAGTGATCGT ACAACCAATT ATTTAAAGTT AATAAAAAATG
    GAGCACTTCA TATTTAACGA AATATTACAT GCCAGAAGAG
    TCGCAAATAT TTCTAGATAT
8801 TTTTTAAAGA AAATTCTATA AAAAGTCTTA AAGGCATATA
    TATAAAAAC T ATATATTTAT ATTTTGGTTT GGTTCGAATT
    TGTTTTACTC AATACCAAAC
8901 TAAATTAGAC CAAATATAAT TGGGTTTTTA ATCGCGGCC
    ACTAGTCACC GGTGTAGCTT GCGTAATCA TGGTCATAGC
    TGTTCCTGT GTGAAATTGT
9001 TATCCGCTCA CAATTCCACA CAACATACGA GCCGGAAGCA
    TAAAGTGTA AGCCTGGGGT GCCTAATGAG TGAGCTAACT
    CACATTAATT GCGTTGCGCT
9101 CACTGCCCGC TTTCCAGTCG GGAAACCTGT CGTGCCAGCT
    GCATTAATGA ATCGGCCAAC GCGCGGGGAG AGGCGGTTTG
    CGTATTGGGC GCTCTTCCGC
9201 TGCGCACGCT GCGCACGCTG CGCACGCTTC CTCGCTCACT
    GACTCGCTGC GCTCGGTCGT TCGGCTGCGG CGAGCGGTAT
    CAGCTCACTC AAAGGCGGTA

```

FIG 8B CONT.

```

9301 ATACGGTTAT CCACAGAATC AGGGGATAAC GCAGGAAAGA
    ACATGTGAGC AAAAGGCCAG CAAAAGGCCA GGAACCGTAA
    AAAGGCCGCG TTGCTGGCGT
9401 TTTTCCATAG GCTCCGCCCC CCTGACGAGC ATCACAAAAA
    TCGACGCTCA AGTCAGAGGT GGCGAAAACCC GACAGGACTA
    TAAAGATAACC AGGCGTTTCC
9501 CCCTGGAAGC TCCCTCGTGC GCTCTCCTGT TCCGACCCCTG
    CCGCTTACCG GATACCTGTC CGCCTTTCTC CCTTCGGGAA
    GCGTGGCGCT TTCTCATAGC
9601 TCACGCTGTA GGTATCTCAG TTCGGTGTAG GTCGTTGCT
    CCAAGCTGGG CTGTGTGCAC GAACCCCCCG TTCAGCCCGA
    CCGCTGCGCC TTATCCGGTA
9701 ACTATCGTCT TGAGTCCAAC CCGGTAAGAC ACGACTTATC
    GCCACTGGCA GCAGCCACTG GTAACAGGAT TAGCAGAGCG
    AGGTATGTAG GCGGTGCTAC
9801 AGAGTTCTTG AAGTGGTGGC CTAACCTACGG CTACACTAGA
    AGGACAGTAT TTGGTATCTG CGCTCTGCTG AAGCCAGTTA
    CCTTCGGAAA AAGAGTTGGT
9901 AGCTCTTGAT CCGGCAAACA AACCACCGCT GGTAGCGGTG
    GTTTTTTTGT TTGCAAGCAG CAGATTACGC GCAGAAAAAA
    AGGATCTCAA GAAGATCCTT
10001 TGATCTTTTC TACGGGGTCT GACGCTCAGT GGAACGAAAA
    CTCACGTAA GGGATTTTGG TCATGAGATT ATCAAAAAGG
    ATCTTCACCT AGATCCTTTT
10101 AAATTAATAA TGAAGTTTTA AATCAATCTA AAGTATATAT
    GAGTAAACTT GGTCTGACAG TTACCAATGC TTAATCAGTG
    AGGCACCTAT CTCAGCGATC
10201 TGTCTATTTT GTTCATCCAT AGTTGCCTGA CTCCCCGTCTG
    TGTAGATAAC TACGATACGG GAGGGCTTAC CATCTGGCCC
    CAGTGCTGCA ATGATACCGC
10301 GAGACCCACG CTCACCGGCT CCAGATTTAT CAGCAATAAA
    CCAGCCAGCC GGAAGGGCCG AGCGCAGAAG TGGTCCTGCA
    ACTTTATCCG CCTCCATCCA
10401 GTCTATTAAT TGTGCGGGG AAGCTAGAGT AAGTAGTTCG
    CCAGTTAATA GTTTGCGCAA CGTTGTTGCC ATTGCTACAG
    GCATCGTGGT GTCACGCTCG
10501 TCGTTTGGTA TGGCTTCATT CAGCTCCGGT TCCCAACGAT
    CAAGGCGAGT TACATGATCC CCCATGTTGT GCAAAAAGC
    GGTAGCTCC TTCGGTCCTC
10601 CGATCGTTGT CAGAAGTAAG TTGGCCGCAG TGTTATCACT
    CATGGTTATG GCAGCACTGC ATAATTCTCT TACTGTCATG
    CCATCCGTAA GATGCTTTTC
10701 TGTGACTGGT GAGTACTCAA CCAAGTCATT CTGAGAATAG
    TGTATGCGGC GACCGAGTTG CTCTTGCCCC GCGTCAATAC
    GGGATAATAC CGCGCCACAT
10801 AGCAGAACTT TAAAGTGCT CATCATTTGA, AAACGTTCTT
    CGGGGCGAAA ACTCTCAAGG ATCTTACCGC TGTTGAGATC
    CAGTTCGATG TAACCCACTC

```

FIG 8B CONT.

```
10901 GTGCACCCAA CTGATCTTCA GCATCTTTTA CTTTCACCAG
      CGTTTCTGGG TGAGCAAAAA CAGGAAGGCA AAATGCCGCA
      AAAAAGGGAA TAAGGGCGAC
11001 ACGGAAATGT TGAATACTCA TACTCTTCCT TTTTCAATAT
      TATTGAAGCA TTTATCAGGG TTATTGTCTC ATGAGCGGAT
      ACATATTTGA ATGTATTTAG
11101 AAAAATAAAC AAATAGGGGT TCCGCGCACA TTTCCCCGAA
      AAGTGCCACC TGACGTCTAA GAAACCATTA TTATCATGAC
      ATTAACCTAT AAAAATAGGC
11201 GTATCACGAG GCCCTTTCGT CTCGCGCGTT TCGGTGATGA
      CGGTGAAAAC CTCTGACACA TGCAGCTCCC GGAGACGGTC
      ACAGCTTGTC TGTAAGCGGA
11301 TGCCGGGAGC AGACAAGCCC GTCAGGGCGC GTCAGCGGGT
      GTTGGCGGGT GTCGGGGCTG GCTTAACTAT GCGGCATCAG
      AGCAGATTGT ACTGAGAGTG
11401 CACCATATGC GGTGTGAAAT ACCGCACAGA TGCGTAAGGA
      GAAAATACCG CATCAGGCGC CATTGCCAT TCAGGCTGCG
      CAACTGTTGG GAAGGGCGAT
11501 CGGTGCGGGC CTCTTCGCTA TTACGCCAGC TGGCGAAAGG
      GGGATGTGCT GCAAGGCGAT TAAGTTGGGT AACGCCAGGG
      TTTTCCCAGT CACGACGTTG
11601 TAAAACGACG GCCAGTGAAT TACACCGGTG TGATCATGGG CCG
```

FIG 8B CONT.




FIG. 9

atgaagatgagacgctacaagctctttctcatgttctgtatggccggcctgtgcctcatctcctctgcacttctcaagaccct  
gtcctatgtcaccttccccgagaactggcctccctcagccctaacctgggtgccagctttttctggaacaatgccccgtca  
cgccccaggccagccccgagccaggaggccctgacctgtgcgtacccactctactcccactcgccccgtgtgcagcc  
gtgcccggccagcaaggcggcgaggagctccaccgggtggacttgggtgtgcccaggacaccaccagagtatttctgt  
gcgcaccaaggccggcggtctgtctcaaacccggcaccaagatgtggagaggccgccccgggacggccggag  
gagaagcctgagggggccaacggctcctggccggcgccacccgggtacctcctgagcggccgggagcgacgg  
ggggccgaggcgccccggcgcaagtgggtggagtgcgtgtgcctgccggctggcacggacccagctgcggcgtgcc  
cactgtggtgcagtactccaacctgcccaccaaggagcggtggtgccaggggagggtgccgcggcgctcatcaacgc  
catcaacgtcaaccacgagttcgacctgtggacgtgcgcttcacgagctgggogagctggggacgcctttgtggtgtg  
cgagtccaacttcacggcttatggggagcccgggcgctcaagttccgggagatgtgaccaatggcaccttcgagtaca  
tcgccacaagggtgctctatgtcttctggaccacttccccggcgggcgccggcaggacggctggtatcgccgacgactac  
ctgcgcaccttctcaccaggacggcgctctcgcggtgcgcaacctgcggcccgacgacgtcttcattgacgatgc  
ggacgagatccccggccgtgacggcgctcttctcaagctctacgatggctggaccgagcccttcgcttcacatgcg  
caagtgcctctacggcttcttctggaagcagccgggcaccctggaggtggtgtcaggctgcacggtggacatgtgcagg  
cagtgtatgggtggacggcatccgctgcggcgccgagcagctacacatgcccaacttcagacagtatgagaaccgc  
accggccacatcctggtgcagtggctgctgggcagccccctgcacttcgcccgtggcactgtcctggtgttcacgcc  
cgagggcatctactcaagctcgtgtccgcccagaatggcgacttcccacgctggggtgactacgaggacaagcgggac  
ctgaactacatccggcgctgatccgcaccgggggtggttcacggcacgcagcaggagtacccgcctgcagacccc  
agcgagcacatgtatcgccccagctgtgaagaactacgaccggttcactacgtgtggacaacccctaccagga  
gcccaggagcacggcgggcggggtggcgccacaggggtcccagggaaggccgccccgggggaaactgg  
acgaggcggaagtctag

FIG. 10




FIG 11






FIG 12





FIG 13



**FIG. 14**

1/15

## SEQUENCE LISTING

<110> PLANT RESEARCH INTERNATIONAL BV  
 BAKKER, Hendrikus A.C.  
 FLORACK, Dionisius E.A.  
 BOSCH, Hendrik J.

<120> GNTIII expression in plants

<130> b28b2A - P033313W0

<150> US-60/365,769

<151> 2002-03-19

<150> US-60/368,047

<151> 2002-03-26

<160> 27

<170> PatentIn version 3.2

<210> 1

<211> 1642

<212> DNA

<213> Homo sapiens

<400> 1

```

ccatgggtgat gagacgctac aagctctttc tcatgttctg tatggccggc ctgtgcctca    60
tctccttctt gcacttcttc aagaccctgt cctatgtcac cttccccga gaactggcct    120
ccctcagccc taacctgggtg tccagctttt tctggaacaa tgccccggtc acgccccagg    180
ccagcccccga gccaggaggc cctgacctgc tgcgtacccc actctactcc cactcgcccc    240
tgctgcagcc gctgcccggc agcaaggcgg ccgaggagct ccaccgggtg gacttggtgc    300
tgcccgaggga caccaccgag tatttcgtgc gcaccaaggc cggcggcgctc tgcttcaaac    360
ccggcaccaa gatgtctggag agggccggccc cgggacggcc ggaggagaag cctgaggggg    420
ccaacggctc ctggggccgg cggccacccc ggtacctcct gagcgcccgg gagcgacggg    480
ggggccgagg cggccggcgc aagtgggtgg agtgcggtg cctgcccggc tggcacggac    540
ccagctgcgg cgtgcccact gtggtgcagt actccaacct gcccaccaag gagcggctgg    600
tgcccgaggga ggtgcgcgc cgcgtcatca acgccatcaa cgtcaaccac gagtctgacc    660
tgctggacgt gcgcttccac gagctggggc acgtgggtga cgcctttgtg gtgtgcgagt    720
ccaacttcac ggcttatggg gagccgcggc cgtcaagtt ccgggagatg ctgaccaatg    780
gcaccttcga gtacatccgc cacaagggtg tctatgtctt cctggaccac ttcccggccg    840
gcgccgggca ggacggctgg atcggcgacg actacctgcg caccttcctc acccaggacg    900
gcgtctcgcg gctgcgcaac ctgcgggccc agcagctctt catcattgac gatgcggacg    960
agatcccggc ccgtgacggc gtccttttcc tcaagctcta cgatggctgg accgagccct   1020
tcgcttccca catgcgcaag tcgctctacg gcttcttctg gaagcagccg ggcaccctgg   1080
aggtggtgtc aggtgcacg gtggacatgc tgcaggcagt gtatgggctg gacggcatcc   1140
gcctgcggcg ccgccagtag tacaccatgc ccaacttcag acagtatgag aaccgcaccg   1200
gccacatcct ggtgcagtgg tcgctgggca gccccctgca cttcgccggc tggcactgct   1260
cctggtgctt cagcgccgag ggcattctact tcaagctcgt gtccgcccag aatggcgact   1320
tcccacgctg gggtgactac gaggacaagc gggacctgaa ctacatccgc ggcctgatcc   1380
gcaccggggg ctggttcgac ggcacgcagc agggattacc gcctgcagac cccagcgagc   1440
acatgtatgc gcccaagtac ctgctgaaga actacgaccg gttccactac ctgctggaca   1500
acccctacca ggagcccagg agcacggcgg cgggcggggtg gcgccacagg ggtcccaggg   1560
gaaggccgcc cggccggggc aaactggacg aggcggaagt cgaacaaaaa ctcatctcag   1620
aaggagatct gaattaggat cc                                     1642

```

<210> 2

<211> 544

<212> PRT

<213> Homo sapiens

<400> 2

```

Met Val Met Arg Arg Tyr Lys Leu Phe Leu Met Phe Cys Met Ala Gly
1          5          10          15
Leu Cys Leu Ile Ser Phe Leu His Phe Phe Lys Thr Leu Ser Tyr Val
20          25          30

```

2/15

Thr Phe Pro Arg Glu Leu Ala Ser Leu Ser Pro Asn Leu Val Ser Ser  
 35 40 45  
 Phe Phe Trp Asn Asn Ala Pro Val Thr Pro Gln Ala Ser Pro Glu Pro  
 50 55 60  
 Gly Gly Pro Asp Leu Leu Arg Thr Pro Leu Tyr Ser His Ser Pro Leu  
 65 70 75 80  
 Leu Gln Pro Leu Pro Pro Ser Lys Ala Ala Glu Glu Leu His Arg Val  
 85 90 95  
 Asp Leu Val Leu Pro Glu Asp Thr Thr Glu Tyr Phe Val Arg Thr Lys  
 100 105 110  
 Ala Gly Gly Val Cys Phe Lys Pro Gly Thr Lys Met Leu Glu Arg Pro  
 115 120 125  
 Pro Pro Gly Arg Pro Glu Glu Lys Pro Glu Gly Ala Asn Gly Ser Ser  
 130 135 140  
 Ala Arg Arg Pro Pro Arg Tyr Leu Leu Ser Ala Arg Glu Arg Thr Gly  
 145 150 155 160  
 Gly Arg Gly Ala Arg Arg Lys Trp Val Glu Cys Val Cys Leu Pro Gly  
 165 170 175  
 Trp His Gly Pro Ser Cys Gly Val Pro Thr Val Val Gln Tyr Ser Asn  
 180 185 190  
 Leu Pro Thr Lys Glu Arg Leu Val Pro Arg Glu Val Pro Arg Arg Val  
 195 200 205  
 Ile Asn Ala Ile Asn Val Asn His Glu Phe Asp Leu Leu Asp Val Arg  
 210 215 220  
 Phe His Glu Leu Gly Asp Val Val Asp Ala Phe Val Val Cys Glu Ser  
 225 230 235 240  
 Asn Phe Thr Ala Tyr Gly Glu Pro Arg Pro Leu Lys Phe Arg Glu Met  
 245 250 255  
 Leu Thr Asn Gly Thr Phe Glu Tyr Ile Arg His Lys Val Leu Tyr Val  
 260 265 270  
 Phe Leu Asp His Phe Pro Pro Gly Gly Arg Gln Asp Gly Trp Ile Ala  
 275 280 285  
 Asp Asp Tyr Leu Arg Thr Phe Leu Thr Gln Asp Gly Val Ser Arg Leu  
 290 295 300  
 Arg Asn Leu Arg Pro Asp Asp Val Phe Ile Ile Asp Asp Ala Asp Glu  
 305 310 315 320  
 Ile Pro Ala Arg Asp Gly Val Leu Phe Leu Lys Leu Tyr Asp Gly Trp  
 325 330 335  
 Thr Glu Pro Phe Ala Phe His Met Arg Lys Ser Leu Tyr Gly Phe Phe  
 340 345 350  
 Trp Lys Gln Pro Gly Thr Leu Glu Val Val Ser Gly Cys Thr Val Asp  
 355 360 365  
 Met Leu Gln Ala Val Tyr Gly Leu Asp Gly Ile Arg Leu Arg Arg Arg  
 370 375 380  
 Gln Tyr Tyr Thr Met Pro Asn Phe Arg Gln Tyr Glu Asn Arg Thr Gly  
 385 390 395 400  
 His Ile Leu Val Gln Trp Ser Leu Gly Ser Pro Leu His Phe Ala Gly  
 405 410 415

3/15

Trp His Cys Ser Trp Cys Phe Thr Pro Glu Gly Ile Tyr Phe Lys Leu  
                     420                    425                    430  
 Val Ser Ala Gln Asn Gly Asp Phe Pro Arg Trp Gly Asp Tyr Glu Asp  
                     435                    440                    445  
 Lys Arg Asp Leu Asn Tyr Ile Arg Gly Leu Ile Arg Thr Gly Gly Trp  
                     450                    455                    460  
 Phe Asp Gly Thr Gln Gln Glu Tyr Pro Pro Ala Asp Pro Ser Glu His  
                     465                    470                    475                    480  
 Met Tyr Ala Pro Lys Tyr Leu Leu Lys Asn Tyr Asp Arg Phe His Tyr  
                     485                    490                    495  
 Leu Leu Asp Asn Pro Tyr Gln Glu Pro Arg Ser Thr Ala Ala Gly Gly  
                     500                    505                    510  
 Trp Arg His Arg Gly Pro Glu Gly Arg Pro Pro Ala Arg Gly Lys Leu  
                     515                    520                    525  
 Asp Glu Ala Glu Val Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn  
                     530                    535                    540

<210> 3  
 <211> 31  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Synthetic

<400> 3  
 atactcgagt taacaatgaa gatgagacgc t

31

<210> 4  
 <211> 35  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Synthetic

<400> 4  
 tatggatcct aattcagatc ctcttctgag atgag

35

<210> 5  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Synthetic

<400> 5  
 ccatggatgat gagacgctac

20

<210> 6  
 <211> 32  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Synthetic

<400> 6

4/15

gtttaaacct aggatcctaa ttcagatcct ct

32

<210> 7  
 <211> 1602  
 <212> DNA  
 <213> Homo sapiens

<400> 7  
 atgaagatga gacgctacaa gctctttctc atgttctgta tggccggcct gtgcctcatc 60  
 tccttctctgc acttcttcaa gaccctgtcc tatgtcacct tccccgaga actggcctcc 120  
 ctcagcccta acctggtgtc cagctttttc tggaacaatg ccccggtcac gccccaggcc 180  
 agccccgagc caggaggccc tgacctgctg cgtacccac tctactcca ctgccccctg 240  
 ctgcagccgc tgccgcccag caaggcggcc gaggagctcc accgggtgga cttggtgctg 300  
 cccgaggaca ccaccgagta ttctgtgctc accaaggcgg gcggcgtctg cttcaaaccc 360  
 ggcaccaaga tgctggagag gccgcccccg ggacggccgg aggagaagcc tgaggggggc 420  
 aacggctcct cggcccgggc gccacccccg tacctcctga gcgcccggga gcgcacgggg 480  
 ggccgaggcg cccggcgcaa gtgggtggag tgctgtgtcc tgcccggctg gcacgggacc 540  
 agctgcggcg tgcccactgt ggtgcagtac tccaacctgc ccaccaagga gcggctggtg 600  
 cccagggagg tgccgcggcg cgtcatcaac gccatcaacg tcaaccacga gttcgacctg 660  
 ctggagctgc gcttcacaga gctggggcag gtgggtggag cctttgtggg gtgcgagtcc 720  
 aacttcacgg cttatgggga gccgcggccg ctcaagttcc gggagatgct gaccaatggc 780  
 accttcgagt acatccgcca caaggtgtctc tatgtcttcc tggaccactt cccgcccggc 840  
 ggccggcagg acggctggat cggcgacgac tacctgcgca ccttcctcac ccaggacggc 900  
 gtctcggggc tgcgcaacct gcggcccgac gacgtcttca tcattgacga tgcggacgag 960  
 atccccggcc gtgacggcgt ccttttctc aagctctacg atggctggac cgagcccttc 1020  
 gccttcacga ctcgcaagtc gctctacggc ttcttctgga agcagccggg caccctggag 1080  
 gtgggtgtcag gctgcacggg ggacatgctg caggcagtggt atgggctgga cggcatccgc 1140  
 ctgcgcccgc gccagtaact caccatgccc aacttcagac agtatgagaa ccgcaccggc 1200  
 cacatcctgg tgcaagtgtc gctgggcagc cccctgcact tcgcccggctg gcactgctcc 1260  
 tgggtgctta cgcccagggg catctacttc aagctcgtgt ccgcccagaa tggcgacttc 1320  
 ccacgctggg gtgactacga ggacaagcgg gacctgaact acatccgcgg cctgatccgc 1380  
 accggggggc ggttcgacgg cagcgagcag gagtaccgcg ctgcagaccc cagcgagcac 1440  
 atgtatgcgc ccaagtacct gctgaagaac tacgaccggg tccactacct gctggacaac 1500  
 ccctaccagg agcccaggag cacggcggcg ggccgggtgg gccacagggg tcccgaaggga 1560  
 aggccgcccg cccgggggcaa actggacgag gcggaagtct ag 1602

<210> 8  
 <211> 7027  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Synthetic

<400> 8  
 catgattacg ccaagctagc ggccgcattc ccgggaagct agggccaccgt ggcccgcctg 60  
 caggggaagc ttgcatgcct gcagatcccc ggggatcctc tagagtcgac ctgcagtga 120  
 gcgtgaccgc gtcgtgcccc tctctagaga taatgagcat tgcagtctta agttataaaa 180  
 aattaccaca taattttttt gtcacacttg attgaagtgc agtttatcta tctttataca 240  
 tatattttaa ctttaactcta cgaataatat aatctatagt actacaataa tatcagtgtt 300  
 ttagagaatc atataaatga acagtttagac atggctctaaa ggacaattga gtattttgac 360  
 aacaggactc tacagtttta tcttttttagt gtgcattgtgt tctccttttt ttttgcaaat 420  
 agcttcacct atataatact tcatccattt tattagtaca tccatttagg gtttaggggtt 480  
 aatgggtttt atagactaat ttttttagta catctatttt attctatttt agcctctaaa 540  
 ttaagaaaac taaaactcta ttttagtttt tttatttaat aatttagata taaaatagaa 600  
 taaaataaag tgactaaaaa ttaaacaat accctttaag aaattaaaaa aactaaggaa 660  
 acatttttct tgtttcgagt agataatgcc accctgttaa acgcccgtcg agagtctaac 720  
 ggacaccaac cagcgaaacca gcagcgtcgc gtcggggcaa gcgaagcaga cggcacggca 780  
 tctctgtcgc tgccctctga cccctctcga gagtccgct ccaccgttgg acttgctccg 840  
 ctgtcggcat ccagaaattg cgtggcggag cggcagacgt gagccggcac ggcaggcggc 900  
 ctctctccct tctcacggca cggcagctac gggggattcc tttcccaccg ctcttcgct 960  
 ttcccttctc cggccgcccgt aataaataga caccctctcc acaccctctt tccccaacct 1020  
 cgtgttggtt ggagcgaca cacacacaac cagatctccc ccaaatccac ccgtcggcac 1080  
 ctccgcttca aggtacgccc ctctctctcc ccccccccc ctctctacct tctctagatc 1140  
 ggcgttccgg tccatgcatt gcttagggccc ttaggttcta ctctgttca tgtttgtgtt 1200  
 agatccgtgt ttgtgttaga tccgtgtcgc gtagcgttct acacggatgc gacctgtacg 1260  
 tcagacacgt tctgattgct aacttgccag tgtttctctt tggggaatcc tgggatggct 1320  
 ctagccgttc cgcagacggg atcgatttca tgattttttt tgtttcgttg catagggttt 1380  
 ggtttgccct tttcctttat ttcaatatat gccgtgcact tgtttgtcgg gtcacttttt 1440

5/15

catgcttttt	tttgtcttgg	tttgtgatgat	gtggctctgg	tgggcggctg	ttctagatcg	1500
gagtagaatt	ctgtttcaaa	ctacctgggt	gatttatata	ttttggatct	gtatgtgtgt	1560
gccatacata	ttcatagtta	cgaattgaag	atgatggatg	gaaatatcga	tctaggatag	1620
gtatacatgt	tgatgcgggt	tttactgatg	catatacaga	gatgcttttt	gttcgcttgg	1680
tttgtgatgt	gtgggtgtgt	tgggcggctg	ttcattcgtt	ctagatcggg	gtagaatact	1740
gtttcaaaat	acctgggtga	tttattaatt	ttggaactgt	atgtgtgtgt	catacatctt	1800
catagttacg	agtttaagat	ggatggaaat	atcgatctag	gatagggtata	catgttgatg	1860
tgggttttac	tgatgcatat	acatgatggc	atatgcagca	tctattcata	tgctctaacc	1920
ttgagtacct	atctattata	ataaacaagt	atgttttata	attattttga	tcttgatata	1980
cttggatgat	ggcatatgca	gcagctatat	gtggattttt	ttagccctgc	cttcatacgc	2040
tatttatattg	cttgggtactg	tttcttttgt	cgatgctcac	cctgttggtt	ggtgttactt	2100
ctgcagggtta	cccccggggt	cgaccatggt	aaggggcagc	caccaccacc	accaccacat	2160
ggctcgctct	gtagaaaacc	caacccgtga	aatcaaaaaa	ctcgacggcc	tgtgggcatt	2220
cagctctggat	cgcgaaaact	gtggaaattga	tcagcgttgg	tgggaaagcg	cgttacaaga	2280
aagccgggca	attgctgtgc	caggcagttt	taacgatcag	ttcgccgatg	cagatattcg	2340
taattatgcg	ggcaacgtct	ggtatcagcg	cgaagtcttt	ataccgaaaag	gttgggcagg	2400
ccagcgatc	gtgctgcgtt	tcgatgcggg	cactcattac	ggcaaagtgt	gggtcaataa	2460
tcaggaaagt	atggagcatc	agggcggcta	tacgccattt	gaagccgatg	tcacgcctga	2520
tgttattgcc	gggaaaagtg	tacgtatcac	cgtttgtgtg	aacaacgaac	tgaactggca	2580
gactatcccc	ccgggaatgg	tgattaccga	cgaaaacggc	aagaaaaagc	agtccttactt	2640
ccatgatattc	tttaactatg	ccggaatcca	tcgcagcgta	atgctctaca	ccacgcccga	2700
cacctggggtg	gacgatatac	ccgtgggtgac	gcatgtcgcg	caagactgta	accacgcgtc	2760
tgttgactgg	caggtgggtg	ccaatgggtga	tgatcagcgtt	gaactgcgtg	atgcggatca	2820
acaggtgggt	gcaactggac	aaggcactag	cgggactttg	caagtgggtga	atccgcacct	2880
ctggcaaccg	ggtagaaggtt	atctctatga	actgtgcgtc	acagccaaaa	gccagacaga	2940
gtgtgatata	taccgccttc	gcgtcggcat	ccggtcagtg	gcagtgaagg	gcgaacagtt	3000
cctgattaac	cacaaaacgt	tctactttac	tggctttggt	cgatcatgaag	atgcggactt	3060
acgtggcaaa	ggattcgata	acgtgctgat	ggtgcacgac	cacgcattaa	tggactggat	3120
tggggccaac	tcctaccgta	cctcgcatta	cccttacgct	gaagagatgc	tcgactgggc	3180
agatgaacat	ggcactcgtg	tgattgatga	aactgctgct	gtcggcttta	acctctcttt	3240
aggcattggt	ttcgaagcgg	gcaacaagcc	gaaagaactg	tacagcgaag	aggcagtcac	3300
cggggaaaact	cagcaagcgc	acttacaggg	gattaaagag	ctgatagcgc	gtgacaaaaa	3360
ccaccaaaagc	gtgggtgatgt	ggagtattgc	caacgaaccg	gatacccgct	cgcaagtga	3420
cgggaatatt	tcgccactgg	cggaaagcac	gcgtaaaact	gacccgacgc	gtccgcacac	3480
ctgcgtcaat	tgaaatgtct	gcgacgctca	caccgatacc	atcagcgatc	tctttgatgt	3540
gctgtgcctg	aaccgttatt	acggatggta	tgtccaaaagc	ggcgatttgg	aaacggcaga	3600
gaaggtaactg	gaaaaagaac	ttctggcctg	gcaggagaaa	ctgcatcagc	cgattatcat	3660
caccgaatac	ggcgtggata	cgtagccgg	gctgcactca	atgtacaccg	acatgtggag	3720
tgaagagtat	cagtgtgcat	ggctgggat	gtatcaccgc	gtctttgatc	gcgtcagcgc	3780
cgtcgtcggg	gaacaggtat	ggaatttcgc	cgattttcgc	acctcgcaag	gcatattgcg	3840
cgttggcggg	aacaagaaag	ggatcttcac	tcgcgaccgc	aaaccgaagt	cggcggcttt	3900
tctgctgcaa	aaacgctgga	ctggcatgaa	cttcgggtgaa	aaaccgcagc	agggaggcaa	3960
acaatgataa	tgagctcggt	taaaactgag	gcactgaagt	cgcttgatgt	gctgaattgt	4020
tttgtgatgtt	ggtggcgtat	tttgtttaaa	taagtaagca	tggctgtgat	tttatcatat	4080
gatcgatctt	tgggtgtttta	tttaacacat	tgtaaaatgt	gtatctatta	ataactcaat	4140
gtataagatg	tgttcattct	tcggttgcca	tagatctgct	tatttgacct	gtgatgtttt	4200
gactcaaaaa	caactcaata	aactcatgga	aatcatgga	atatgtccac	ctgtttcttg	4260
aagagttcat	ctaccattcc	agtggcatt	tatcagtggt	gcagcggcgc	tgtgctttgt	4320
aacataacaa	ttgttacggc	atatatccaa	cggccggcct	agctagccac	ggtggccaga	4380
tccactagtt	ctagagcggc	cgcttaattc	actggccgtc	gttttacaac	gtcgtgactg	4440
ggaaaaccct	ggcgttaccc	aacttaatcg	ccttgacgca	catccccctt	tcgccagctg	4500
gcgtaatagc	gaagaggccc	gcaccgatcg	cccttcccaa	cagttgcgca	gcctgaatgg	4560
cgaatggcgc	ctgatgcggg	attttctcct	tacgcactcg	tgcggtattt	cacaccgat	4620
atgggtgact	ctcagtacaa	tctgctctga	tgccgcatag	ttaagccagc	cccgaacccc	4680
gccaacaccc	ctgacgcgc	cctgacgggc	ttgtctgctc	ccggcatccg	cttacagaca	4740
agctgtgacc	gtctccggga	gctgcatgtg	tcagaggttt	tcaccgtcat	caccgaaacg	4800
cgcgagacga	aagggcctcg	tgatacgcct	atttttatag	gttaatgtca	tgataataat	4860
ggttttcttag	acgtcaggtg	gcacttttcg	gggaaatgtg	cgcggaaccc	ctatttggtt	4920
atctttctaa	atacatctca	atattgtatc	gctcatgaga	caataaccct	gataaatgct	4980
tcaataatat	tgaaaaagga	agagtatgag	tattcaacat	ttccgtgtcg	cccttattcc	5040
cttttttgcg	gcattttgcc	ttctgttttt	tgtcacccca	gaaacgcctg	tgaagtaaaa	5100
agatgctgaa	gatcagttgg	gtgcacgagt	gggttacatc	gaactggatc	tcaacagcgg	5160
taagatccct	gagagttttc	gccccgaaga	acgttttcca	atgatgagca	ctttttaaagt	5220
tctgctatgt	ggcgcggtat	tatccccgat	tgacgcgggg	caagagcaac	tcggctcgccg	5280
catacactat	tctcagaatg	acttggttga	gtactcacca	gtcacagaaa	agcatcttac	5340
ggatggcatg	acagtaagag	aattatgcag	tgtgtccata	acctagatgt	ataaactcgc	5400
ggccaactta	cttctgacaa	cgatcggagg	accgaaggag	ctaaccgctt	ttttgcacaa	5460
catgggggat	catgtaaact	gccttgatcg	ttgggaacgg	gagctgaatg	aagccatacc	5520
aaacgacgag	cgtgacacca	cgatgcctgt	agcaatggca	acaacgttgc	gcaaacattt	5580
aactggcgaa	ctacttactc	tagcttcccg	gcaacaatta	atagactgga	tggaggcgga	5640
taaagttgca	ggaccacttc	tgcgtcgggc	ccttcgggct	ggctggttta	ttgctgataa	5700



6/15

atctggagcc	ggtgagcgtg	ggtctcgcg	tatcattgca	gcactggggc	cagatggtaa	5760
gccctcccgt	atcgtagtta	tctacacgac	ggggagtcag	gcaactatgg	atgaacgaaa	5820
tagacagatc	gctgagatag	gtgcctcact	gattaagcat	tggttaactgt	cagaccaagt	5880
ttactcatat	atactttaga	ttgatttaaa	acttcatttt	taatttaaaa	ggatctaggt	5940
gaagatcctt	tttgataatc	tcatgaccaa	aatcccttaa	cgtgagtttt	cgttccactg	6000
agcgtcagac	cccgtagaaa	agatcaaagg	atcttcttga	gatccttttt	ttctgcgcgt	6060
aatctgctgc	ttgcaaacaa	aaaaaccacc	gctaccagcg	gtggtttggt	tgccggatca	6120
agagctacca	actctttttc	cgaaggtaac	tggtttcagc	agagcgcaga	taccaaatat	6180
tgtccttcta	gtgtagccgt	agttaggcca	ccacttcaag	aactctgtag	caccgcctac	6240
atacctcgct	tgctaatcc	tgttaccagt	ggctgctgcc	agtggcgata	agtcgtgtct	6300
taccgggttg	gactcaagac	gatagttacc	ggataaggcg	cagcggtcgg	gctgaacggg	6360
gggttcgtgc	acacagccca	gcttgagcgc	aacgacctac	accgaactga	gatacctaca	6420
gcgtgagcat	gtgaaagcg	ccacgcttcc	cgaaggagga	aaggcggaca	ggtatccggg	6480
aagcggcagg	gtcggaaacg	gagagcgcac	gagggagcct	ccagggggaa	acgcctggta	6540
tctttatagt	cctgtcgggt	ttcgcacact	ctgacttgag	cgtcgatttt	tgtgatgctc	6600
gtcagggggg	cggagcctat	ggaaaaacgc	cagcaacgcg	gcctttttac	ggttcctggc	6660
cttttgcgtg	cttttgcctc	acatgttctt	tcttgcgtta	tcccctgatt	ctgtggataa	6720
ccgtattacc	gcctttgagt	gagctgatac	cgctcgccgc	agccgaacga	ccgagcgcag	6780
cgagtcagtg	agcagggag	cggaaagagc	cccaatacgc	aaaccgcctc	tcccgcgcgc	6840
ttggccgatt	cattaatgca	gctggcacga	cagggtttcc	gactggaaag	cgggcagtgga	6900
gcgcaacgca	attaatgtga	gttagctcac	tattaggga	ccccaggctt	tacactttat	6960
gcttcgggct	cgtatgttgt	gtggaattgt	gaacggataa	caatttcaca	caggaaacag	7020
ctatgac						7027

<210> 9  
 <211> 6818  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Synthetic

<400> 9						
cctgcagatc	cccggggatc	ctctagagtc	gacctgcagt	gcagcgtgac	ccggctcgtgc	60
ccctctctag	agataatgag	cattgcatgt	ctaagttata	aaaaattacc	acatattttt	120
ttgttcacac	ttgtttgaag	tgcagtttat	ctatctttat	acatatattt	aaactttaat	180
ctacgaataa	tataatctat	agtactacaa	taatatcagt	gttttagaga	atcatataaa	240
tgaacagtta	gacatggctt	aaaggacaat	tgagtatttt	gacaacagga	ctctacagtt	300
ttatcttttt	agtgtgcatg	tggtctcctt	tttttttgca	aatagcttca	cctatataat	360
acttcatcca	ttttattagt	acatccattt	agggtttagg	gttaatgggt	tttatagact	420
aattttttta	gtacatctat	tttatcttat	tttagcctct	aaattaagaa	aactaaaact	480
ctatttttagt	ttttttattt	aataatttag	atataaaaata	gaataaaaata	aagtgactaa	540
aaattaaaca	aatacccttt	aagaaattaa	aaaaactaag	gaaacatttt	tcttgtttcg	600
agtagataat	ggcagcctgt	taaacgcctg	cgacgagctt	aacggacacc	aaccagcgaa	660
ccagcagcgt	cgcgtcgggc	caagcgaagc	agacggcacg	gcactctctg	cgctgcctct	720
ggacccctct	cgagagttcc	gctccaccgt	tggaacttgct	ccgctgtcgg	catccagaaa	780
ttgcgtggcg	gagcggcaga	cgtgagccgg	cacggcaggc	ggcctcctcc	tcctctcacg	840
gcacggcagc	tacgggggat	tcctttccca	ccgctccttc	gctttccctt	cctcgcccgc	900
cgtaataaat	agacaccccc	tccacacccc	cttcccccaa	cctcgtgttg	ttcggagcgc	960
acacacacac	aaccagatct	cccccaaatc	caccctcgcc	cacctccgct	tcaaggtagc	1020
ccgctcgtcc	tccccccccc	cccctctcta	ccttctctag	atcggcgctc	cggctccatgc	1080
atggttaggg	cccggtagtt	ctacttctgt	tcatgtttgt	gttagatccg	tgtttgtgtt	1140
agatccgtgc	tgtagcgtt	cgtacacgga	tgcgacctgt	acgtcagaca	cgttctgatt	1200
gctaacttgc	cagtgtttct	ctttggggaa	tcctgggatg	gctctagccg	ttccgcagac	1260
gggatcgatt	tcatgatatt	ttttgtttcg	ttgcataggg	tttggtttgc	ccttttctct	1320
tatttcaata	tatgcgtgct	acttgtttgt	cgggtcatct	tttcatgctt	ttttttgtct	1380
tggttgtgat	gatgtgggtt	gggtgggcgg	tcgttctaga	tcggagtaga	attctgtttc	1440
aaactacctg	gtggatttat	taattttgga	tctgtatgtg	tgtgccatgc	atattcatag	1500
ttacgaattg	aagatgatgg	atggaaatat	cgatctagga	taggtataca	tgttgatgcg	1560
ggttttactg	atgcataatc	agagatgctt	ttgtttcgct	tggttgtgat	gatgtgggtg	1620
ggttgggcgg	tcgttcattc	gttctagatc	ggagtagaat	actgtttcaa	actaccgtgt	1680
gtatttatta	attttggaa	tgtagtgtgt	tgtcatacat	cttcatagtt	acgagtttaa	1740
gatggatgga	aatatcgatc	taggataggt	atacatgttg	atgtgggttt	tactgatgca	1800
tatacatgat	ggcatatgca	gcattctatt	ataatgttct	accttgagta	cctatctatt	1860
ataataaaca	agtagtgggt	ataatatttt	tgactttgat	atacttggat	gatggcatat	1920
gcagcagcta	tatgtggatt	tttttagccc	tgcttccata	cgctatttat	ttgcttggta	1980
ctgtttcttt	tgtcgtgctt	cacctgtgtg	tttgggtgta	cttctgcagg	gtacccccgg	2040
ggctgaccat	ggtagatgaga	cgctacaagc	tctttctcat	gttctgtatg	gccggcctgt	2100
gcctcatctc	cttctgcac	ttcttcaaga	ccctgtccta	tgtcaccttc	ccccgagaac	2160
tggcctccct	cagccctaac	ctgggtgtcca	gctttttctg	gaacaatgcc	ccggtcacgc	2220

7/15

cccaggccag	ccccgagcca	ggaggccctg	acctgctgcg	tacccactc	tactccact	2280
cgccctgct	gcagcgctg	ccgcccagca	aggcggccga	ggagctccac	cggtggact	2340
tggtgctgcc	cgaggacacc	accgagtatt	tcgtgcgcac	caaggccggc	ggcgtctgct	2400
tcaaacccgg	caccaagatg	ctggagaggg	ccccccggg	acggccggag	gagaagcctg	2460
agggggccaa	cggctcctcg	gcccggcggc	caccccgta	cctcctgagc	gcccgggagc	2520
gcacgggggg	ccgaggcgcc	cggcgcaagt	gggtggagtg	cgtgtgcctg	cccggctggc	2580
acggaccag	ctgcggcgtg	cccactgtgg	tgcagtactc	caacctgccc	accaaggagc	2640
ggctggtgcc	caggggaggtg	ccgcgcgcgc	tcactcaacgc	catcaacgtc	aaccacgagt	2700
tcgacctgct	ggactgtcgc	ttccacgagc	tggcgacgt	ggaggacgcc	tttgtggtgt	2760
gcgagtcaca	cttcacggct	tatggggagc	cgcgccgct	caagttccgg	gagatgctga	2820
ccaatggcac	cttcgagtac	atccgccaca	agggtgctcta	tgtcttcctg	gaccacttcc	2880
cgcccgccgg	ccggcaggac	ggctggatcg	ccgacgacta	cctgcgcacc	ttctcacc	2940
aggagggcgt	ctcgcggctg	gcacacctgc	ggcccgacga	cgtcttcac	attgacgatg	3000
ggagcgagat	cccgcccggt	cgagcgctcc	ttttcctcaa	gctctacgat	ggctggaccg	3060
agcccttcgc	cttcacatg	cgcaagtcgc	tctacggctt	cttctgggaag	cagccgggca	3120
ccctggagggt	gggtgcaggc	tgcacgggtg	acatgctgca	ggcagtgat	gggctggagc	3180
gcacccgctt	gcgcgcgcgc	cagtactaca	cattgccccaa	cttcagacag	tatgagaacc	3240
gcacccggcca	catctgggtg	cagtggctgc	tggcgagccc	cctgcacttc	gcccggctggc	3300
actgctcctg	gtgcttcacg	cccagaggca	tctacttcaa	gctcgtgtcc	gcccagaatg	3360
gcgacttccc	acgctgggggt	gactacgagg	acaagcggga	cctgaactac	atcccgggcc	3420
tgatccgcac	cgggggctgg	ttcgacggca	cgagcagga	gtaccgcct	gcagacccca	3480
gcagcgacat	cttgctgcgc	aagtacctgc	tgaagaacta	cgaccgggtt	cactacctgc	3540
tggacaaccc	ctaccaggag	cccagggagca	cggcgggggg	cgggtggcgc	cacaggggtc	3600
ccgaggggaag	gcccggcgcc	cggggcaaac	tggacgaggc	ggagtcgaa	caaaaaactca	3660
tctcagaaga	ggatctgaat	taggatccta	ggtttaaact	gagggcactg	aagtcgcttg	3720
atgtgctgaa	tgtttgtgga	tgttgggtgg	gtattttgtt	taataaagta	agcatggctg	3780
tgattttatc	atatgatcga	tctttgggggt	ttattttaac	acattgtaaa	atgtgtatct	3840
attaataact	caatgtataa	gatgtgttca	ttcttcggtt	gccatagatc	tgcttatttg	3900
acctgtgatg	ttttgactcc	aaaaacaaaa	atcacaactc	aataaaactca	tggaatatgt	3960
ccacctgttt	cttgaagagt	tcacttacca	ttccagttgg	catttatcag	tgttgacgag	4020
gcgctgtgct	ttgtaacata	acaattgttc	acggcatata	tccacggccg	gcctagctag	4080
ccacggtggc	cagatccact	agttctagag	cgcccgctta	attcactggc	cgctcgttta	4140
caacgctgga	actgggaaaa	ccctggcggt	accacaactta	atcgccctgc	agcacatccc	4200
cccttcgcca	gctggcgtaa	tagcgaagag	gcccgcaccg	atcgcccttc	ccaacagttg	4260
cgcagcctga	atggcgaaatg	gcgcctgatg	cgggtattttc	tccttacgca	tctgtgcgggt	4320
atttcacacc	gcataatggg	cactctcagt	acaatctgct	ctgatgccgc	atagttaaag	4380
cagcccccag	acccgccaac	acccgctgac	gcgcctgac	gggcttgtct	gctcccggca	4440
tccgcttaca	gacaagctgt	gaccgtctcc	ggagctgca	tgtgtcagag	gttttcaccg	4500
tcactaccga	aacgcgcgag	acgaaagggc	ctcgtgatac	gcctattttt	ataggttaat	4560
gtcatgataa	taatggtttc	ttagacgtca	ggtaggcactt	ttcggggaaa	tgtgcgcgga	4620
acccctattt	gtttattttt	ctaaatacat	tcaaatatgt	atccgctcat	gagacaataa	4680
ccctgtataa	gtattgaaaa	atattgaaaa	aggaagagta	tgagtattca	acatttccgt	4740
gtcgccctta	ttcccttttt	tgcggcattt	tgccctcctg	tttttgctca	cccagaaacg	4800
ctggtgaaag	taaaagatgc	tgaagatcag	ttgggtgcac	gagtggttta	catcgaactg	4860
gatctcaaca	gcggtaagat	ccttgagagt	tttcgccccg	aagaacgttt	tccaatgatg	4920
agcactttta	aagttctgct	atgtggcgcg	gtattatccc	gtattgacgc	cgggcaagag	4980
caactcggtc	gcgcataca	ctattctcag	aatgacttgg	ttgagtactc	accagtcaca	5040
gaaaagcatc	ttacggatgg	catgacagta	agagaattat	gcagtgtctg	cataaccatg	5100
agtgataaca	ctgcggccaa	cttacttctg	acaacgatcg	gaggaccgaa	ggagctaacc	5160
gcttttttgc	acaacatggg	ggatcatgta	actgccttgg	atcgttggga	accggagctg	5220
aatgaagcca	taccaaaacga	cgagcgtgac	accacgatgc	ctgtagcaat	ggcaacaacg	5280
ttgcgcaaac	tattaaactgg	cgaactactt	actctagctt	cccggcaaca	attaatagac	5340
tggatggagg	cggataaagt	tgcaggacca	cttctgcgct	cggcccttcc	ggctggctgg	5400
tttattgctg	ataaatctgg	agccggtgag	gctgggtctc	gcggtatcat	tgacagactg	5460
gggcccagatg	gtaagccctc	ccgtatcgta	gttatctaca	cgacggggag	tcaggcaact	5520
atggatgaac	gaaatagaca	gatcgtgag	ataggtgcct	cactgattaa	gcattggtaa	5580
ctgtcagacc	aagtttactc	atatatactt	tagattgatt	taaaacttca	tttttaattt	5640
aaaaggatct	aggtgaagat	cctttttgat	aatctcatga	ccaaaatccc	ttaacgtgag	5700
ttttcgtttc	actgagcgtc	agacccgta	gaaaagatca	aaggatcttc	ttgagatcct	5760
ttttttctgc	gcgtaatctg	ctgcttgcaa	acaaaaaac	caccgctacc	agcggtggtt	5820
tgtttgccgg	atcaagagct	accaactctt	tttccgaagg	taactggctt	cagcagagcg	5880
cagataccaa	atactgtcct	tctagtgtag	ccgtagttag	gccaccactt	caagaactct	5940
gtagcaccgc	ctacatacct	cgtctgttac	atctctgtac	cagtggctgc	tgccagtggc	6000
gataagtcgt	gtcttaccgg	gttggaactca	agacgatagt	taccggataa	ggcgagcgg	6060
tcgggctgaa	cgggggggttc	gtgcacacag	cccagcttgg	agcgaacgac	ctacaccgaa	6120
ctgagatacc	tacagcgtga	gcattgagaa	agcgccacgc	ttcccgaagg	gagaaaaggc	6180
gcagagtcac	cagggtcgga	acaggagagc	acaggagagc	gcacgaggga	gcttccaggg	6240
ggaaacgcct	gggtatcttta	tagtctgtgc	gggtttcgcc	acctctgact	tgagcgtcga	6300
tttttgat	gctcgtcagg	ggggcgagc	ctatggaaaa	acgccagcaa	cgcggccttt	6360
ttacggttcc	tggccttttg	ctggcctttt	gctcacatgt	tctttcctgc	gttatccctt	6420
gattctgtgg	ataaccgtat	taccgccttt	gagtgaagctg	ataccgctcg	ccgcagccga	6480

8/15

acgaccgagc	gcagcgagtc	agtgagcgag	gaagcggaag	agcgcccaat	acgcaaaccg	6540
cctctccccc	cgcgttggcc	gattcattaa	tgcagctggc	acgacaggtt	tcccgaactg	6600
aaagcgggca	gtgagcgcaa	cgcaattaat	gtgagttagc	tcactcatta	ggcaccaccag	6660
gctttacact	ttatgcttcc	ggctcgtatg	ttgtgtggaa	ttgtgagcgg	ataacaattt	6720
cacacaggaa	acagctatga	ccatgattac	gccaaagctag	cggccgcatt	cccgggaagc	6780
tagggccaccg	tggccgcct	gcaggggaag	cttgcatg			6840

<210> 10  
 <211> 7545  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Synthetic

<400> 10

cgattaaaaa	tctcaattat	atttggctcta	atttagtttg	gtattgagta	aaacaaattc	60
gaaccaaacc	aaaatataaa	tatatagttt	ttatatatat	gcctttaaga	ctttttatag	120
aattttcttt	aaaaaatatc	tagaaatatt	tgcgactctt	ctggcatgta	atatttcggt	180
aaatatgaag	tgctccattt	ttattaactt	ttaaataattg	gttgtagcat	cactttctta	240
tcaagtgtta	ctaaaatgcg	tcaatctctt	tggtcttcca	tattcatatg	tcaaaaccta	300
tcaaaaattct	tatatatctt	tttcgaattt	gaagtgaatt	ttcgataatt	taaaattaaa	360
tagaacatat	cattatattag	gtatcatatt	gatttttata	cttaattact	aaatttggtt	420
aactttgaaa	gtgtacatca	acgaaaaatt	agtcaaacga	ctaaaaataa	taaatatcat	480
gtgttattaa	gaaaattctc	ctataagaat	attttaatag	atcatatggt	tgtaaaaaaa	540
ataatttttt	actaacacat	atatttactt	atcaaaaatt	tgacaaagta	agattaaaat	600
aatattcatc	taacaaaaaa	aaaaccagaa	aatgctgaaa	acccggcaaa	accgaaccac	660
tccaaaccga	tatagttggt	ttggtttgat	tttgatataa	accgaaccac	ctcgggccat	720
ttgcacccct	aatcataata	gctttaatat	ttcaagatat	tattaaagta	acgttgctca	780
tatcctggaa	atattgcaaa	atgaatcaag	cctatatggc	tgtaatatga	atttaaaagc	840
agctcgatgt	ggtggtaata	tgtaattttac	ttgattctaa	aaaaatatcc	caagtattaa	900
taatttctgc	tgggaagaag	gttagctacg	atttacagca	aagccagaat	acaatgaacc	960
ataaagtgtg	tgaagctcga	aatatacgaa	ggaacaaata	tttttaaaaa	aatacgcgat	1020
gacttggaaac	aaaagaaagt	gatataattt	ttgttcttaa	acaagcatcc	cctctaagaa	1080
atggcagttt	tcctttgcat	gttaactatta	tgctcccttc	gttacaaaaa	ttttggacta	1140
ctattgggaa	cttcttctga	aaatagtggt	caccgcttaa	ttaaggcgcg	ccatgccccg	1200
gcaagcgggc	gcttaattaa	atttaaatgt	tbaactagg	aaatccaagc	ttgggctgca	1260
ggccaatccc	atgtcttttg	aagcagctca	acattgatct	ctttctcgag	gtcattcata	1320
tgcttgagaa	gagagtcggg	atagtcacaa	ataaaaacaa	ggtaagatta	cctgggtcaaa	1380
agtgaaaaca	tcagttaaaa	ggtgggtataa	agtaaaatat	cggtaatata	aggtggccca	1440
aagtgaattt	tactcttttc	tactattata	aaaattgagg	atgtttttgt	cggtagctttg	1500
atagctcatt	tttgtatgaa	ttgggtttta	agtttatctg	cttttggaag	tgcatatctg	1560
tatttgagtc	gggttttaag	ttcgtttgct	tttgtaataa	cagagggatt	tgtataagaa	1620
atatctttaa	aaaaacccat	atgctaattt	gacataattt	ttgagaaaaa	tatatattca	1680
ggcgaattct	cacaatgaac	aataataaga	ttaaaatagc	ttccccctgt	tgacgcat	1740
gggtattttt	cttagtaaaa	ataaaagata	aacttagact	caaaacattt	acaaaaacaa	1800
cccctaaagt	tcctaaagcc	caaagtgtca	tccacgatcc	atagcaagcc	cagccccacc	1860
caaccacaacc	caaccacacc	cagtcacagc	aactggacaa	tagtctccac	acccccccac	1920
tatcacctgt	agttgtccgc	acgcaccgca	cgctctcgag	ccaaaaaaaa	aaaaagaaaag	1980
gaaaaaaaga	aaaaagaaaa	acagcaggtg	gggtccgggtc	gtggggggcg	gaaacgcgag	2040
gaggatcgcg	agccagcgac	gaggccggcc	ctccccccgc	ttccaaagaa	acgcccccca	2100
tcgccactat	atacatacc	ccccctctcc	tcccatcccc	ccaaccctac	caccaccacc	2160
accaccacct	ccacctcttc	ccccctcgct	gccggacgac	gcctcccccc	tccccctcag	2220
ccgcccggcg	cccggttaacc	accccggccc	tctcctcttt	ctttctccgt	tttttttttc	2280
cgtctcggtc	tcgatctttg	gccttggttag	tttgggtggg	cgagaggcgg	cttcgtgcgc	2340
gcccagatcg	gtgcgcggga	ggggcgggat	ctcgcggtcg	gggctctcgc	cggcgtggat	2400
ccggcccgga	tctcgcgggg	aatggggctc	tcggatgtag	atctgcgac	cggcgtgtgt	2460
ggggggagatg	atgggggggt	taaaattttc	gccatgctaa	acaagatcag	gaagaggggga	2520
aaagggcact	atgggtttata	tttttatata	tttctgctgc	ttcgtcaggc	ttagatgtgc	2580
tagatctttc	tttctctctt	ttgtgggtag	aatttgaatc	cctcagcatt	gttcacgtgt	2640
agtttttctt	ttcatgattt	gtgacaaatg	cagcctcgtg	cggagctttt	ttgtaggtag	2700
accatggcct	ctccggagag	gagaccagtt	agatattagg	cagctacagc	agctgatatg	2760
gccgcgggtt	gtgatatcgt	taaccattac	attgagacgt	ctacagtga	ctttaggaca	2820
gagccacaaa	caccacaaga	gtggattgat	gatctagaga	gggtgcaaga	tagataacct	2880
tgggttgggtg	cttaggttga	gggtgtgtgt	gctggatttg	cttacgctgg	gccttggaaag	2940
gctaggaacg	ccttagattg	gacagttgag	agtactgttt	acgtgtcaca	taggcataca	3000
agggttggggc	taggatccac	attgtacaca	catttgctta	agtcctatga	ggcgcaagggt	3060
tttaagtctg	tgggtgtgtg	tatagccctt	ccaaacgatc	catctgttag	gttgcatgag	3120
gctttgggat	acacagcccc	gggtacattg	cgcgcagctg	gatacaagca	tgggtggatgg	3180
catgatgttg	gtttttggca	aagggaattt	gagttgccag	ctcctccaag	gccagttagg	3240

9/15

ccagttacc	agatctgagg	taccctgagc	tcggctcgag	cgtgtgcgtg	tccgtcgtac	3300
gttctggccg	gccgggcctt	gggcgcgcga	tcagaagcgt	tgcgttggcg	tgtgtgtgct	3360
tctggtttgc	tttaatttta	ccaagtttgt	ttcaagggtg	atcgcggtg	caaggcccgt	3420
gtgctttaaa	gacccaccgg	cactggcagt	gagtggtgct	gcttgtgtag	gctttggtac	3480
gtatgggctt	tatttgcttc	tggatgttgt	gtactacttg	ggttgttga	attattatga	3540
gcagttgcgt	attgtaattc	agctgggcta	cctggacatt	gttatgtatt	aataaatgct	3600
ttgctttctt	ctaaagatct	ttaagtgtcg	aattcatatt	tcctcctgca	gggtttaaac	3660
ttgccgtggc	ctattttcag	aagaagttcc	caatagtagt	ccaaaatttt	tgtaacgaag	3720
ggagcataat	agttacatgc	aaaggaaaac	tgccattctt	tagaggggat	gcttgtttaa	3780
gaacaaaaaa	tatatcactt	tcttttgttc	caagtcattg	cgtatttttt	taaaaaattt	3840
tgttccttcg	tatatctcga	gcttcaatca	ctttatgggt	ctttgtattc	tggctttgct	3900
gtaaatcgta	gctaaccctt	ttcctagcag	aaattattaa	tacttgggat	atttttttag	3960
aatcaagtaa	attacatatt	accaccacat	cgagctgctt	ttaaattcat	attacagcca	4020
tataggcttg	attcattttg	caaaaatttc	aggaatttga	caacgttaac	ttataatat	4080
cttgaaatat	taaagctatt	atgattaggg	gtgcaaatgg	accgagttgg	ttcggtttat	4140
atcaaaatca	aaccaaacca	actatatcgg	tttggattgg	ttcggttttg	ccgggttttc	4200
agcattttct	ggtttttttt	ttgttagatg	aatattattt	taactcttact	ttgtcaaatt	4260
tttgataagt	aaatatatgt	gttagtaaaa	attaattttt	tttacaacaa	tatgatctat	4320
taaaatattc	ttataggaga	attttcttaa	taacacatga	tatttattta	tttagtcgt	4380
ttgactaatt	tttcgttgat	gtacactttc	aaagtttaacc	aaatttagta	attaagtata	4440
aaaatcaata	tgaatactaa	ataatgatat	gttctattta	attttaaatt	atcgaaattt	4500
cacttcaaat	tcgaaaaaa	tataataaaa	ttttgataga	ttttgacata	tgaatatgga	4560
agaacaaaaga	gattgacgca	ttttagtaac	acttgataag	aaagtgtatg	tacaaccaat	4620
tatttaaagt	taataaaaa	ggagcacttc	atattttaacg	aaatattaca	tgccagaaga	4680
gtcgcataata	tttctagata	ttttttaaag	aaaattctat	aaaaagtctt	aaaggcatat	4740
atataaaaa	tatatattta	tatttttggt	tggttcgaat	ttgttttact	caataccaaa	4800
ctaaattaga	ccaaatataa	ttgggatttt	taattcgcgc	ccactagtca	ccggtgtagc	4860
ttggcgtaat	catggtcata	gctgtttcct	gtgtgaaatt	gttatccgct	cacaattcca	4920
cacaacatac	gagccggaag	cataaagtgt	aaagcctggg	gtgcctaata	agtgaagctaa	4980
ctcacattaa	ttgcgttgcg	ctcactgccc	gctttccagt	cgggaaaacct	gtcgtgccag	5040
ctgcattaat	gaatcgccca	acgcgcgggg	agagggcggt	tgcgtattgg	gcgctcttcc	5100
gctgcgcacg	ctgcgcacgc	tgcgcacgct	tcctcgcctc	ctgactcgct	gcgctcggtc	5160
gttcggctgc	ggcgagcggt	atcagctcac	tcaaaggcgg	taatacgggt	atccacagaa	5220
tcaggggata	acgcaggaaa	gaacatgtga	gcaaaaaggc	agcaaaaagg	caggaaacgt	5280
aaaaaggccg	cgttgctggc	gtttttccat	aggctccgcc	cccctgacga	gcatcacaaa	5340
aatcgacgct	caagtcagag	gtggcgaaac	ccgacaggac	tataaagata	ccaggcggtt	5400
ccccctggaa	gctccctcgt	gcgctctcct	gttccgacct	tgccgcttac	cggataacct	5460
tccgccttct	tcccttcggg	aagcgtggcg	ctttctcata	gctcacgctg	taggtatctc	5520
agttcgggtg	aggtcgttcg	ctccaagctg	ggctgtgtgc	acgaaccccc	cgttcagccc	5580
gaccgctgcg	ccttatccgg	taactatcgt	cttgagtcca	acccggtaag	acacgactta	5640
tcgccactgg	cagcagccac	tggttaacagg	attagcagag	cgaggtatgt	aggcggtgct	5700
acagagttct	tgaagtgggt	gcctaactac	ggctacacta	gaaggacagt	atttggatat	5760
tgcgtctcgc	tgaagccagt	taccttcgga	aaaagagttg	gtagctcttg	atccggcaaa	5820
caaaccaccg	ctggtagcgg	tggttttttt	gtttgcaagc	agcagattac	gcgcagaaaa	5880
aaaggatctc	aagaagatcc	tttgatcttt	tctacggggg	ctgacgctca	gtggaacgaa	5940
aactcacggt	aagggatttt	ggtcatgaga	ttatcaaaaa	ggatcttcac	ctagatcctt	6000
ttaaattaaa	aatgaagttt	taaatcaatc	taaagtatat	atgagtaaac	ttggtctgac	6060
agttaccaat	gcttaatcag	tgaggcacct	atctcagcga	tctgtctatt	tcgttcaccc	6120
atagttgcct	gactccccgt	cgtgtagata	actacgatac	gggagggtct	accatctggc	6180
cccagtgctg	caatgatacc	gcgagaccca	cgctcaccgg	ctccagattt	atcagcaata	6240
aaccagccag	ccggaagggc	cgagcgagga	agtggtctct	caactttatc	cgctccatc	6300
cagtcctatta	attgttgccg	ggaagctaga	gtaagttagt	cgccagttaa	tagtttgctg	6360
aacgttggtg	ccattgtctac	aggcatcggt	gtgtcacgct	cgctcgtttg	tatggcttca	6420
ttcagctccg	gttcccaacg	atcaaggcga	gttacatgat	cccccatggt	gtgcaaaaaa	6480
gcggttagct	cttcgggtcc	tccgatcggt	gtcagaagta	agttggccgc	agtggtatca	6540
ctcatgggtta	tggcagcact	gcataattct	cttactgtca	tgccatccgt	aagatgcttt	6600
tctgtgactg	gtgagtactc	aaccaagtca	ttctgagaat	agtgtatgct	gcgaccgagt	6660
tgtctctggc	cggcgtcaat	acgggataat	accgcgccac	atagcagaac	tttaaaagtg	6720
ctcatctatg	gaaaacgttc	ttcggggcga	aaactctcaa	ggatcttacc	gctgttgaga	6780
tcaggttcga	tgtaacccac	tcgtgacccc	aactgatctt	cagcatcttt	tactttcacc	6840
agcgtttctg	ggtgagcaaa	aacaggaagg	caaaatgccg	caaaaaaggg	aataaggcg	6900
acacggaaat	tgtgaatact	catactcttc	ctttttcaat	attattgaag	catttatcag	6960
ggttatcgct	gttagagcgg	atacatattt	gaatgtattt	agaaaaataa	acaaataggg	7020
gttcgcgcga	cattttcccc	aaaagtgcc	cctgacgtct	aagaaaccat	tatttatcat	7080
acattaacct	ataaaaaatg	gcgtatcacg	aggccctttc	gtctcgcgcg	tttcgggtgat	7140
gacggtgaaa	acctctgaca	catgcagctc	ccggagacgg	tcacagcttg	tctgtaagcg	7200
gatgccggga	gcagacaagc	cagtcagggc	gcgtcagcgg	gtgttgccgg	gtgtcggggc	7260
tggcttaact	atgcggcatc	agagcagatt	gtactgagag	tgaccatat	gcggtgtgaa	7320
ataccgcaca	gatgcgtaag	gagaaaaatc	cgcatcaggc	gccattcggc	attcaggctg	7380
cgcaactggt	gggaaggcgg	atcgggtcgg	gcctcttcgc	tattacgcca	gctggcgaaa	7440
gggggatgtg	ctgcaaggcg	attaagttgg	gtaacgccag	ggttttccca	gtcacgacgt	7500

10/15

tgtaaaacga cggccagtga attacaccgg tgtgatcatg ggccg

7545

<210> 11  
 <211> 11643  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Synthetic

<400> 11  
 cgattaaaaa cccaattata tttggtctaa tttagtttgg tattgagtaa aacaaattcg 60  
 aaccaaacca aaatataaat atatatgttt tatatatatg cctttaagac tttttataga 120  
 attttcttta aaaaatatct agaaatatct gcgactcttc tggcatgtaa ttttctgta 180  
 aatatgaagt gctccatttt tattaacttt aaataattgg ttgtacgac accttcttat 240  
 caagtgttac taaaatgcgt caatctcttt gtctctccat attcatatgt caaaatctat 300  
 caaaattctt atatatcttt ttcgaatttg aagtgaatt tcgataattt aaaattaaat 360  
 agaacatatac attatttagg tatcatattg atttttatac ttaattacta aatttggtta 420  
 actttgaaag tgtacatcaa cgaataatta gtcaaacgac taaaataaat aaatatcatg 480  
 tgttatttaag aaaattctcc tataagaata ttttaataga tcatatgttt gtaaaaaaaa 540  
 ttaattttta ctaaacacata tattacttta tcaaaaattt gacaaagtaa gattaaaaata 600  
 atattcatct aacaaaaaaa aaaccagaaa atgctgaaaa cccggcaaaa ccgaaccaat 660  
 ccaaaccgat atagtgtggt tggtttgatt ttgatataaa ccgaaccaac tcggtccatt 720  
 tgcaccccta atcataatag ctttaatat tcaagatat attaagttta cgttgtcaat 780  
 atcctggaaa ttttgcaaaa tgaatcaagc ctatatggct gtaatatgaa tttaaaagca 840  
 gctcgatgtg gtggtaatat gtaatttact tgattctaaa aaaatatccc aagtattaat 900  
 aatttctgct aggaagaagg ttagctacga ttacagcaa agccagaata caaagaacca 960  
 taaagtgatt gaagctcgaa atatacgaag gaacaaatat ttttaaaaaa atacgcgaatg 1020  
 acttggaaca aatgagcatt atatatcttt tgttcttaaa caagcatccc ctctaaagaa 1080  
 tggcagtttt cctttgcatg taactattat gctcccttcg aaaggcgcgc atgccccctg 1140  
 tattgggaat tcttctgaaa atagtggcca ccgcttaatt aaggcgcgc atgccccctg 1200  
 cagatccccg gggatcctct agagctgacc tgcagtgcag cgtgaccccg tcgtgccctt 1260  
 ctctagagat gcctgtctaa gttataaaaa attaccacat attttttttg 1320  
 tcacacttgt ttgaagtgcg gtttatctat cttatatacat atatttaaac tttaatctac 1380  
 gaataatata atctatagta ctacaataat atcagtgttt tagagaatca tataaatgaa 1440  
 cagtttagaca tggctctaaag gacaattgag tattttgaca acaggactct acagttttat 1500  
 ctttttagtg tgcattgttt cctctttttt ttgtcacaata gcttcacctt tataataactt 1560  
 catccatttt attagtacat ccatttaggg ttttagggta atgggtttta tagactaatt 1620  
 ttttttagtac atctatttta ttctatttta gcctctaaat taagaaaact aaaactctat 1680  
 ttttagtttt ttatttaata atttagatat aaaatagaat aaaataaagt gactaaaaat 1740  
 taaacaaata ccttttaaga aattaaagaa catttttctt gtttcgagta 1800  
 gataatgccg gcctgttaaa cgcctgcgac gagtctaacg gacaccaacc agcgaaccag 1860  
 cagcgtcgcg tcgggccaag cgaagcagac ggcacggcat ctctgtcgct gcctctggac 1920  
 cctctctgag agttccgctc caccgttgga ctgtctcgc tgtcggcatc cagaaaattg 1980  
 gtggcggagc ggcagacgtg agccggcagc ctagcggcc cctctctctc ctcacggcac 2040  
 ggcagctacg ggggattcct tcccaccgc tcttctgct tccctctctc gcccgccgta 2100  
 ataaatagac acccctcca caccctctt cccaacctc gtgtgtgtcg gagcgacac 2160  
 acacacaacc agatctcccc caaatccacc cgtcggcacc tccgcttcaa ggtacgccg 2220  
 tcgtcctacc cccccccc tctctacct ctctagatcg gcgttccggg ccatgcatgg 2280  
 tttagggccc gtagttctac ttctgttcat gtttgtgtta gatccgtgtt tgtgttagat 2340  
 ccgtgctgct agcgttcgta cacggatgag acctgtacgt cagacacgtt ctgattgcta 2400  
 acttgccagt gtttctcttt ggggaatcct gggatggctc tagccgttcc gcagacggga 2460  
 tcgatttcat gatttttttt gtttcgttg atagggtttg gtttgccctt ttcctttatt 2520  
 tcaatatatg ccgtgcactt gtttgtcggg tcatctttt atgctttttt ttgtcttggt 2580  
 tgtgatgatg tggctctggt gggcggctcg tctagatcgg agtagaatc tgtttcaaac 2640  
 tacttgggtg atttattaat ttggatctg tatgtgtgtg ccatacatat tcatagttac 2700  
 gaattgaaga tgaatgatgg aaatatcgat ctaggatagg tatacatggt gatgcgggtt 2760  
 ttactgatgc atatacagag atgctttttg ttcgcttggt tgtgatgatg tgggtgtggt 2820  
 gggcggctcg tcattcgttc tagatcggag tagaatactg ttcaaaacta cctgggtgat 2880  
 ttatttaatt ttggaactgta tgtgtgtgtc atacatcttc atagttacga gtttaagatg 2940  
 gatggaaata tcgacttagg ataggtatag atgttgatgt atgttttact gatgcataa 3000  
 catgatggca tatgcagcat ctattcatat gctctaacct ttagtaccta tctattataa 3060  
 taaacaagta tgttttataa ttattttgat ctgtatatac ttggatgatg gcatatgcag 3120  
 cagctatatg tggatttttt tagccctgcc ttcatacgtt atttatttgc ttggtactgt 3180  
 ttcttttgcg gatgctcacc ctgttgtttg gtgttacttc tgcagggtac ccccggggtc 3240  
 gaccatgggt atgagcgtc acaagctctt tctcatgttc tgtatggcg gcctgtgcct 3300  
 catctctctc ctgcacttct tcaagaccct gtcctatgtc acctccccg gagaactggc 3360  
 ctccctcagc cctaaccctg tgtccagctt tttctggaac aatgccccg tcacgcccc 3420  
 ggcagcccc gagccaggag gccctgacct gctgcgtacc ccactctact cccactgcc 3480  
 cctgctgcag ccgctgccgc ccagcaaggc ggcgaggag ctccaccggg tggacttgg 3540

11/15

gctgcccag	gacaccaccg	agtatttcgt	gcgcaccaag	gccggcggcg	tctgcttcaa	3600
acccggcacc	aagatgctgg	agaggccccc	ccggggacgg	ccggaggaga	agcctgaggg	3660
ggccaacggc	tcctcgcccc	ggcggccacc	ccggtacctc	ctgagcggcc	gggagcgac	3720
ggggggccga	ggcggccggc	gcaagtgggt	ggagtgcgtg	tgctgccccg	gctggcacgg	3780
accacgctgc	ggcgtgcccc	ctgtggtgca	gtactccaac	ctgcccacca	aggagcggct	3840
ggtgcccagg	gaggtgcccgc	gccgcgtcat	caacgccatc	aacgtcaacc	acgagttcga	3900
cctgctggac	gtgcgcttcc	acgagctggg	gcagctgggtg	gacgcctttg	tggtgtgcga	3960
gtccaaacttc	acggcttatg	gggagccgcg	gccgctcaag	ttccgggaga	tgctgaccaa	4020
tggcaccttc	gagtacatcc	gccacaagg	gctctatgtc	ttcctggacc	acttcccggc	4080
cggcggccgg	caggacggct	ggatcgccga	cgactacctg	cgcaccttcc	tcaccagga	4140
cggcgtctcg	cggctgcgca	acctgcggcc	gcagcagctc	ttcatcattg	acgatgcgga	4200
cgagatcccg	gcccgtgacg	gcgtcctttt	cctcaagctc	tacgatggct	ggaccgagcc	4260
cttcgccttc	cacatgcgca	agtcgctcta	cggcttcttc	tggaagcagc	cgggcaccct	4320
ggagggtggtg	ctaggtgca	cgggtggacat	gctgcaggca	gtgtatgggc	tggaaggcat	4380
ccgctgctgc	cgccgccagt	actacaccat	gcccacttcc	agacagtatg	agaaccgcac	4440
cggccacatc	ctggtgcagt	ggctgctggg	cagccccctg	cacttcgccc	gctggcactg	4500
ctcctgggtgc	ttcacgcccg	agggatctta	cttcaagctc	gtgtccgccc	agaatggcga	4560
cttcccacgc	tgggtgact	acgaggacaa	gcgggacctg	aactacatcc	gcggcctgat	4620
ccgcaccggg	ggctgggtcg	acggcacgca	gcaggagtac	ccgcttgacg	acccacgca	4680
gcacatgtat	gcgcccgaag	acctgctgaa	gaactacgac	cggttccact	acctgctgga	4740
caacccctac	caggagccca	ggagcacggc	ggcgggcggg	tggcgccaca	ggggctccga	4800
cggaaggccg	cccgcccggg	gcaaaactgga	gcaggcgga	gtcgaacaaa	aactcatctc	4860
agaagaggat	ctgaattagg	atcctagggt	taaaactgagg	gcactgaagt	cgcttgatgt	4920
gctgaattgt	ttgtgatgtt	gggtggcgtat	tttgtttaaa	taagtaagca	tggtgtgat	4980
tttatcatat	gatcgatctt	tgggggtttta	tttaacacat	tgtaaaatgt	gtatctatta	5040
ataactcaat	gtataagatg	gtttcattct	tcggttgcca	tagatctgct	tatttgacct	5100
gtgatgtttt	gactccaaaa	acaaaaatca	caactcaata	aactcatgga	atatgtccac	5160
ctgtttcttg	aagagttcat	ctaccattcc	agttggcatt	tatcagtggt	gcagcggcgc	5220
tgtgctttgt	aacataacaa	ttgttcacgg	catatatcca	cggccggcct	agctagccac	5280
ggtggccaga	tcacataggg	gcaagcggcc	gcttaattaa	atttaaatgt	ttaaactagg	5340
aaatccaagc	ttgggtgca	ggtcaatccc	attgcttttg	aagcagctca	acattgatct	5400
ctttctcgag	gtcattcata	tgcttgagaa	gagagtcggg	atagtcacaa	ataaaacaaa	5460
ggtaaagatta	cctgggtcaaa	agtgaaaaca	tcagttaaaa	ggtggtataa	agtaaaatat	5520
cggtaaataaa	aaagtgaatt	taactttttc	tactattata	tactattata	aaaattgagg	5580
atgtttttgt	cggtactttg	atagctcatt	tttgtatgaa	ttgggtttta	agtttattcg	5640
cttttgga	tgcatatctg	tatttgagtc	gggttttaag	ttcgtttgct	tttgtaataa	5700
cagagggat	tgtataagaa	atatctttta	aaaaaacccat	atgctaattt	gacataattt	5760
ttgagaaaaa	tatatattca	ggcgaattct	cacaatgaac	aataataaga	ttaaaatagc	5820
tttccccctg	tgacgcgcat	gggtattttt	tctagtaaaa	ataaaagata	aacttagact	5880
caaaacattt	acaaaaacaa	cccctaaagt	tcctaaagcc	caaagtgtca	tccacgatcc	5940
atagcaagcc	cagcccaacc	caacccaacc	caacccaccc	cagtcacgcc	aactggacaa	6000
tagtctccac	acccccccac	tatcacgctg	agttgtccgc	acgcaccgca	cgctctcgag	6060
ccaaaaaaaa	aaaaagaaag	aaaaaaaaga	aaaagaaaaa	acagcaggtg	ggtccgggtc	6120
gtggggggcg	gaaacgcgag	gaggatcgcg	agccagcgac	gaggccggcc	ctccctccgc	6180
ttccaaagaa	acgcccccca	tcgccaatct	atcacatacc	ccccctctcc	tcccatcccc	6240
ccaacccctac	caccaccacc	accaccacct	ccacctcttc	ccccctcgct	gccggacgac	6300
gcctcccccc	tccccctccg	cgcgcggcgc	gccggtaacc	accccgcccc	tctcctcttt	6360
ctttctccgt	tttttttttc	cgctcgggtc	tcgatctttg	gccttggtag	tttgggtggg	6420
cgagaggcgg	cttcgtgcgc	gcccagatcg	gtgcgcggga	ggggcgggat	ctcgcggctg	6480
gggctctcgc	cggcgtggat	cggcccgga	tctgcggggg	aatggggctc	tcggatgtag	6540
atctgcgac	gcgcgtgtgt	gggggagatg	atgggggggt	taaaatttcc	gccatgctaa	6600
acaagatcag	gaagagggga	aaagggcact	atggtttata	tttttatata	ttctgtctgc	6660
ttcgtcaggc	ttagatgtgc	tagatctttc	ttcttctttt	ttgtgggtag	aatttgaatc	6720
cctcagcatt	gttcacgggt	agtttttctt	ttcatgattt	gtgacaaatg	cagcctcgctg	6780
cggagctttt	ttgtaggtag	accatggctt	ctccggagag	gagaccagtt	gagattaggc	6840
cagctacagc	agctgatatg	gccgcgggtt	gtgatatcgt	taaccattac	attgagacgt	6900
ctacagtga	ctttaggaca	gagccacaaa	caccacaaga	gtggattgat	gatctagaga	6960
ggttgcaaga	tagataccct	tggttggttg	ctgaggttga	gggtgtttgt	gctggatttg	7020
cttagctggg	gccttggaag	gctagggaac	cttagcattg	gacagttgag	agtactgttt	7080
acgtgtcaca	taggcatcaa	agggtgggccc	taggatccac	attgtacaca	catttgctta	7140
agtctatgga	ggcgcaaggt	tttaagtctg	tggttgctgt	tataggcctt	ccaaacgatc	7200
catctggttag	gttgcatgag	gctttgggat	acacagcccg	gggtacattg	cgcgacgtg	7260
gatacaagca	tgttggttg	catgatgttg	gtttttggca	aagggaattt	gagttgccag	7320
ctcctccaa	gccagttagg	ccagttaccc	agatctgagg	taccttgagc	tcggtcgag	7380
cgtgtgcgtg	tccgtcgtac	gttctggccg	gccgggcctt	gggcgcgcga	tcagaagcgt	7440
tgctgtggcg	tgtgtgtgct	tctgggttgc	tttaatttta	ccaagtgtgt	ttcaaggtgg	7500
atcgcgtgg	caaggcccg	gtgctttaaa	gaaccaccgg	cactggcagt	gagtggtgct	7560
gcttggttag	gctttgggtac	gtatgggctt	tatttgcttc	tggtgtgtgt	gtactacttg	7620
ggtttggtga	attattatga	gcagttgcgt	attgtaatcc	agctgggcta	cctggacatt	7680
gttatgtatt	aataaatgct	ttgctttctt	ctaaagatct	taaagtgtgt	aattcatatt	7740
tcctcctgca	gggttttaaac	ttgcccgtggc	ctattttcag	aagaattccc	aatagtagtc	7800

12/15

caaaatTTTT	gtaacgaagg	gagcataata	gttacatgca	aaggaaaact	gccattcttt	7860
agaggggatg	cttgTTtaag	aacaaaaaat	atatcacttt	cttttgttcc	aagtcattgc	7920
gtatTTTTtt	aaaaatattt	gttccttcgt	atatttcgag	cttcaatcac	tttatgggtc	7980
tttgTattct	ggctttgctg	taaatcgtag	ctaacccttc	tcctagcaga	aattattaat	8040
acttgggata	TTTTtttaga	atcaagtaaa	ttacatatata	ccaccacatc	gagctgcttt	8100
taaattcata	ttacagccat	ataggcttga	ttcattttgc	aaaattttcca	ggatattgac	8160
aacgttaact	taataatata	ttgaaatatt	aaagctatta	tgattagggg	tgcaaatgga	8220
ccgagttggg	tcgggtttata	tcaaaatcaa	accaaaccac	ctatatcggt	ttggattggg	8280
tcgggtttgc	cgggttttca	gcattttctg	gttttttttt	tgtagatga	atattatttt	8340
aatcttactt	tgtcaaatTT	ttgataagta	aatatatgtg	ttagtaaaaa	ttaatTTTT	8400
ttacaacat	atgatctatt	aaaatattct	tataggagaa	ttttcttaat	aacacatgat	8460
atTTatttat	tttagtcgtt	tgactaatTT	ttcgttgatg	tacactttca	aagttaacca	8520
gaatttagta	TTaagtataa	aaatcaatat	gatacctaata	taatgatata	ttctatttaa	8580
TTTTaaatta	tcgaaatTTc	acttcaaat	cgaaaaagat	atataagaat	tttgatagat	8640
tttgacatat	gaatatggaa	gaacaagag	attgacgcat	tttagtaaca	cttgataaga	8700
aagtgatcgt	acaaccaatt	atttaaggt	aataaaaaat	gagcacttca	tatttaacga	8760
aatattacat	ggcagaagag	tcgcaaatat	ttctagatat	TTTTtaaaaa	aaattctata	8820
aaaagtctta	aaggcatata	tataaaaaact	atatatttat	atTTtggttt	gggtcgaatt	8880
tgTTTTactc	aatacacaac	taaattagac	caaatataat	tggtttttta	atcgcgcccc	8940
actagtcacc	gggtgtagctt	ggcgtaataca	tggtcatagc	tggttcctgt	gtgaaattgt	9000
tatccgctca	caattccaca	caacatacga	gccggaagca	taaagtgtaa	agcctggggg	9060
gcctaatgag	tgagctaaat	cacattaatt	gcgttgcgct	cactgccccg	tttccagtcg	9120
ggaaacctgt	cgtgccagct	gcattaatga	atcgcccaac	gcgcggggag	aggcggtttg	9180
cgtattgggc	gctcttccgc	tgcgcacgct	gcgcacgctg	cgacacgctc	ctcgctcact	9240
gactcgctgc	gctcggctcg	tcggctgcgg	cgagcggtat	cagctcactc	aaaggcggta	9300
atacggttat	ccacagaatc	aggggataaac	gcaggaaaaga	acatgtgagc	aaaaggccag	9360
caaaaggcca	ggaaccgtaa	aaaggccgcg	ttgctggcgt	TTTTccatag	gctccgcccc	9420
cctgacgagc	atcacaaaaa	tcgacgctca	agtcagaggt	ggcgaaaccc	gacaggacta	9480
taaagatacc	aggcgTTTTc	ccctggaagc	tcctcgtgc	gctctcctgt	tcggaccctg	9540
ccgcttaccg	gatacctgtc	cgcttctctc	ccctcgggaa	gcgtggcgct	ttctcatagc	9600
tcacgctgta	gggtatctcag	ttcggtgtag	gtcgctcgct	ccaagctggg	ctgtgtgcac	9660
gaaccccccg	ttcagccccga	ccgctgcgccc	ttatccggta	actatcgtct	tgagtcacac	9720
ccggtaagac	acgacttatc	gccactggca	gcagccactg	gtaacaggat	tagcagagcg	9780
aggtagttag	cgggtgctac	agagttcttg	aaagtggggc	ctaactacgg	ctacactaga	9840
aggacagtat	ttggtagctg	cgtctgctg	aagccagtta	ccttcggaaa	aagagttggg	9900
agctcttgat	ccggcaaaaca	aaccaccgct	ggtagcgggt	gtttttttgt	ttgcaagcag	9960
cagattacgc	gcagaaaaaa	aggatctcaa	gaagatcctt	tgatcttttc	tacgggggtc	10020
gagcgttaccg	ggaacgaaaa	ctcacgttaa	gggttttttg	tcagagatt	atcaaaaaag	10080
atcttcacct	agatcctttt	aaattaaaaa	tgaagtttta	aatcaatcta	aagtatatat	10140
gagtaaaact	ggcttgacag	ttaccaatgc	ttaatcagtg	aggcacctat	ctcagcgatc	10200
tgtctatttc	gattcatccat	agttgcctga	ctccccgtcg	tgtagataac	tacgatacgg	10260
gagggcttac	ctatctggcc	cagtgctgca	atataccgc	gagacccacg	ctcaccggct	10320
ccagatttat	cagcaataaa	ccagccagcc	ggaaggggcg	agcgagaaag	tggtcctgca	10380
actttatccg	cctccatcca	gtctattaat	tggtgccggg	aagctagagt	aagtagttcg	10440
ccagttataa	gtttgcgcaa	cgttggtgcc	attgctacag	gcacgtgggt	gtcacgctcg	10500
tcgtttggtg	tggtttcatt	cagctccggg	tcccaacgat	caaggcgagt	tacatgatcc	10560
cccattgtgt	gcaaaaaaag	ggttagctcc	ttcggtcctc	cgatcggtgt	cagaagtaag	10620
ttggccgcag	tggttatcact	catgggtatg	gcagcactgc	ataattctct	tactgtcatg	10680
ccatccgtaa	gatgcttttc	tgtgactggg	gagtaactca	ccaagtcatt	ctgagaatag	10740
tgtatgcggc	gaccgagttg	ctcttgcccg	gcgtcaatac	gggataatac	cgcgcacacat	10800
agcagaactt	taaaagtgct	catcattgga	aaacgttctt	cggggcgaaa	actctcaagg	10860
atcttaccgc	tggttgagatc	cagttcgatg	taaccactc	gtgcacccaa	ctgatcttca	10920
gcacctttta	ctttcaccag	cgtttctggg	tgagcaaaaa	caggaaggca	aaatgccgca	10980
aaaaagggaa	taagggcgac	acggaaatgt	tgaatactca	tactcttcct	ttttcaatat	11040
tattgaagca	tttatcaggg	ttattgtctc	atgagcggat	acatatTTtga	atgtatttag	11100
aaaaataaac	aaataggggt	tccgcgcaca	tttccccgaa	aagtgccacc	tgacgtctaa	11160
gaaaccatta	ttatcatgac	attaacctat	aaaaataggc	gtatcacgag	gccctttcgt	11220
ctcgcgcggt	tcgggtgatga	cggtgaaaaa	cttgacaca	tgacagctcc	ggagacgggt	11280
acagcttgct	tgaagcggga	tgccgggagc	agacaaggcc	gtcagggcgc	gtcagcgggt	11340
gttggcgggt	gtcggggctg	gcttaactat	gcggcatcag	agcagattgt	actgagagtg	11400
caccatatgc	gggttgaaat	accgcacaga	tgcgtaaagg	gaaaaataccg	catcaggcgc	11460
cattcgccat	tcaggctgcg	caactgttgg	gaaggcgat	cgggtcgggg	ctcttcgcta	11520
ttacgcagc	tggcgaagg	gggatgtgct	gcaaggcgat	taagttgggt	aacgccaggg	11580
ttttccagct	cacgacgttg	taaaacgacg	gccagtgaa	tacaccgggt	tgatcatggg	11640
ccg						11643

<210> 12  
 <211> 115  
 <212> DNA  
 <213> Artificial Sequence

13/15

&lt;220&gt;

&lt;223&gt; Synthetic

&lt;400&gt; 12

catgattacg ccaagctagc ggccgcatc cggggaagct aggccaccgt ggccgcctg b0  
caggggaagc ttgcatgcct gcagatcccc ggggatcctc tagagtcgac ctgca 115

&lt;210&gt; 13

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic

&lt;400&gt; 13

gggtaccccc ggggtcgac 19

&lt;210&gt; 14

&lt;211&gt; 17

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic

&lt;400&gt; 14

taatgagctc gtttaaa 17

&lt;210&gt; 15

&lt;211&gt; 55

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic

&lt;400&gt; 15

cggccggcct agctagccac ggtggccaga tccactagtt ctagagcggc cgctt 55

&lt;210&gt; 16

&lt;211&gt; 38

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic

&lt;400&gt; 16

cctgcagatc cccggggatc ctctagagtc gacctgca 38

&lt;210&gt; 17

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic

&lt;400&gt; 17

gggtaccccc ggggtcgac 19

&lt;210&gt; 18

&lt;211&gt; 138



14/15

<212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Synthetic  
  
 <400> 18  
 tggccaccgc ttaattaagg cgcgccatgc ccgggcaagc ggccgcttaa ttaaatttaa 60  
 atgtttaaac taggaaatcc aagcttgggc tgcagggtcaa tcccatgtgt tttgaagcag 120  
 ctcaacattg atctcttt 138

<210> 19  
 <211> 14  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Synthetic  
  
 <400> 19  
 ggtaccctga gctc 14

<210> 20  
 <211> 41  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Synthetic  
  
 <400> 20  
 gaattcatat ttcctcctgc agggttttaa cttgccgtgg c 41

<210> 21  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Synthetic  
  
 <400> 21  
 cggcccacta gtcaccggtg t 21

<210> 22  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Synthetic  
  
 <400> 22  
 gcgcacgctg cgcacgctgc gcacgct 27

<210> 23  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Synthetic  
  
 <400> 23  
 acaccggtgt gatcatgggc cg 22

15/15

<210> 24  
 <211> 69  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Synthetic

<400> 24  
 tggccaccgc ttaattaagg cgcgccatgc cccctgcaga tccccgggga tcctctagag 60  
 tcgacctgc 69

<210> 25  
 <211> 144  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Synthetic

<400> 25  
 cggccggcct agctagccac ggtggccaga tccactaggg gcaagcggcc gcttaattaa 60  
 atttaaatgt tttaaactagg aaatccaagc ttgggctgca ggtcaatccc attgcttttg 120  
 aagcagctca acattgatct cttt 144

<210> 26  
 <211> 14  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Synthetic

<400> 26  
 ggtaccctga gctc 14

<210> 27  
 <211> 41  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Synthetic

<400> 27  
 gaattcatat ttcctcctgc agggtttaaa cttgccgtgg c 41

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
25 September 2003 (25.09.2003)

PCT

(10) International Publication Number  
**WO 2003/078614 A3**

(51) International Patent Classification<sup>7</sup>: C12N 15/82,  
9/10, A61K 38/02

(21) International Application Number:  
PCT/IB2003/001562

(22) International Filing Date: 18 March 2003 (18.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/365,769 19 March 2002 (19.03.2002) US  
60/368,047 26 March 2002 (26.03.2002) US

(71) Applicant (for all designated States except US): PLANT  
RESEARCH INTERNATIONAL B.V. [NL/NL];  
Droevendaalsesteeg 1, NL-6708 PB Wageningen (NL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BAKKER, Hen-  
drikus, Antonius, Cornelius [DE/DE]; Drachenfeld

75, NL30627 Hanover (DE). FLORACK, Dionisius,  
Ellisabeth, Antonius [NL/NL]; Van Doesburglaan 160,  
NL-6708 MD Wageningen (NL). BOSCH, Hendrik,  
Jan [NL/NL]; Win Sonneveldstraat 17, NL-6708 NA  
Wageningen (NL).


(74) Agents: MARSHALL, Cameron, J. et al.; Carpmals  
& Ransford, 43 Bloomsbury Square, London WC1A 2RA  
(GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,  
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,  
UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,

[Continued on next page]

(54) Title: GNTIII (UDP-N-ACETHYLGLUCOSAMINE:BETA-D MANNOSIDE BETA (1,4)-N-ACETHYLGLUCOSAMINY  
LTRANSFERASE III) EXPRESSION IN PLANTS



(57) Abstract: The invention relates to the field of glycoprotein processing in transgenic plants used as cost efficient and contamination safe factories for the production of recombinant biopharmaceutical proteins or pharmaceutical compositions comprising these glycoproteins. The invention provides a plant comprising a functional mammalian enzyme providing mammalian GnTII (EC 2.4.1.144) that is normally not present in plants, said plant additionally comprising at least a second mammalian protein or functional fragment thereof that is normally not present in plants.



SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

**(88) Date of publication of the international search report:**

8 January 2004

# INTERNATIONAL SEARCH REPORT

International Application No. ...  
PCT/ 03/01562

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/82 C12N9/10 A61K38/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, SEQUENCE SEARCH, FSTA, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01 29242 A (MONSANTO CO) 26 April 2001 (2001-04-26) cited in the application	1-16, 20, 21, 23-26, 30, 32, 33, 48, 50, 51, 53, 54
X	page 5, line 5 - line 22 page 32, line 14 - page 33, line 13  page 52, line 7 - line 11 page 8, line 26 - page 9, line 1  -/--	31, 35, 36, 42-45, 47

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the international search

21 October 2003

Date of mailing of the international search report

04 11. 2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Schönwasser, D

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/JP 03/01562

## C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 00 29603 A (NEOSE TECHNOLOGIES INC (US)) 25 May 2000 (2000-05-25) cited in the application</p> <p>page 7, line 20 -page 8, line 16 page 27, line 14 -page 28, line 2</p>	<p>1-7, 9, 10, 13-15, 20, 21, 23-26, 32, 48, 50, 53</p>
A	<p>LEROUGE P ET AL: "N-glycoprotein biosynthesis in plants: recent developments and future trends" PLANT MOLECULAR BIOLOGY, vol. 38, 1998, pages 31-48, XP002140796 ISSN: 0167-4412 cited in the application figures 1-3, 7</p>	<p>1-16, 20, 21, 23-26, 32, 33, 48, 50, 51, 53, 54</p>
X	<p>page 45, column 1, line 10 - line 18; figures 1, 8</p>	<p>31, 35, 36</p>
A	<p>TANIGUCHI N. ET AL.: "A glycomic approach to the identification and characterization of glycoprotein function in cells transfected with glycosyltransferase genes" PROTEOMICS, vol. 1, no. 2, February 2001 (2001-02), pages 239-247, XP008020255 cited in the application the whole document</p>	<p>1-16, 20, 21, 23-26, 32, 33, 48, 50, 51, 53, 54</p>
A	<p>WO 99 29879 A (VON SCHAEWEN ANTJE) 17 June 1999 (1999-06-17)</p> <p>the whole document</p>	<p>1-16, 20, 21, 23-26, 32, 33, 48, 50, 51, 53, 54</p>
A	<p>IHARA Y ET AL: "CDNA CLONING, EXPRESSION, AND CHROMOSOMAL LOCALIZATION OF HUMAN N-ACETYLGLUCOSAMINYLTRANSFERASE III (GNT-III)" JOURNAL OF BIOCHEMISTRY, vol. 113, no. 6, 1993, pages 692-698, XP002948287 ISSN: 0021-924X the whole document</p>	<p>1-16, 20, 21, 23-26, 32, 33, 48, 50, 51, 53, 54</p>

-/--

## INTERNATIONAL SEARCH REPORT

Internat. Application No  
PCT, 10 03/01562

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>VOELKER T A ET AL: "IN-VITRO MUTATED PHYTOHEMAGGLUTININ GENES EXPRESSED IN TOBACCO SEEDS ROLE OF GLYCANS IN PROTEIN TARGETING AND STABILITY" PLANT CELL, vol. 1, no. 1, 1989, pages 95-104, XP002257470 ISSN: 1040-4651 page 97, column 1, paragraph 3; figure 2 page 102, column 1, paragraph 3 page 95, column 2, paragraph 2</p>	31, 42-45
X	<p>WO 01 31045 A (STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK) 3 May 2001 (2001-05-03) cited in the application page 13, line 25 - line 35; figure 5</p>	31, 35, 36, 47
P, X	<p>YOSHIDA K ET AL: "Molecular biology and application of plant peroxidase genes." APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, vol. 60, no. 6, February 2003 (2003-02), pages 665-670, XP002257469 ISSN: 0175-7598 page 665, column 2, line 25 - line 28 Abstract: first sentence page 667, column 1, paragraph 1 -page 668, column 1, paragraph 2</p>	31, 42-45
P, X	<p>WO 03 011878 A (GLYCART BIOTECHNOLOGY AG) 13 February 2003 (2003-02-13) '0009!; '0010!; '0012!; '0020!-'0024!; '0064!</p>	31, 35, 36
A	<p>RAYON CATHERINE ET AL: "N-glycosylation of phytohemagglutinin expressed in bean cotyledons or in transgenic tobacco cells" PLANT PHYSIOLOGY AND BIOCHEMISTRY (PARIS), vol. 34, no. 2, 1996, pages 273-281, XP008023386 ISSN: 0981-9428 the whole document</p>	31

---  
-/--

## INTERNATIONAL SEARCH REPORT

Internat. Application No. ....

PCT/ 13/01562

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	MOKRZYCKI-ISSARTEL NATHALIE ET AL: "A transient tobacco expression system coupled to MALDI-TOF-MS allows validation of the impact of differential targeting on structure and activity of a recombinant therapeutic glycoprotein produced in plants." FEBS LETTERS, vol. 552, no. 2-3, 25 September 2003...(2003-09-25),.. pages 170-176, XP002257472 ISSN: 0014-5793 the whole document	31, 35, 36
A	GRABENHORST ECKART ET AL: "The cytoplasmic, transmembrane, and stem regions of glycosyltransferases specify their in vivo functional sublocalization and stability in the Golgi" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 51, 17 December 1999 (1999-12-17), pages 36107-36116, XP002257473 ISSN: 0021-9258 the whole document	37-41
A	TANG B L ET AL: "THE TRANSMEMBRANE DOMAIN OF N-GLUCOSAMINYLTRANSFERASE I CONTAINS A GOLGI RETENTION SIGNAL" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 267, no. 14, 1992, pages 10122-10126, XP002911162 ISSN: 0021-9258 the whole document	37-41



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/IB 03/01562

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 17-19, 27-29, 34, 46, 52  
because they relate to subject matter not required to be searched by this Authority, namely:  
A meaningful search for claims 17-19, 27-29, 34, 46, 52 is not possible because said claims are directed to an essentially biological process for the production of plants - Rule 39.1(ii) PCT.
2. ☒ Claims Nos.: 22, 42, 47, 49 (no search); 31, 35, 36, 38-41 (incomplete search).  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-16,20,21,23-26,30,32,33,48,50,51,53,54

A plant host cell system comprising GnTIII; methods for obtaining a heterologous glycoprotein having bisected oligosaccharides by expressing GnTIII; a method for obtaining a desired glycoprotein involving GnTIII transformed plants, a method for increasing galactosylation of a heterologous glycoprotein by using GnTIII transformed plants, use of above mentioned plant host system; methods for expressing a GnTIII and a transgenic plant expressing said GnTIII

2. Claims: 31,35,36,42-45,47

A plant derived glycoprotein comprising bisected oligosaccharides, use of said glycoprotein, a composition comprising said glycoprotein, a nucleic acid encoding said glycoprotein, a vector and a plant comprising said nucleic acid; a method for providing a transgenic plant

3. Claims: 37-41

A hybrid protein comprising an active site of GnTIII and a transmembrane region

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 22,42-47,49 (no search); 31,35,36,38-41 (incomplete search)

Dependent claims 22 and 49 relate inter alia to a nucleic acid encoding a heterologous "glycopraexin".

The application provides no support within the meaning of Article 6 PCT and no disclosure within the meaning of Article 5 PCT for such a product. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). The lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, no search has been carried out for said claims.

Invention 2:

Present claims 31,35 and 36 relate to an extremely large number of possible plant derived glycoproteins. Support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the claimed glycoproteins. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compositions of glycoproteins disclosed in Fig. 1 and 9 and Tables 1 and 2.

In analogy to the above remark present claims 42-47 relate to an extremely large number of possible nucleic acids, which are not defined in the application. It is not possible to know e.g. from Fig. 1, 9 or Tables 1 or 2, which sequences the nucleic acids have, that code for the glycoproteins with bisected oligosaccharides. Consequently, no search could be carried out for subject-matter of claims 42-47.

Invention 3:

Further, present claims 38-41 relate to an extremely large number of possible proteins. In fact, the claims contain so many options, that a lack of clarity and conciseness within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear, namely to claims 38-41 in the sense of "HYBRID protein according to claim 37... (instead of "protein acc. to claim 37...", - which could be the protein residing in the ER or Golgi) as supported by information on p. 40, 1.21-23 and 1. 26-32 and P. 41, 1.1-11 and 34-36 of the description.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/03/01562

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0129242	A	26-04-2001	AU 1573601 A CA 2388432 A1 EP 1224309 A2 WO 0129242 A2	30-04-2001 26-04-2001 24-07-2002 26-04-2001
WO 0029603	A	25-05-2000	AU 1826100 A CA 2351022 A1 EP 1131415 A2 JP 2002530087 T WO 0029603 A2 US 2002001831 A1	05-06-2000 25-05-2000 12-09-2001 17-09-2002 25-05-2000 03-01-2002
WO 9929879	A	17-06-1999	DE 19754622 A1 AU 760394 B2 AU 2268899 A CA 2312734 A1 WO 9929879 A1 EP 1038014 A1 JP 2002509696 T	10-06-1999 15-05-2003 28-06-1999 17-06-1999 17-06-1999 27-09-2000 02-04-2002
WO 0131045	A	03-05-2001	AU 1738401 A BR 0015031 A CA 2389217 A1 EP 1228231 A1 JP 2003512076 T WO 0131045 A1 TR 200201121 T2 AU 1738301 A WO 0131044 A1 US 2003024012 A1	08-05-2001 18-06-2002 03-05-2001 07-08-2002 02-04-2003 03-05-2001 21-01-2003 08-05-2001 03-05-2001 30-01-2003
WO 03011878	A	13-02-2003	WO 03011878 A2 US 2003175884 A1	13-02-2003 18-09-2003

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**